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Abstract
Hyperglycemia is prevalent in critical care, as patients experience stress-induced
hyperglycemia, even with no history of diabetes. Hyperglycemia has a signifi-
cant impact on patient mortality, outcome and health care cost. Tight regulation
can significantly reduce these negative outcomes, but achieving it remains clini-
cally elusive, particularly with regard to what constitutes tight control and what
protocols are optimal in terms of results and clinical effort.
Hyperglycemia in critical care is not largely benign, as once thought, and has
a deleterious effect on outcome. Recent studies have shown that tight glucose
regulation to average levels from 6.1–7.75 mmol/L can reduce mortality 17–45%,
while also significantly reducing other negative clinical outcomes. However, clin-
ical results are highly variable and there is little agreement on what levels of
performance can be achieved and how to achieve them.
A typical clinical solution is to use ad-hoc protocols based primarily on ex-
perience, where large amounts of insulin, up to 50 U/hr, are titrated against
glucose measurements variably taken every 1–4 hours. When combined with the
unpredictable and sudden metabolic changes that characterise this aspect of crit-
ical illness and/or clinical changes in nutritional support, this approach results
in highly variable blood glucose levels. The overall result is sustained periods
of hyper- or hypo- glycemia, characterised by oscillations between these states,
which can adversely affect clinical outcomes and mortality. The situation is ex-
acerbated by exogenous nutritional support regimes with high dextrose content.
Model-based predictive control can deliver patient specific and adaptive con-
trol, ideal for such a highly dynamic problem. A simple, effective physiological
model is presented in this thesis, focusing strongly on clinical control feasibility.
This model has three compartments for glucose utilisation, interstitial insulin
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and its transport, and insulin kinetics in blood plasma. There are two patient
specific parameters, the endogenous glucose removal and insulin sensitivity. A
novel integral-based parameter identification enables fast and accurate real-time
model adaptation to individual patients and patient condition.
Three stages of control algorithm developments were trialed clinically in the
Christchurch Hospital Department of Intensive Care Medicine. These control
protocols are adaptive and patient specific. It is found that glycemic control util-
ising both insulin and nutrition interventions is most effective. The third stage of
protocol development, SPRINT, achieved 61% of patient blood glucose measure-
ments within the 4–6.1 mmol/L desirable glycemic control range in 165 patients.
In addition, 89% were within the 4–7.75 mmol/L clinical acceptable range. These
values are percentages of the total number of measurements, of which 47% are
two-hourly, and the rest are hourly. These results showed unprecedented tight
glycemic control in the critical care, but still struggle with patient variability and
dynamics.
Two stochastic models of insulin sensitivity for the critically ill population
are derived and presented in this thesis. These models reveal the highly dynamic
variation in insulin sensitivity under critical illness. The stochastic models can de-
liver probability intervals to support clinical control interventions. Hypoglycemia
can thus be further avoided with the probability interval guided intervention as-
sessments. This stochastic approach brings glycemic control to a more knowledge
and intelligible level.
In “virtual patient” simulation studies, 72% of glycemic levels were within
the 4–6.1 mmol/L desirable glycemic control range. The incidence level of hy-
poglycemia was reduced to practically zero. These results suggest the clinical
advances the stochastic model can bring. In addition, the stochastic models re-
flect the critical patients’ insulin sensitivity driven dynamics. Consequently, the
models can create virtual patients to simulated clinical conditions. Thus, protocol
developments can be optimised with guaranteed patient safety.
Finally, the work presented in this thesis can act as a starting point for many
other glycemic control problems in other environments. These areas include the
cardiac critical care and neonatal critical care that share the most similarities to
the environment studied in this thesis, to general diabetes where the population
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is growing exponentially world wide. Furthermore, the same pharmacodynamic
modelling and control concept can be applied to other human pharmacodynamic
control problems. In particular, stochastic modelling can bring added knowledge
to these control systems. Eventually, this added knowledge can lead clinical
developments from protocol simulations to better clinical decision making.

Chapter 1
Introduction
Automated blood glucose control has been a major pursuit of many researchers
for at least three decades due to the toll taken by diabetes and its complications.
The incidence of both Type 1, Type 2 and insulin dependent Type 2 diabetes is
growing and predicted to reach epidemic incidence level in western populations
[Alberti and Zimmet, 1998; King, 1999; ADA (American Diabetes Association),
2002; Nyomba et al., 2003; IDF (International Diabetes Federation), 2003; Wild
et al., 2004; Williams, 2005; CDC (Centers for Disease Control and Prevention),
2005, 2006; Koster et al., 2006; Lee et al., 2006; Li et al., 2006; Mainous et al.,
2006; Milton et al., 2006; Narayan et al., 2003, 2006; Hossain et al., 2007]. In 2001,
over 120 million people were affected by diabetes worldwide, and this number is
expected to rise to 300 million by the year 2025, with annual costs growing
exponentially with the number of cases [Thomson et al., 2001; ADA (American
Diabetes Association), 2002; Nyomba et al., 2003; IDF (International Diabetes
Federation), 2003; Wild et al., 2004; Williams, 2005; CDC (Centers for Disease
Control and Prevention), 2005, 2006; Koster et al., 2006; Lee et al., 2006; Li
et al., 2006; Mainous et al., 2006; Milton et al., 2006; Narayan et al., 2003, 2006;
Hossain et al., 2007]. In addition, the cost of diabetes and its complications
are predicted to reach up to 10% of health care costs by 2020 [ADA (American
Diabetes Association), 1998; PWC (PriceWaterhouseCoopers), 2001]. In New
Zealand, the New Zealand Ministry of Health [2002] conservatively estimates that
in 1996 almost 5000 adults were newly diagnosed with diabetes, approximately
81,000 were known to have diabetes, and almost 1500 deaths were attributable to
diabetes. In addition, the number of new diagnoses of diabetes in 2011 is forecast
to exceed 11,000, the number of people known to be living with diabetes may
exceed 145,000, and the number of deaths attributable to diabetes may exceed
2,100.
2 CHAPTER 1 INTRODUCTION
Elevated blood glucose levels, or hyperglycemia are a result of dysfunctional
glucose regulatory mechanisms, which implies some degree of impaired insulin
secretion and/or insulin resistance. Untreated hyperglycemia, over time, can
lead to costly complications such as retinopathy, cataracts, ulcers, skin infec-
tions, heart disease, peripheral vascular disease, cerebrovascular disease (stroke)
and neuropathy (nervous system disease), to name a few of the more serious and
costly long-term outcomes of this chronic disease [Barrett-Connor and Khaw,
1988; Alberti and Zimmet, 1998; Capes et al., 2000; Bistrian, 2001; Van den
Berghe et al., 2001; Livingstone and Ferns, 2003; Ben-Mahmud et al., 2006]. The
immune system also fails to function optimally in the presence of high blood
glucose levels [Marik and Raghavan, 2004; Jeandidier and Boullu-Sanchis, 2006;
Turina et al., 2005]. At 8 mmol/L, the immune response is only 50% or less effec-
tive, and at 10 mmol/L, the immune response is essentially completely ineffective
[Weekers et al., 2003]. An ineffective immune response can have obvious signifi-
cant consequences in terms of fighting off bacterial or viral infections, in addition
to the other complications noted. The overall outcome is a chronic disease state
with costly long-term complications that impose significant health and economic
burden on the patient, their families, and the broader society.
The prevalence of hyperglycemia in critical care has grabbed its own research
focus in recent years due to several landmark studies by Van den Berghe et al.
[2001, 2003] and Krinsley [2003b, 2004]. These studies led to several additional
clinical and model-based studies [Van den Berghe et al., 2006; Van den Berghe,
2004a; Krinsley, 2003a; Chase et al., 2005c; Doran et al., 2004b; Wong et al.,
2006b; Laver et al., 2004; Goldberg et al., 2004b]. As a result, it has become
a significant research area in its own right, and has been recently reviewed by
Chase et al. [2006b, 2007].
Critically ill patients often experience stress-induced hyperglycemia, even
with no history of diabetes [Bloomgarden, 2003; Capes et al., 2000; Christensen,
2001; Coursin and Murray, 2003; Esposito et al., 2003; Finney et al., 2003; Krins-
ley, 2003a; McCowen et al., 2001; Mizock, 2001; Ousman, 2002; Peck, 2004;
Umpierrez et al., 2002; Van den Berghe et al., 2001, 2003]. The increased counter-
regulatory hormone and cytokine response stimulates endogenous glucose pro-
duction and increases effective insulin resistance. Absolute and relative insulin
deficiency is also a contributing factor. In addition, some steroid-based therapies
antagonise insulin action and production, further exacerbating the problem.
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Studies also indicate that high glucose content nutritional support regimes
result in excess blood glucose levels [Patino et al., 1999; Weissman, 1999; Woolf-
son, 1980; Elia et al., 2005]. More recently, reductions in enteral nutrition [Elia
et al., 2005; Ahrens et al., 2005; Kim et al., 2003] or its carbohydrate content
[Patino et al., 1999] led to reductions in glycemic levels. In addition, the reduced
use of dextrose as a diluent in intravenous medication resulted in reductions in
glycemia [Krajicek et al., 2005]. Similarly, analysis of carbohydrate feeding lev-
els with respect to the American College of Chest Physicians (ACCP) guidelines
indicated that 33–66% reductions in carbohydrate content reduced the risk of
mortality compared to feeding at the current ACCP guideline levels [Krishnan
et al., 2003]. Finally, reducing either feed or glucose diluent has also been shown
to alleviate the impact of the hyperglycemic counter-regulatory response that
drives this problem [Mizock, 2001; McCowen et al., 2001; Thorburn et al., 1995;
Larsen et al., 2002].
Clinically, hyperglycemia can be a marker of severity of illness and is directly
associated with mortality. In addition, it is also associated with increases in
other negative clinical outcomes, including severe infection [Bistrian, 2001], sep-
sis and septic shock [Das, 2003; Branco et al., 2005; Oddo et al., 2004; Marik and
Raghavan, 2004], myocardial infarction [Capes et al., 2000], and polyneuropa-
thy and multiple-organ failure [Van den Berghe et al., 2001; Langouche et al.,
2005]. In each of these cases or patient subgroups, lower blood glucose levels
were associated with reduced mortality and/or complications. Similar studies
have associated early hyperglycemia (in a patient stay) with mortality in trauma
patients [Laird et al., 2004; Jeremitsky et al., 2005; Holm et al., 2004]. Finally,
there is also evidence of significant reductions in the need for dialysis, bacteremia
testing and the number of blood transfusions with aggressive blood glucose con-
trol using intensive insulin therapy [Van den Berghe et al., 2001, 2003; Krinsley,
2003b]. All of these results point towards the conclusion that the control of blood
glucose levels in critical care have a significant clinical impact.
1.1 Significance of Glycemic Control in Critical Care
There are two initial landmark studies that have observed and defined the glycemic
control problem in the intensive care units (ICU) and the impact of tight control
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on mortality and other clinical outcomes. First, Van den Berghe et al. [2001,
2003] showed that tight blood glucose control to less than 6.1 mmol/L reduced
cardiac surgical ICU patient mortality by up to 45% in a randomised controlled
trial. Krinsley [2003b, 2004] reported a 17–29% total reduction in mortality
over a wider, more critically ill, ICU population with a higher glucose limit of
7.75 mmol/L. This mortality reduction was observed by comparing the controlled
groups to a matched cohort of retrospective data with enough patients to show
statistical power for the intervention.
An interesting point arises from comparing the retrospective study of Krinsley
[2003b, 2004] with the randomised trial of Van den Berghe et al. [2001, 2003] for
any such study. Van den Berghe et al. [2001, 2003] made a comparison to an
essentially equally treated and matched cohort whose average blood glucose was
allowed, or more specifically, controlled, to be relatively high (9–10 mmol/L).
However, as recent evidence has shown, the higher glucose levels in the control
group may have skewed the differences in clinical outcome between groups [Chase
et al., 2006b]. Thus, comparing two cohorts of similar given hyperglycemia and
condition subjected to different glycemic treatments may provide a more objective
comparison rather than having a group deliberately controlled to a less desirable
level of care.
In particular, given that the benefit of tight control appears to be continuous
or analog with increasingly tight and lower glucose levels, a comparison of a
high level to a lower level may well predetermine the clinical study’s outcome
or skew it. In contrast, comparing two matched cohorts who received the best
care approach available for glycemic levels and similar care otherwise (e.g. a
retrospective recent past cohort) more directly shows the difference of introducing
a new tight glycemic control approach.
Hence, the retrospective before-after study design of Krinsley [2003b, 2004]
may be more appropriate for investigating the effects of introducing tighter glyce-
mic control into the ICU. More specifically, a randomised controlled trial (RCT)
in a single hospital risks contamination in care across groups as well as requir-
ing a no-change in care or specifically controlled group. In the latter choice,
as in Van den Berghe et al. [2001], it is difficult to pick a controlled glycemic
level indicative of otherwise unaltered care. Thus, the control group is either
contaminated or essentially undefined in a RCT unless different hospitals with
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matched cohorts are used. However, this last choice is effectively equivalent to
the retrospective cohort used in before-after trials. Nevertheless, in either study,
the outcome shows that tight control does have a significant impact despite any
criticisms of either study format [Chase et al., 2007].
Currently, the exact reasons for the reductions in mortality and other clinical
outcomes are not fully known, but have been extensively analysed in these original
and other works [Bellomo and Egi, 2005; Diringer, 2005; Finney et al., 2003;
Krinsley, 2003a; Langouche et al., 2005; Mesotten et al., 2004; Van den Berghe,
2004b,a; Van den Berghe et al., 2005]. However, recent studies by Weekers et al.
[2003] on a rabbit model do indicate some major causes. Specifically, tight control
reduces glucotoxicity due to high blood glucose, or hyperglycemia, which in turn:
1. Reduces oxidative stress and superoxides.
2. Reduces stress hormone responses.
3. Reduces damage to the endothelium and vascular walls [Langouche et al.,
2005].
4. Increases immune response and bacteriocidal activity.
These results have been supported by a variety of recent, closely related studies
[Soop et al., 2002; Hansen et al., 2003; Jeschke and Herndon, 2004; Butler et al.,
2005; Dandona et al., 2006; Gubern et al., 2006]. All of these studies exam-
ine aspects of systemic inflammation that is common in critical illness, immune
response, and the resulting impact or damage at a cellular level.
Both Van den Berghe et al. [2001, 2003] and Krinsley [2003b, 2004] used
ad-hoc glycemic control protocols that did not employ models or control theory,
and relied only on exogenous (intravenous) insulin intervention to reduce blood
glucose levels. In particular, they were both rules-based protocols based on clin-
ical experience and titration-based sliding scale. They were also both altered as
needed by clinical staff and thus not necessarily general to any or all patients.
The main clinical differentiators of these two landmark studies are the glycemic
limits used and the levels of critical illness of the cohorts, as measured by Acute
Physiology and Chronic Health Evaluation II (APACHE II) score. In particular,
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Krinsley [2003b, 2004] studied a broader, more representative critical care cohort
with a much greater level of critical illness, reporting an average APACHE II
score of 16.9 (IQR: 13–24). Due perhaps to the severity of illness of their cohort,
a higher titration limit and goal was established. In contrast, Van den Berghe
et al. [2001, 2003] reported a much lower median APACHE II score of 9 (IQR:
6–13), in combination with their much lower glycemic target limit.
Two important results can be drawn from these two initial clinical studies.
First, tighter control with lower glycemic limits appears to offer increased ben-
efit in terms of reduced mortality and reductions in other measurable negative
clinical outcomes. Second, the level of critical illness is generally proportional
to observed hyperglycemia and insulin resistance [Van den Berghe et al., 2003;
Krinsley, 2003a; Lind and Lithell, 1994; Christiansen et al., 2004; Mentula et al.,
2005; Basi et al., 2005], which will result in a decreased ability to reduce blood
glucose with insulin alone for more critically ill cohorts. However, neither study
addressed issues such as blood glucose variability, time within a desired glycemic
band, nor other typical control system oriented performance metrics that would
help further clarify the requirements for tight glycemic control. For example, how
tight must the controlled glycemic range be around an average value, and what
target level or range is most optimal.
These two conclusions, together with other unaddressed issues, form the basis
of the overall glycemic control problem definition in the critically ill population.
In addition, the potential for applying dynamic systems modelling and control
methods to achieve significant clinical improvements is clear. More specifically,
while other studies are being undertaken to further validate many of the results
already available across broader populations and cohorts, the clinical evidence
for tight control is greater than for the oftentimes current practice of tolerating
a level of hyperglycemia [Angus and Abraham, 2005].
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1.2 Glycemic Control Problem Outline
There are typically three main elements in any control problem:
1. Sensors and signal processing — measurement of controlled parameters
2. Dynamic modelling and parameter identification — placing measurements
into a dynamic systems framework to better identify trends and future
response to intervention
3. Control method or protocol — application of steps 1 and 2 to optimise
intervention and response.
Sensors and signal processing determine the quality and frequency of data for
the controller. The dynamic model and parameter identification methods relate
to the (predictive) accuracy of any controller, and thus its ability to safely and
accurately lower glucose levels in this case. Finally, the control algorithm employs
both these elements to determine the appropriate intervention to achieve a set
performance goal. Generically, these three elements are all inter-related and lower
complexity or quality from one is typically offset by requiring greater quality or
complexity from the others. Figure 1.1 shows a schematic of the basic control
schemes employed to outline the general control problem and its major elements
in the context of glycemic control.
While evidence for, and a desire to provide, quality glycemic management in
the critical care are growing, intensive care units also present a highly controlled
environment where the general glycemic control problem can be stripped down
to its most basic form. In particular, the inputs and outputs of the control sys-
tem are more easily measured, monitored, and modelled in critical care, given
the typical use of intravenous insulin, and intravenous or enteral nutrition de-
livery. Thus, starting from the intensive care unit, the glycemic control system
that arises from this platform can be extended to other glycemic control prob-
lems, and eventually benefit general diabetic patients in everyday life. Figure
1.2 shows this pathway starting from intensive care working its way down the
pyramid, where the number of variables, non-linearities and uncertainties that
increases the difficulty of the control design problem increases at each level. Very
importantly, although each layer of the pyramid poses different conditions and
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Figure 1.1 Basic model-based glycemic control system schematic showing the primary blocks
encompassing sensing, actuation and control implementation. The control system boundary is
shown by dash-dot lines, and the nutritional input line is dashed to indicate that this quantity
may be controlled as part of glycemic control or set based on other clinical requirements. Sensor
errors are shown as a separate block due to their potential size and impact on control. There
may be some error in the actuators or pumps depending on their design specifications such
as dosing limits and precision. This schematic diagram shows all possible set up of glycemic
control systems. Arrows are suggestive and may not all exist in one setting.
problems that may be encountered, they share the same fundamental metabolic
system models for the pharmacokinetics of insulin and the pharmacodynamic in-
teraction of glucose and insulin. Therefore, glycemic control research in the ICU
holds an important role as the central portion or key to future, broader diabetes
solutions.
1.3 Sensors and Signal Processing
In glycemic control, the primary measurement available is plasma glucose level.
Current glucose sensing methods can be broken into four broad areas for control
applications. These areas represent distinctions in quality, time, software storage
and links, and data density, all of which impact the resulting control problem.
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Figure 1.2 Pyramid description of glycemic control problems in terms of ability to control
variables based on knowledge of their value or input (vertical axis), and the range of variables
to be considered and resulting level of uncertainty (horizontal axis).
Lab or Gold Standard Measures consist of laboratory reference measure-
ments using standard techniques. They offer the lowest error (< 3%) and
best repeatability [Peet et al., 2002]. Turnaround time for results can be
quite long due to the logistics of sending samples to a lab. However, modern
blood gas analysers can now be installed in specific units offering similar
results to clinical staff within 1–3 min [Peet et al., 2002; Beneteau-Burnat
et al., 2004; Papadea et al., 2002].
Point of Care Tests (POCT) can be linked directly to patient databases and
records and are becoming standard in many ICUs. They range from blood
gas analysers to specialised POCT pin-prick test strip devices. Accuracy
ranges from blood gas analysers (< 3%) [Peet et al., 2002; Beneteau-Burnat
et al., 2004; Godje et al., 1997; Solnica et al., 2001] to pin-stick results
(typically 7–12%) [Louie et al., 2000; Buhling et al., 2003]. Data density is
typically no greater than hourly due to discomfort and the effort required
around other clinical duties.
Pin-Stick Bedside Test Kits are the current standard in many ICUs and most
ambulatory diabetic individuals. They offer rapid results in less than 30
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seconds and require only 1–2 min of total clinical effort, but have errors
of 7–12% over common glycemic ranges [Chen et al., 2003; Solnica et al.,
2003; Weitgasser et al., 1999; Johnson and Baker, 1998, 1999; DirectNet,
The Diabetes Research in Children Network Study Group, 2005; Demers
et al., 2003]. They are rarely used more than hourly. In critical care, pin-
stick measures can be used to extract subcutaneous blood or sampled from
an arterial line. The latter approach eliminates the 5–20 min lag in plasma
glucose levels that can exist between plasma and interstitial fluid [Rebrin
et al., 1999; Wilinska et al., 2004; Boyne et al., 2003].
Semi-Invasive “Continuous” Sensors are emerging sensors offering automat-
ed or semi-automated measurements of blood glucose concentration. The
most commonly reported types, at this writing, are the continuous glu-
cose measurement system (CGMS) from Minimed/Medtronic Inc. and the
GlucoWatchTM Biographer [DirectNet, The Diabetes Research in Children
Network Study Group, 2004; Goldberg et al., 2004a; Weinzimer et al., 2003].
They offer very frequent measurements every 5–15 min, but with errors up
to 40% reported over a wide variety of studies [DirectNet, The Diabetes
Research in Children Network Study Group, 2004; Goldberg et al., 2004a;
Weinzimer et al., 2003; Garg et al., 1999; Dunn et al., 2004; Pitzer et al.,
2001; Tierney et al., 2000, 2001; Tsalikian et al., 2004; Javid et al., 2005;
Kovatchev et al., 2004; Gilligan et al., 2004; Klonoff, 2002].
Portable blood gas analysers offer the best quality results for fitting models
to determine control inputs due to their lower error. At the other end of the
spectrum, emerging sensors, such as the CGMS from Medtronic Inc., offer very
high data density, but with much greater error. The standard pin-stick bedside
testing kit is still the most commonly used measure in all situations. It offers
greater ease of use than a portable or local blood gas analyser with slightly
greater error, but much lower data density than emerging continuous sensors.
Finally, note that plasma insulin measurement would offer added information for
modelling and control. However, the lab turnaround time for this measurement
is generally too long to be of direct use in real-time clinical control.
Hence, there is a significant tradeoff involved in selecting the type of mea-
surement or accounting for the type available in a specific clinical setting. Less
frequent measurement requires greater prediction capability from the model.
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More frequent measurement allows potentially much simpler models. In contrast,
greater errors will require more intensive signal processing, as well as models more
robust to those errors in patient specific parameter fitting and prediction.
Perhaps the most common clinical measurement issue in glycemic control
is frequency. More frequent measurement than most typical clinical practice
has been a hallmark of both initial landmark glycemic control studies [Van den
Berghe et al., 2001, 2003; Krinsley, 2003b, 2004], varying between 1 and 4 hours.
However, specialised additional staff were required to manage the extra workload
reported. Other pilot studies and surveys have reported the extra clinical burden
of intensive insulin therapy for glycemic control as “burdensome” or “taxing”
[Mackenzie et al., 2005; Bland et al., 2005; Waeschle et al., 2005; Di Nardo et al.,
2004; Scholtz et al., 2005]. Hence, the ability to limit or automate measurement
via implanted continuous sensors could be seen as critical. Thus, emerging sensors
offer significant promise for automating glycemic control in this regard.
Frequent measurement and its impact on glycemic control have also been
studied both in simulation [Wong et al., 2005; Chase et al., 2005a; Lonergan
et al., 2006b] and clinically [Chase et al., 2005a; Wong et al., 2006a,b], including
the analysis of long-term retrospective data [Hann et al., 2005]. Results show
that fewer, less frequent measurements often result in greater glycemic variation
in critical care and poorer outcome [Doran, 2004; Shaw et al., 2005; Lonergan
et al., 2006b], as might be expected from a strictly control system perspective.
Similar results have been seen in treating ambulatory diabetic individuals [Hirsch
and Brownlee, 2005; McDonnell et al., 2005].
Overall, the different types of measurement offer a series of fundamental
tradeoffs. Typically, a given unit will have a standard set of measures and prac-
tices, which the control engineer will have to work with, removing choice in the
types of sensors. It might be expected that if current semi-invasive sensors con-
tinue to improve, they will come to replace many of the other types. However,
significant hurdles related to error, ease of use, and reliability remain [Klonoff,
2005a,b]. Hence, while there may currently be little choice in many practical
cases, this area is rapidly developing.
Currently, pin-stick bedside test kits are most commonly found in ICUs, with
typical error of 7–12% and offer results in 30 seconds or less. The tradeoff between
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its fast turnover time and comparatively small error, and its labour requirement
and associated discomfort will need to be investigated to achieved specific control
performance goals.
1.4 Model-Based Glycemic Control
Currently, most typical ICU practice in glycemic management is comprised of
ad-hoc protocols based primarily on experience, where relatively large amounts
of intravenous insulin, up to 50 U/h, are titrated against glucose measurements
variably taken every 1–4 hours. When combined with the unpredictable and
sudden metabolic changes that characterise this aspect of critical illness and/or
clinical changes in nutritional support, this approach results in highly variable
blood glucose levels. The overall result is sustained periods of hyper- or hypo-
glycemia, characterised by oscillations between these states, which can adversely
affect clinical outcomes and mortality. The situation is exacerbated by exogenous
nutritional support regimes with high dextrose content. Hence, there is an emerg-
ing, strong need for the more rigorous analysis and methods that model-based
control methods bring to this type of problem.
A physiological model that captures the glucose-insulin system dynamics
is thus the basis for more optimally addressing the glycemic control problem.
Metabolic modelling of the glucose-insulin system has a very deep history in
the published literature. The vast majority of these models have their roots in
basic compartment modelling with differential equations [Carson and Cobelli,
2001]. To date, the primary use of metabolic models has been the development
of model-based measures to assess metabolic parameters, with a particular focus
on measuring insulin sensitivity [e.g. Bergman et al., 1979, 1981, 1985; Pacini and
Bergman, 1986; Yang et al., 1987; Mari, 1998; Mari et al., 2001, 2003; Lotz et al.,
2006b; Toffolo et al., 1999, 2006].
However, a model for glycemic control in the ICU needs to be applicable
for real-time clinical control, addressing the needs and limitations typical of most
ICUs. Metabolic models that are complex in physiological details, although accu-
rate given rigorous laboratory data, are not often practical for real-time glycemic
control utilising less frequent and noisier blood glucose measurements. Therefore,
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a model suitable for glycemic control in the ICU needs to satisfy the following
basic criteria:
• Accurately capture insulin and glucose pharmacokinetics, and glucose-insulin
pharmacodynamics typical of critically ill patients.
• Feature a simple structure preferably requiring only blood glucose levels as
physiological feedback.
• Address inter- and intra-patient variability over time.
• Have rapidly identifiable patient specific model parameters.
Given an accurate model satisfying these criteria, model-based glycemic con-
trol can offer individualised control adaptable to the critically ill patients’ highly
dynamic physiological condition. Furthermore, such a physiological model may
also be used as a patient simulator for protocol development given realistic pa-
tient specific parameters [Hann et al., 2005; Wong et al., 2006a; Lonergan et al.,
2006b,a]. Additional knowledge of critically ill population’s variable dynamics
can further enhance model-based control with more accurate predictive perfor-
mance.
1.5 Control Performance Measures
Understanding the difficulties and defining desired controller performance is the
first step to controller design. A variety of performance metrics have been used
in different critical care glycemic studies, with their differences often confounding
direct comparisons between studies. These metrics can be summarised as four
basic goals:
Average Blood Glucose Level: calculated over all measurements [Krinsley,
2003b, 2004] or over limited measurements, such as first morning measure-
ment [Van den Berghe et al., 2001, 2003]. The average is the simplest
performance measure and the one used in both landmark clinical studies.
However, it provides no further information on glucose excursions or tight-
ness of control. An important consideration is the use of a trapezoidal mean
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to obtain the proper mean value if the sampling period is irregular [Doran,
2004; Shaw et al., 2005]. In addition, an average value should utilise all
blood glucose measurements and not just a morning average, as in Van den
Berghe et al. [2001, 2006], which can hide variability and poor control.
Time in a Glycemic Band: calculated as the time or percentage of measure-
ments in a specific band, such as 4–6.1 mmol/L [Lonergan et al., 2006b;
Wong et al., 2006a,b] or 4.5–6.1 mmol/L [Plank et al., 2006]. Maximising
this metric is essentially equivalent to minimising the Hyperglycemic Index
(HGI) or area under the blood glucose level curve [Van den Berghe, 2004b;
Vogelzang et al., 2004]. This metric provides a surrogate measure of the
average value, as well as an indication of the tightness of the glycemic con-
trol result. Using multiple overlapping or contiguous bands provides a good
definition of the total glucose distribution under control.
Glucose Variability: measured as the standard deviation or 90% interval over
the data. This metric has only been employed recently [Chase et al., 2005a;
McDonnell et al., 2005] and measures the tightness of blood glucose control
around the average or target value. It is also increasingly important in man-
aging Type 1 diabetes [Kovatchev et al., 2004, 2005; Hirsch and Brownlee,
2005]. However, it provides no indication of the absolute glycemic levels
obtained and some methods assume normal or other statistical distribu-
tions that may not match the data. Hence, confidence intervals determined
from the data may prove more useful. Note that recent studies indicate
the variability in control may be a critical determinant of outcome [Chase
et al., 2007].
Hypoglycemic Episodes: measured as the number or percentage of measure-
ments that are below a defined hypoglycemic threshold. The typical defini-
tion is 2.2 mmol/L, although some studies use higher thresholds [Lonergan
et al., 2006b; Plank et al., 2006]. Variability also captures some of this
information when associated with the average or median glucose values.
More importantly, this measure is a critical indicator of the safety of the
control methods used.
To date, only the first metric, the average glucose value, has been correlated
with the clinical mortality outcome for different cohorts of patients. More specif-
ically, it is currently assumed, based on limited results to date, that tight control
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and mortality are linked by average glucose value obtained. However, recent
results also linked range and/or peak glucose values to critical care mortality
[Christiansen et al., 2004; Doran, 2004; Holm et al., 2004; Krinsley, 2003a; Shaw
et al., 2005], providing impetus to using other metrics as well. Finally, variability
indicating the tightness of control may also play a significant role in determin-
ing outcome [Chase et al., 2007], as well as reducing exposure to hyperglycemic
levels.
In addition, as discussed in Section 1.1, studies by Van den Berghe et al. [2001,
2003] and Krinsley [2003b, 2004] showed potential correlation between the level of
critical illness and achievable glycemic regulation, rather than achieving mortality
reduction more evenly across the cohort. Thus, using the same protocol with a
different cohort may not obtain substantially the same results, and similarly for
a different protocol on substantially the same cohort. Therefore, protocols that
produce similar results in one metric, but different outcomes in others, may have
different overall clinical outcomes.
Hence, a controller designed with a “well-balanced” goal that is adaptable to
different levels of illness would be considered ideal. Nevertheless, the consequent
protocol should fit inside the limitations of a given ICU’s clinical practice and
work flow. In particular, with the ICU being a very intense environment, minimal
labour requirements and good ergonomics are critical factors in control protocol
design, particularly for ensuring compliance and uptake of the resulting protocol
by clinical staff.
1.6 Critical Care Glycemic Control Summary
The significance of glycemic management in critical care is undeniable by the
17–45% reduction in mortality when average blood glucose levels are regulated
to between 6.1–7.75 mmol/L. This level of change or impact for a single clinical
protocol is rarely seen in intensive care research and represents a chance to cre-
ate an atypical disruptive step change in care. In addition, intensive care units
present a highly controlled environment ideal for model-based glycemic control
development and validation. Sharing similar insulin-glucose metabolic dysfunc-
tions, solutions to the critical care hyperglycemia problem may eventually extend
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to wider populations suffering from diabetes.
With current sensor technology allowing real-time control loops to be closed,
model-based glycemic control offers significant advantages over traditional ad-hoc
protocols where vicious cycles of hyper- and/or hypo- glycemia are not uncom-
mon. Hence, there are significant opportunities to improve safety and quality of
care. Model-based glycemic control thus offers the following advantages:
• It is accurate and adaptable to different patients
• It is adaptable to evolving critical illness
• It provides systematic glycemic reduction or regulation
• It will perform to specifically designed performance criteria
• It can deliver predictions of intervention outcomes
• It ensures better patient safety, particularly against hypoglycemia
The last two points are what drives the glycemic control development towards
model predictive control (MPC). These two qualities of MPC promise more in-
telligible glycemic control solution over other methods. Finally, during model
and controller design, ICU environment requirements and limitations must be
carefully considered, and the desired controller performance goals be carefully
chosen.
In the rest of this thesis, Chapter 2 presents a physiological model for model-
based glycemic control in the ICU, addressing the model requirements raised in
Section 1.4. Chapter 3 then presents the parameter identification method for fast
identification of model parameters. Control protocols are explored in Chapter 4,
where some clinical trial results are presented and controller performance matrices
discussed. Finally, the highly dynamic glucose-insulin metabolism of the critically
ill is studied and modelled in Chapters 5 and 6, creating a stochastic metabolic
control model to improve results. The consequent critical care patient simulator is
presented in Chapter 7. The thesis concludes in Chapters 8 and 9 with conclusions
and future avenues of suggested research effort.
Chapter 2
Glucose-Insulin Regulatory Model
The basis of many control problems is a dynamic system model. An accurate
biomedical control system model can capture, as well as predict, patient be-
haviour. Such a model offers a safe and fast means for protocol development
without the limitation of clinical data scarcity [Stokes, 2000].
For decades, the human glucose-insulin system dynamics have been exten-
sively studied, and models were created with different levels of detail and com-
plexity to suit different applications. The vast majority of existing models have
their roots in basic compartmental modelling with differential equations [Car-
son and Cobelli, 2001], and their complexity range from second [Lehmann and
Deutsch, 1992; Ackerman et al., 1965] to 19th [Parker et al., 1999] order. To date,
the primary use of metabolic models has been the development of model-based
measures to assess metabolic parameters, with a particular focus on measuring
insulin sensitivity [e.g. Bergman et al., 1979, 1981, 1985; Pacini and Bergman,
1986; Yang et al., 1987; Toffolo et al., 1999, 2006; Mari, 1998; Mari et al., 2001,
2003]. The main feature in the development of many metabolic models has been
increasing levels of physiological accuracy and/or resolution with a concomitant
increase in the number of patient specific parameters to be identified and the
overall model complexity.
In recent years, control-relevance has been getting more attention in metabolic
system modelling as the demand and potential for automated glycemic control
grows. Ideally, the most detailed physiological model can offer the most accurate
predictive control. Yet, with increasing model complexity and the concomitantly
increasing number of variables to be identified, clinically available data density
and control computation time caps the complexity of clinically feasible control
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models. Hence, control-relevant models need to be simple, yet accurately cap-
ture and predict clinical observations. In addition, critical care situations typi-
cally have a lesser amount of data available for fitting patient specific parameters
compared to the frequent sampling typical of clinical physiology studies. Con-
sequently, most clinical model-based control applications look for the simplest
model to be effective.
This chapter presents the essence of the glucose-insulin physiology, and ex-
amines several forms of existing metabolic control-relevant models. Finally, a
system model is presented with a suitable depth of dynamics for glycemic control
application in the intensive care environment.
2.1 Physiological Basis of the Glucose-Insulin System
Given the extensive history of metabolic modelling of the glucose-insulin system,
this thesis will not go into great length in this regard. In particular, a number
of very good reviews exist that offer a broader overview [e.g. Carson and Cobelli,
2001; Parker and Doyle, 2001; Ferrannini and Mari, 2004; Lehmann and Deutsch,
1996]. A briefer overview of the basic model types used for clinical glycemic
control is presented to illustrate the basic approaches employed in the field thus
far. For reference, the fundamental physiological basis of the glucose-insulin
system dynamics are illustrated in Figure 2.1.
Metabolic control systems and models start with titration models and con-
trollers, such as the bio-stator [Albisser et al., 1974]. However, perhaps the best
known model is the Minimal Model of Bergman et al. [1979, 1981]. This simple
compartment model has two equations for glucose disappearance, and one for
insulin kinetics:
Glucose disappearance:
G˙ = (X − P1)G(t) + P1Gb + P (t) (2.1)
X˙ = −P2X(t) + P3(I(t)− Ib) (2.2)
I˙ = −nI(t) + u(t)
V
(2.3)
Insulin Kinetics:
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Figure 2.1 Basic outline of the fundamental physiology of glucose sources, insulin sources
and their utilisation to remove glucose. Bi-directional arrows indicate potential for flow in both
directions of glucose and/or insulin. Exogenous insulin is assumed intravenously administered
in this case, and exogenous glucose appears via absorption from the gut or intravenous nutrition.
where t is the time, G(t) is the total plasma glucose concentration at time t, X(t)
is proportional to insulin action in a remote compartment, and I(t) is the plasma
insulin concentration. Inputs to the system include P (t), glucose appearance
from external glucose sources, and u(t), exogenous insulin. There are two terms
that define the steady state or basal plasma glucose and insulin levels under no
external influences, Gb and Ib. Three patient specific parameters, P1, P2 and P3,
arise from this model, with the ratio P3/P2 being the insulin sensitivity index.
Signs of P1 and P2 are changed from the original publication in Equations (2.1)
and (2.2) to have these parameters numerically positive valued per accepted sign
conventions. A graphical representation of this Minimal Model definition is shown
in Figure 2.2.
This model has since evolved into several forms, which are reported across a
wide range of the literature. Most of the existing compartment models used for
physiological studies or control have some origin in the Minimal Model. More
importantly, this model clearly illustrates the three basic dynamic terms that
must be captured for any glycemic control problem:
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1. Insulin pharmacokinetics and distribution — from exogenous input to ac-
tion in the periphery
2. Glucose pharmacokinetics and/or appearance, where meal models for P (t)
in Equation (2.1) would add compartments
3. Glucose-insulin pharmacodynamics accounting for the insulin-mediated re-
moval of glucose
For each point, more or less compartments or terms may be used, as compared
to Equations (2.1)–(2.3). Additionally, nonlinearities for specific observed, or
hypothesized, physiological dynamics may be added as necessary. Finally, terms
or parameters may be re-defined such that they look similar in these equations,
but have somewhat different physiological meanings. Thus, this model is a basis
for most compartment models that followed, although significant evolution has
occurred since its introduction.
However, the Minimal Model has some significant limitations, particularly
with regard to use in clinical glycemic control [Doran et al., 2004a,b]. More
specifically, it does not account for saturation of glucose removal by insulin [Pri-
geon et al., 1996; Natali et al., 2000; Rizza et al., 1981], saturation of insulin
transport [Thorsteinsson, 1990; Frost et al., 1973; Ellemann et al., 1987; Prigeon
et al., 1996], measurable and unmeasurable glucose compartments [Cobelli et al.,
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1992, 1999; Vicini et al., 1997; Caumo et al., 1999], or the dynamics of insulin
receptors and their mass [Hovorka et al., 2004], to name a few. All of these issues
have been raised in the extensive physiological modelling literature, and several
modified versions of this model developed as a result.
Another low-order model developed for glycemic management was created by
Salzsieder et al. [1990a], and focused on Type I diabetes. This model has been
verified in dogs [Salzsieder et al., 1985; Fischer et al., 1987], as well as humans
[Salzsieder et al., 1990a,b; Fischer et al., 1990]. The third order differential equa-
tion system contains glucose (G) and insulin (I) effects, as well as overall net
endogenous glucose balance (EGB):
G˙ = EGB(t) + CHO(t) (2.4)
˙EGB = −(b1 + b2)EGB(t)− b3(I(t) + I∗(t)) + b1(b0 − CHO(t)) (2.5)
I˙ = −kI(t) + Iexg(t) + IG(t) (2.6)
where G(t), the blood glucose concentration, and I(t), the plasma insulin, are
both measurable state variables. The net overall endogenous glucose balance,
EGB(t) is not directly measurable. Five patient specific model parameters k and
bi (i = 0, . . . , 3) are to be identified. Absorption patterns of meals are described
by CHO(t), and Iexg is the exogenous insulin. IG(t) is the artificial beta cell
algorithm developed by Salzsieder et al. [1990a] for feedback control. I∗ is the
insulin equivalent of muscular exercise. The symbols in Equations (2.4)–(2.6)
are modified from the original paper for easy readability and consistency in this
thesis. This model can be presented graphically, as shown in Figure 2.3
This model is successful at capturing steady state behaviour and slow dy-
namics for Type I diabetics. However, the model has incomplete representation
of kinetics in glucose utilisation after interruption of insulin therapy, and overes-
timates glucosuria in the presence of insulin [Fischer et al., 1990]. These short-
comings are a result of under-modelling the insulin compartment, which is also a
major identified weakness of the Minimal Model [Doran et al., 2004a,b].
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Figure 2.3 Glucose-insulin model of Salzsieder et al. [1990a,b]
At the other end of the spectrum of model complexity, the most detailed
control-relevant physiological model to date is the 19th order compartmental
model of Parker et al. [1999]. This model was also developed for glycemic man-
agement of Type I diabetic patients. A schematic of the model is shown in Figure
2.4 with several compartments or other terms defined for each box shown in the
figure.
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Figure 2.4 Schematic of the glucose-insulin system model of Parker et al. [1999]
Individual compartment models within the boxes shown are obtained by mass
balance, and the brain and periphery represents slow or delayed effects. With
measurements from a continuous glucose measuring (CGM) system, this model
was designed for model predictive control (MPC). However, as current CGM
sensors lack the desired clinical accuracy, studies by Parker et al. [1999, 2001]
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showed successful simulation results that are yet to be fully realised in clinical
testing. Nevertheless, the model is physiologically faithful to all known dynamics.
Another major issue with such a detailed and complex model is computational
time involved in patient parameter identification. The use of a ”nominal patient”
with parameters based on mean values reported in the literature can reduce com-
putational intensity, making MPC possible with such a model [Parker and Doyle,
2001]. However, careful sensitivity studies must be carried out to identify criti-
cal parameters, which should be patient specific, such as insulin sensitivity, and
thus ensure crucial dynamics are not lost through over-simplifying the parameter
identification process and/or over over-reliance on population parameters.
Finally, another model was designed for MPC by Hovorka et al. [2004], and
was originally intended for Type I diabetic patients. However, it has recently
been taken in similar form into an intensive care unit control setting [Plank
et al., 2006]. A graphical representation of this model is shown in Figure 2.5.
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Figure 2.5 Glucose-insulin compartmental model of Hovorka et al. [2004]. Q1 and Q2 are
glucose masses in the accessible and inaccessible compartments, I is plasma insulin, xi represent
insulin action of glucose transport, disposal and endogenous glucose production.
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This model features many different transfer rates ki between compartments
and losses. EGP0 represents endogenous glucose production (EGP) extrapolated
to zero insulin concentration. F c01 is the total non-insulin-dependent glucose flux,
and is dependent on F01 to be identified for individual patients:
F c01 =
 F01 if G ≥ 4.5 mmol/LF01G
4.5
otherwise
(2.7)
FR is the renal glucose clearance defined:
FR =
{
0.003(G− 9)VG if G ≥ 9 mmol/L
0 otherwise
(2.8)
Overall, the model uses 9 population values or generic constants, and requires a
further 6 patient specific parameters to be identified. Nonlinearity comes from
insulin action on parameters of glucose production, glucose distribution/transport
and glucose disposal, and difference in the activation/deactivation profile of the
three insulin actions.
All these models were developed with control-relevance in mind. They all
share some fundamental similarity in the way that they each address the basic
glucose-insulin interaction. Greater degrees of detail are added according to the
different focus of each group. In particular, Salzsieder et al. [1990a], Parker et al.
[1999] and Hovorka et al. [2004] all considered non-linearities in their models to
better match clinically observed dynamics. Nevertheless, the Minimal Model,
being “minimal”, still captures the essential glucose-insulin dynamics, and has
thus served as a starting point for countless studies.
In the next section, a Glucose-Insulin Regulatory model is developed from the
Minimal Model. This model proposes a balance between simplicity and accuracy
to best address control-relevance in the intensive care units. In particular, model
parameters must be identifiable without intensive data collection to suit an ICU
environment. The Minimal Model is used as a starting point because it describes
the fundamental dynamics in the simplest form. Model non-linearities are added
to improve necessary control accuracy while maintaining the generalisability of
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the model, particularly with respect to data acquisition limitation in the critical
care environment.
2.2 Glucose-Insulin Regulatory Dynamic System Model
for Critically Ill Patients
Intensive care units represent a highly controlled environment where most glucose-
insulin system inputs and outputs can be accounted for and modelled. The Mini-
mal Model by Bergman et al. [1981] is a simple model that effectively captures the
fundamental dynamics of the glucose-insulin system. Thus it serves as a starting
point in this thesis for developing a control-relevant dynamic system model. How-
ever, several significant changes required to create a more physiologically relevant
and more clinically accurate model are discussed in detail in this section.
As identified by various groups over the years, the first required addition
to this model is one that accounts for un-utilised insulin in the blood plasma or
insulin that has bound and then unbound to cell walls, tissues or insulin receptors.
This addition has a similar effect to splitting the insulin compartment into a slow
path and a fast path, which indicates the existence of fast and slow absorption
channels and the presence of local insulin degradation [e.g. Cobelli et al., 1999;
Turnheim and Waldhausl, 1988; Hovorka et al., 2003]. Hence, it defines a more
accurate pharmacokinetic model for insulin distribution.
More specifically, Turnheim and Waldhausl [1988] studied the pharmacoki-
netic modelling of intravenous insulin injection, and concluded that the concen-
tration of plasma insulin following a bolus injection declines with at least two
exponentials or two different rates. The first is a rapidly disappearing compo-
nent of insulin representing elimination from the intravascular space, and the
second is a more slowly disappearing component that reflects elimination from
the interstitial fluid and the tissues that utilise insulin. These two components
have mean half-lives of 2.4 and 50–130 min, respectively.
Next, during the 1970s and 1980s, several papers were published regarding the
plasma insulin disappearance kinetics in humans. Many found flaws in the first
order (linear) assumptions of insulin disappearance that had been predominantly
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used in previous models [e.g. Cobelli et al., 1999; McGuire et al., 1979]. These
flaws were assumed to be based on the narrow range of insulin levels studied,
with the first reported non-proportionality between plasma concentration and
plasma disappearance rate published by Sonksen et al. [1973]. Other experimen-
tal studies were undertaken considering the concentrations resulting from a series
of intravenous insulin infusions at different rates in both normal and diabetic sub-
jects, as reviewed in Thorsteinsson [1990]. These studies concluded that insulin
disappearance is often governed by Michaelis-Menten saturation dynamics.
In addition, insulin mediated glucose clearance is controlled primarily by
insulin sensitivity, which links insulin concentration and glucose levels. As the
dose of exogenous insulin is increased in controlled hyperglycemic clamp studies,
insulin sensitivity decreased [Prigeon et al., 1996]. This result occurs because the
effect of insulin saturates at the receptor and/or in transport, limiting utilisation
[Natali et al., 2000]. Hence, there is a need for a saturable mechanism on insulin
action. Natali et al. [2000] added Michaelis-Menten saturation of insulin action
on fractional glucose extraction in a circulatory model, and obtained good fits
to clinical data with limitations only occurring in the first 60 min, which were
attributed to an irregular onset of insulin action during this initial phase.
Finally, to reduce model complexity and better match known physiological
responses, a term must be included to suppress endogenous insulin secretion
during periods of high exogenous insulin infusion [DeFronzo et al., 1979]. This
situation is often encountered in critical care where relatively high insulin infusion
rates are not uncommon [e.g. Van den Berghe et al., 2001; Doran et al., 2004a].
These large doses occur primarily due to the high levels of insulin resistance
encountered in these patients when they are hyperglycemic.
The glucose-insulin regulatory system model developed by adding all these
terms and modifications is significantly different from the Minimal Model. It is
presented in Equations (2.9)–(2.13), which also includes a simple two compart-
ment model for glucose appearance under enteral infusion feeding. A schematic
of the model is shown in Figure 2.6.
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Figure 2.6 Glucose-insulin regulatory model for critically ill patients
G˙ = −pGG− SI(G+GE)
(
Q
1 + αGQ
)
+
P (t)
VG
(2.9)
Q˙ = −kQ+ kI (2.10)
I˙ =
−nI
1 + αII
+
uex(t)
VI
+
IBe
−Cuex(t)
VI
(2.11)
P (ti < t < ti+1) = P¯i+1 + (P (ti)− P¯i+1)e−kpd(t−ti) where P¯i+1 < P (ti) (2.12)
P (ti < t < ti+1) = P¯i+1 + (P (ti)− P¯i+1)e−kpr(t−ti) where P¯i+1 > P (ti) (2.13)
The symbols G [mmol/L] denotes the glucose above an equilibrium level, GE
[mmol/L], and I [mU/L] is the plasma insulin resulted from exogenous insulin
input. The effect of previously infused insulin being utilized over time in the
interstitium is represented by Q [mU/L], with k [1/min] accounting for the effec-
tive life of insulin in the system. Patient endogenous glucose removal and insulin
sensitivity are pG [1/min] and SI [L/mU/min] respectively. The parameter VI [L]
is the insulin distribution volume and n [1/min] is the constant first order decay
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rate for insulin from plasma. External nutrition and insulin input are expressed
in P (t) [mmol/min] and uex(t) [mU/min] respectively. In Equations(2.12)–(2.13),
kpr [1/min] and kpd [1/min] are the rise and decay rates of exogenous (enteral)
plasma glucose appearance, and P¯i and P¯i+1 are the stepwise consecutive en-
teral glucose feed rates used to model dextrose control. The glucose distribution
volume is VG [L]. Michaelis-Menten functions are used to portray saturations,
with parameter αI [L/mU] used for saturation of plasma insulin disappearance,
and αG [L/mU] for saturation of insulin-stimulated glucose removal. Endoge-
nous insulin production is IB [mU/min] under no presence of exogenous insulin.
The constant C defines the suppression of endogenous insulin production in the
presence of exogenous insulin.
This model has two patient specific parameters, pG and SI . These two pa-
rameters are the critical parameters that distinctively describe the dynamics be-
tween different patients and the dynamics within a single patient. By identifying
these parameters, which are time-varying, for each individual, the model is thus
adaptive to different patients under different metabolic conditions. Both param-
eters exist in the G˙ equation in Equation (2.9). Therefore, the identification of
these parameters only requires measurements in blood glucose levels, G. This
specifically addresses the glycemic control requirements/limitations in an ICU
environment where measurement in Q is not available and the lab turnaround
time for plasma insulin concentration I measurements is too long to be real-time
control applicable.
2.2.1 “Effective” Insulin and Losses
The convolution integral solution to Equation (2.10), Q, represents the “effective”
insulin. This term accounts for un-utilised insulin in the interstitium [Guyton and
Hall, 1996] or insulin that had bound and then unbound to cell walls, tissues or
insulin receptors [Duckworth and Kitabchi, 1981]. Other models typically use
multiple compartments to capture a similar effect, such as the multiple glucose
compartments and paths used in Hovorka et al. [2002, 2003]. This glucose parti-
tioning approach is quite common in various forms [e.g. Carson and Cobelli, 2001;
Callegari et al., 2002; Ollerton, 1989]. In addition, the use of long and short acting
insulin compartments [Hovorka et al., 2002, 2003] provides a similar spreading of
insulin-glucose utilisation over time, as represented by the convolution integral,
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Q. Hence, Q represents the insulin ready in the interstitium for action that has
appeared from the plasma compartment and not yet been utilised.
Existing reported interstitially bonded, or effective, insulin half-life values
associated with intravenous administration range from 25 to 130 minutes [e.g.
Natali et al., 2000; Mari and Valerio, 1997; Turnheim and Waldhausl, 1988].
When the effective insulin half-life parameter, k, approaches infinity, the term
approaches the instantaneous blood insulin concentration, which is analogous to
the Minimal Model of Bergman et al. [1981]. A summary of the definition and
reported clinical values of k, which defines the spreading of insulin action by
transport to the interstitium and its action there, is found in Doran [2004].
The value of k is less than n in Equation (2.11). Therefore, n−k is effectively
the irreversible loss of insulin going from blood plasma to the interstitium. This
loss occurs in the kidneys and liver, and/or as a result of saturation effects that
limit immediate utilisation. More detailed analysis and validation can be found
in [Lotz et al., 2006b].
2.2.2 Saturation Dynamics
The model has been developed to account for a non-linear saturation of exogenous
insulin disappearance rate from plasma in Equation (2.11) and its saturable utili-
sation to reduce blood glucose levels in Equation (2.9). The addition of transient
insulin kinetics via a convolution integral accounts for the accumulation dynamic
seen in prior clinical trials [Doran et al., 2004a], and better matches physiologi-
cal knowledge. This model therefore effectively splits the glucose compartment
into fast and slow (or available and unavailable) compartments over a continuum
rather than discrete states [e.g. Vicini et al., 1997].
Many studies have investigated insulin saturation in vivo. Prigeon et al. [1996]
demonstrated that as peak plasma insulin concentration increases in vivo, insulin
sensitivity, as derived from the Minimal Model drops, which provides evidence
for insulin saturation in the underestimation of SI using the Minimal Model.
Prigeon et al. [1996] proposed two saturable sites; one for insulin transport from
plasma to interstitial sites, the other for insulin action. Many other studies have
also supported one or both of these two saturation mechanisms [e.g. Natali et al.,
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2000; Thorsteinsson, 1990]. Both saturation mechanisms are included in this
model using Michaelis-Menten functions in Equations (2.9) and (2.11).
In Equation (2.11), the disappearance rate of insulin from plasma is directly
proportional to the plasma insulin concentration at low plasma insulin level, but
becomes independent of the plasma insulin level when plasma insulin concen-
tration exceeds a certain threshold. Thorsteinsson [1990] suggested that insulin
removal rate from plasma obeys saturation kinetics that can be expressed as a
Michaelis-Menten function. In Chase et al. [2003], clinical results also suggested
the presence of insulin pooling in plasma, where the effect of insulin on glucose
removal appeared significantly belated. To account for insulin pooling in plasma,
particularly at high doses, the parameter, αI , in Equation (2.11) bounds the
plasma insulin disappearance rate, as shown in Figure 2.7.
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Figure 2.7 Saturation in plasma insulin removal rate
Saturation in insulin-stimulated glucose removal has been evidenced in sev-
eral clinical investigations. Prigeon et al. [1996] reported that insulin sensitivity
decreases as peak plasma insulin concentration increases. Caumo et al. [1999]
also reported decreased insulin sensitivity with increased plasma insulin level,
and that insulin sensitivity becomes independent of plasma insulin level as in-
sulin level increases beyond ∼40 [mU/L]. The Michaelis-Menten parameter, αG,
in Equation (2.9) defines the saturation mechanism on insulin-stimulated glu-
cose removal. The inverse of αG represents the level of insulin integral, Q, or
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delayed insulin, at which the insulin-stimulated glucose removal rate reaches half
maximum.
2.2.3 Equilibrium Blood Glucose
In Equation (2.9), GE is the equilibrium blood glucose level, whereas Bergman
et al. [1981] used the basal blood glucose level. This parameter represents the
patient specific equilibrium state under constant feed and insulin infusion. Due
to ongoing exogenous insulin infusion and carbohydrate nutrition, basal blood
glucose level is difficult to determine for ICU patients. In general, GE can be
obtained for a patient under steady conditions or as a long term moving average
[Hann et al., 2005]. The presence of insulin and/or dextrose infusion does not
affect the physiological meaning of this term.
2.2.4 Endogenous Insulin Production
Equation (2.11) includes the term IB exp
−Cuex(t) as the endogenous insulin pro-
duction rate. Under presence of significant exogenous insulin, uex(t), the en-
dogenous insulin production may be suppressed and effectively removed from the
model. This dynamic reduces model complexity and matches accepted assump-
tions for the suppression of endogenous insulin production by exogenous infusion
[Insel et al., 1975; DeFronzo et al., 1979; Ellemann et al., 1987; Transberg et al.,
1981].
In this model, knowing the possibly variable level of IB between patients is
not critical. As this model is developed for use in intensive care glucose control
applications, exogenous insulin is almost always present and often at higher lev-
els. Therefore, the inclusion of this term is more for physiological completeness,
rather than metabolic control accuracy. Although it may be ignored when study-
ing most critical care intensive insulin therapies, removing this term completely
from Equation (2.11) can sometimes result in the steady state plasma insulin
concentration of zero, which is physiologically inaccurate.
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In reality, the endogenous insulin production rate is highly variable and diffi-
cult to obtain quickly or accurately as it requires basal insulin and/or C-peptide
measurements not typically or quickly available in the ICU [e.g. Ferrannini and
Cobelli, 1987a; Ferrannini et al., 2005; Sherwin et al., 1974; Van Cauter et al.,
1992; Ellemann et al., 1987]. In addition, many hyperglycemic critically ill pa-
tients have been found to be also severely hyperinsulinaemic due to large insulin
doses and/or excess endogenous insulin. This is a result of high insulin resistance
and impaired glucose-insulin regulation. Overestimating a patient’s endogenous
insulin production rate can therefore lead to a controller seeing the patient as
more insensitive to insulin, and thus administering a large amount of insulin that
can result in a hypoglycemic episode. Hence, from a control and physiological
standpoint, it is safest to under estimate its value.
In conclusion, the effect of endogenous insulin is thus primarily included in
the time-varying parameter, pG, that represents the body’s ability to regulate
blood glucose without exogenous insulin during insulin therapies. This approach
essentially presents each patient as a clean slate, which is captured in a patient
specific pG, without making assumptions for clinically unavailable data, IB. This
approach, given the relatively smaller contribution of the −pGG term ensures
any endogenous insulin action is captured without relying on potentially poor
estimates of endogenous insulin. Note that IB may be used directly, as in other
models, if it is regularly measured, which does not occur in critical care. The
consequent result is overall safer insulin administration.
2.2.5 Dextrose Modelling and Control
In this model, non-steady stepwise enteral glucose rate fluxes may also be em-
ployed for control in Equations (2.12)–(2.13). Postprandial glucose kinetics for
an oral glucose load and continuous feeding are characterized by suppression of
net hepatic glucose output [Abumrad et al., 1982; Kiwanuka et al., 2001; Lud-
vik et al., 1997; Radziuk et al., 1978]. Time periods for complete absorption of
an oral glucose load range from 120 to 270 min [Radziuk et al., 1978; Abum-
rad et al., 1982; Cummins, 1952; Consoli, 1992; Ludvik et al., 1995] with a peak
ingested glucose appearance in plasma after 15–40 min [Radziuk et al., 1978;
Ferrannini et al., 1988]. Slower absorption was evidenced in a mixed-meal for-
mulation [Kiwanuka et al., 2001; Pehling et al., 1984]. A high percentage of oral
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glucose appears systemically due to a small first-pass splanchnic uptake [Radziuk
et al., 1978]. Whether such dynamics are applicable to non-steady-state enteral
glucose infusions, where variations in glucose load are much smaller, is unknown.
However, Radziuk et al. [1978] showed no discernible difference in systemic oral
glucose appearances with a half-sized oral glucose load.
The exponential rates for the rise and decay of exogenous glucose appear-
ance, kpr and kpd, are used to simply model the effect of transient net hepatic
glucose output and glucose disposal. Impaired splanchnic and peripheral glu-
cose uptake in diabetes and stress induced hyperglycemia imply a slow decay in
glucose appearance following nutritional feed reduction [Kiwanuka et al., 2001;
Ludvik et al., 1997; Nielsen et al., 1998; Basu et al., 2004, 2001; Firth et al.,
1985]. The rate of peripheral appearance of oral glucose is approximately equal
to the intestinal absorption rate, which implies a rapid rise in glucose appearance
following a nutritional feed increase [Radziuk et al., 1978].
2.2.6 Endogenous Glucose Removal, pG, and Insulin Sen-
sitivity, SI
The most critical model parameters for fitting and prediction accuracy are the
time-varying parameters pG and SI [Hann et al., 2005]. In earlier work by Chase
et al. [2003], the Minimal Model was simplified into a two-compartment model.
This simplified model has two patient specific parameters p1 and p4, which are
essentially P1 and the ratio P3/P2 from the Minimal Model of Equations (2.1)–
(2.3). However, in the model of Equations (2.9)–(2.13), pG and SI have very
different physiological meanings from p1 and p4 in Chase et al. [2003] and the
similar parameters in the Minimal Model [Bergman et al., 1981]. Hence, these
parameters and their time-varying definitions are a primary difference in this
model from its origins.
The model also does not include a specific endogenous glucose production
term, as it is suggested to be at least partly suppressed with significant insulin
administration in both normal and stressed states [Thorell et al., 2004]. In clinical
settings and particularly critical care, endogenous glucose production is not read-
ily measurable, which would make it difficult to accurately include in a model.
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In addition, no literature has yet reported satisfactory estimates or models for
this dynamic, especially in critical care. The effect of endogenous glucose pro-
duction in this model is therefore mitigated into pG, simplifying the model and
providing a reference inter- and intra-patient. Increased endogenous production
rates will thus be absorbed and reflected as lower values of pG, whether consis-
tently or varying over time. Overall, pG thus represents the balance between
endogenous insulin action, non-insulin mediated glucose removal and endogenous
glucose production, all in a single patient specific term.
The definition and methods of determining insulin sensitivity have been ex-
tensively studied, primarily in clinical diabetes research settings. Many stud-
ies suggest insulin sensitivity is highly dependent on experimental protocol and
the dynamic model adopted [e.g. Bettini et al., 1995; Caumo et al., 1999]. Hy-
perinsulinaemic euglycemic clamp tests with different levels of plasma insulin
concentration also give very different insulin sensitivity levels, including intra-
individual variation and saturation effects [Natali et al., 2000; Prigeon et al.,
1996; Katz et al., 1993; Beard et al., 1986; Saad et al., 1994]. In Equations (2.91)
to (2.11), the added saturation mechanism on the effect of insulin thus creates a
unique index of insulin sensitivity, SI , in contrast to other model-based measures.
This approach allows SI to (potentially) more closely approximate the true tissue
sensitivity to insulin. Overall, the SI term represents the effective insulin sen-
sitivity, in inverse proportion to insulin resistance, of the specific patient. It is
uniquely independent of insulin transport and saturation dynamics in this model
formulation.
2.3 Control Model Comparison and Summary
The Minimal Model has been studied widely because of its simplicity and effective
portrayal of the basic dynamic of the glucose-insulin regulatory system. The
model developed for glycemic control in critical care in this chapter kept a simple
structure, while addressing the Minimal Model’s observed clinical inadequacies
for critical care glycemic control. As a result, while structurally similar, the
model presented is significantly different in dynamics and physiological relevance
or accuracy. Table 2.1 compares the model developed in this chapter with the
four models studied in Section 2.1.
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Compared with the Minimal Model of Figure 2.2, the critical care control
model of Figure 2.6 has a more physiologically identified form. The Minimal
Model’s final form in Equations (2.1)–(2.3) lumped many metabolic effects to-
gether, such as interstitial transport rates and different losses in the system.
The model of Equations (2.9)–(2.11), in contrast, is more representative of non-
abstract compartments by definition.
First, the concept of a “remote” insulin action compartment X in the Min-
imal Model is harder to grasp, compared to the interstitial compartment Q in
Equation (2.10). This latter interstitial compartment has been widely studied,
with transport rates experimentally identified [e.g. Nestler et al., 1988; Natali
et al., 2000; Prigeon et al., 1996; Turnheim and Waldhausl, 1988; Kraegen and
Chisholm, 1984]. Second, the different transport/rise/decay rates such as k, pG
and SI have non-abstract physiological meanings for interstitial transport rate,
endogenous glucose removal and insulin sensitivity, which are also widely studied
and can be experimentally tested [e.g. Araujo-Vilar et al., 1998; Avogaro et al.,
1989; Bettini et al., 1995; Prigeon et al., 1996; Kraegen and Chisholm, 1984;
Vicini et al., 1999; Pillonetto et al., 2002]. Many of these studies, although ini-
tiated with the Minimal Model, designed experiments that specifically test for
insulin sensitivity, which is not explicitly expressed in Equations (2.1)–(2.3). In-
stead, insulin sensitivity is the ratio of −P3/P2 where P2 is numerically negative
in the original paper by Bergman et al. [1979, 1981], and can thus end up being
identified with pooling errors [Caumo et al., 1999; Vicini et al., 1999], giving rise
to a current ratio, but incorrect magnitudes for the transport rates P2 and P3.
Additional features that significantly differentiate the critical care model of
Figure 2.6 from the Minimal Model of Figure 2.2 are the two saturation dynamics
and suppression of endogenous insulin production in the presence of exogenous
insulin. These non-linear features are also important in clinical glycemic control
where exogenous insulin utilisation must be accurately captured to enable safe
and precise insulin control.
In further comparison, the model developed by Salzsieder et al. [1990a] of
Figure 2.3 is also simple, and had been verified in dogs [Salzsieder et al., 1985;
Fischer et al., 1987], as well as humans [Salzsieder et al., 1990a,b; Fischer et al.,
1990]. However, this model, being focused on Type I diabetic patients, is not
particularly suitable for critical care. The implementation of model-based con-
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trol by Salzsieder et al. [1990a] also required long term study of a patient’s meal
and exercise patterns, which is not suitable in critical care. As a result, param-
eter fitting is computational intensive, and therefore not suitable for real-time
clinical control. Rapid, real-time parameter identification is very important in
model-predictive control to address time-variability of parameters, as many re-
cent studies have pointed out the importance of accounting for both inter- and
intra-patient variabilities [Parker and Doyle, 2001; Parker et al., 2001; Hovorka
et al., 2004].
The much more complex models developed by Parker et al. [1999] of Figure
2.4 has limited applicability in clinical control, as a result. Although the model
has a very detailed physiological structure and offers the most precise picture of
glucose-insulin metabolism, many assumptions and population parameter values
need to be placed for the model to be useable in real-time clinical control. Hence,
this well-structured model is no more suitable than a simpler, much more easily
identified model.
The model of Hovorka et al. [2004] has a greater breakdown of the glucose
and the insulin actions compared to the Minimal Model. The six compartments
exhibit complex dynamics and interactions between each other. This model has
recently been applied in critical care glycemic management and achieved promis-
ing results [Plank et al., 2006]. However, with 6 patient specific parameters to be
identified, trade-offs between parameters must be cautiously reviewed to maintain
their true physiological meanings and clinical accuracy.
In summary, the model developed in this chapter, presented in Equations
(2.9)–(2.13) and Figure 2.6 is particularly developed for ready clinical applica-
bility. Having a robust model that is adaptable to any patient, while being
physiologically valid and simple, is more the focus of its development than being
metabolically correct in every detail. The model features an interstitial compart-
ment for insulin storage to account for the delay between insulin secretion, or
infusion, and utilization. Saturation dynamics reflect plasma insulin pooling and
saturable interstitial insulin effect, addressing these shortcomings of the Minimal
Model in clinical control applications [Doran et al., 2004a,b; Hann et al., 2006].
Hence, it has all significant clinically observed and relevant linear and non-linear
dynamics, without excessive terms, complexity or dynamics.
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In particular, the four other models studied in this chapter all require exten-
sive data sampling and parameter identification. This significantly disadvantages
the use of these models for clinical glycemic control in a critical care environment
where data sampling is generally infrequent. Parker et al. [1999] designed their
model to be incorporated with a CGM system. However, current CGM technol-
ogy still lacks the measurement accuracy and reliability to achieve the simulated
results presented in Parker et al. [1999]. On contrast, the model developed in
this chapter requires only two parameters to be identified, utilising infrequent
blood glucose measurements alone. Hence, this model is particularly suitable for
control application in the critical care environment.
Finally, the model has been verified using critical care patient data [Hann
et al., 2006] and tested clinically [Chase et al., 2005b,c; Wong et al., 2006a,b; Lon-
ergan et al., 2006a]. These clinical results and related parameter identification
methods are presented and discussed in detail in Chapters 3 and 4. In partic-
ular, the parameter identification method developed in the next chapter further
assesses the generalisability of the model, and enhances its adaptability. Overall,
this model represents a balanced tradeoff of complexity and non-linearity versus
simplicity with respect to the other models presented, which span a range of
these tradeoffs. An overall and detailed review of models in critical care glycemic
control may also be found as part of the review by Chase et al. [2006b].
Chapter 3
Parameter Identification and Dynamic System
Model Validation
To better control glucose levels, model-based [Chee et al., 2003a,b; Plank et al.,
2006; Chase et al., 2005c; Wong et al., 2006a,b] and titration-based or sliding-
scale protocols [Van den Berghe et al., 2001, 2003; Krinsley, 2004, 2003b; Albisser
et al., 1974; Goldberg et al., 2004b; Laver et al., 2004] have been clinically tested.
Model-based methods can be very accurate, but require the ability to identify
patient specific parameters and capture all of the observed dynamics [Chase
et al., 2006b]. Currently, most common parameter identification methods are
non-linear, non-convex and in some cases too computationally intense for real-
time use in most clinical environments [Hovorka and Vicini, 2001]. This chapter
presents an integral-based fitting method for the glucose-insulin system model in
Equations (2.9)–(2.13).
This method has been used in Chase et al. [2005c] and Wong et al. [2006a,b].
The method mathematically reformulates the physiological model for critical care
patients in terms of integrals or areas under the curve(s). As a result, identifying
time-varying patient specific parameters within physiological constraints becomes
linear and convex with minimal computation required, creating a relaxed optimi-
sation for this parameter identification problem.
A fast, accurate identification method is important in the process of refining
and testing a model as many more patients can be studied in a short time. For
non-linear or non-convex methods, any fitting or prediction error can be due to
the model not capturing dynamics or, instead, due to finding a local, rather than
the global, minima. Hence, it can become difficult to differentiate model error
or inadequacy from non-optimal local minima solutions. Using many different
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starting points may find a better, more globally optimal solution, but at the cost
of significantly increased computational time. However, there is still only a prob-
ability of finding the global minimum, rather than the certainty provided by a
convex method. More importantly, a fast, accurate convex method enables con-
fident application in real-time model-based control and medical decision support
applications.
This chapter presents a convex parameter identification method for the non-
linear dynamic system model presented. This method is then used to validate
the model’s ability to fit and predict blood glucose data using nearly 1,300 hours
of retrospective critical care patient data. Parameter values and their sensitivity
are then analysed for robustness and the results summarised.
3.1 Integral-Based Parameter Identification Method
To simplify and linearise the optimisation problem, the parameters VI , VG, n, k,
αG, αI , IB, kpd and kpr in Equations (2.9)–(2.13) can be obtained a priori via the
results of an extensive literature search [e.g. DeFronzo et al., 1979; Turnheim and
Waldhausl, 1988; Thorsteinsson, 1990; Prigeon et al., 1996; Natali et al., 2000;
Doran, 2004]. They are assumed to be non-patient-specific or population-based
constants. In addition, sensitivity analysis shows these parameters are insensitive
[Hann et al., 2005] or tradeoff directly with other parameters [Chase et al., 2004].
Thus, in the latter case, some must be held constant at validated population
values to restrict identification error. Finally, many are also found to have tight
population ranges in the literature indicating little variability between patients
[Doran, 2004], and thus allowing them to be more safely held constant in this
model.
The exogenous feed details P (t) and exogenous insulin uex(t), are control
inputs in a glycemic control problem, and therefore known for parameter identi-
fication. The equilibrium glucose level, GE, can be estimated for a patient under
stable insulin and dextrose infusion as a longer term 12–24 hour moving average.
Finally, pG and SI are left to be identified as time-varying patient specific model
parameters.
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This approach can be thought of as a minimal approach where the major
dynamics are identified first (SI and pG) before secondary parameters can be
modified to better fit the data if required. It is therefore important to ensure
the fitting method for identifying time-varying patient specific parameters is as
least demanding computationally as possible. This way other parameters can be
varied (if required) without significantly affecting the overall computation time.
Computational time is a significant factor to consider in real-time clinical control,
as well as in the process of refining and testing the model on large numbers of
patients or large retrospective data sets, as it directly impacts the turnaround
time between data input and decision making.
Integrating both sides of Equation (2.9) and defining the overall saturated
insulin action in the interstitial compartment as Q¯:
Q¯ = Q/(1 + αGQ) (3.1)
In addition, glucose appearance rate per volume of plasma is redefined as PV :
PV = P (t)/VG (3.2)
The following expression holds for any segment of time from t0 to t:
∫ t
t0
G˙dt =
∫ t
t0
−pGG− SI(G+GE)Q¯+ PV dt
⇒ G(t)−G(t0) = −
∫ t
t0
pGG dt−
∫ t
t0
SI(G+GE)Q¯ dt+
∫ t
t0
PV dt (3.3)
Substituting the total blood glucose level, GT :
GT = G+GE (3.4)
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into Equation (3.3) results in an equivalent expression that is easy to compute
numerically, given measured total glucose levels:
GT (t)−GT (t0) = −
∫ t
t0
pG(GT −GE) dt−
∫ t
t0
SIGT Q¯ dt+
∫ t
t0
PV dt (3.5)
To reduce computational complexity and account for variation over time, the
total time interval is divided into equal segments during which pG and SI are
defined as piecewise constant:
pG =
N∑
i=1
pGi (H(t− ti−1)−H(t− ti)) (3.6)
SI =
N∑
i=1
SIi (H(t− ti−1)−H(t− ti)) (3.7)
where H(t − t0) is the Heaviside function defined H(t − t0) = 0 when t < t0,
and H(t − t0) = 1 , when t ≥ t0. Note that the value of N in Equations (3.6)
and (3.7) may be different depending on the number of hours used per segment.
Finally, the variation in Equations (3.6) and (3.7) can also be defined as linear
or higher order, over these time periods for greater detail, at a cost of increasing
the number of unknown parameters required to parameterise pG and SI over a
given period of time. Other parameters or different length time segments may
also be used with no loss of generality.
The only unknown parameters in Equation (3.5) are pGi and SIi when Equa-
tions (3.6) and (3.7) are used. However, these are constant parameters, such that
after numerically integrating the data, Equation (3.5) can be written as a simple
linear system in terms of these unknown values:
A
[
pGi
SIi
]
= b (3.8)
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where the number of equations for each time segment can be arbitrarily selected
by integrating over different time segments. To ensure that the values obtained
for pG and SI are within physiologically valid ranges, weighted constraints can
be placed on both parameters when solving Equation (3.8).
To compute the integrals in Equation (3.5) over different time segments, the
total blood glucose profile, GT , is approximated using simple linear interpola-
tion between the data points, forming a piecewise linear curve GT−approx. The
error between the patient’s real glucose level GT−real and the approximated curve
GT−approx is defined:
GT−real(t) = GT−approx(t) + ε(t) (3.9)
where the error term, ε(t), should fall within the interval, 0 ≤ |ε(t)| ≤ δ, for
small δ, and δ is a measure of the theoretically best possible fit of the model to
the data.
Using Equation (3.5), GT−real can be calculated in any given time interval
[t0, t] with the constant parameters pGi and SIi as defined in Equations (3.6) and
(3.7):
GT−real(t) = GT−real(t0)− pGi
∫ t
t0
GT−real(t)−GE dt
−SIi
∫ t
t0
GT−real(t)Q¯(t) dt+
∫ t
t0
PV (t) dt
= GT−approx(t0) + pGi(t− t0)GE − pGi
∫ t
t0
GT−approx(t) dt
−SIi
∫ t
t0
GT−approx(t)Q¯(t) dt+
∫ t
t0
PV (t) dt+ E(t) (3.10)
where the error term E(t) arises from using the approximate piecewise linear
blood glucose profile. The magnitude and order of E(t) is defined as
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|E(t)| =
∣∣∣∣ε(t0)− pGi ∫ t
t0
ε(t) dt− SIi
∫ t
t0
ε(t)Q¯(t) dt
∣∣∣∣
≤ |ε(t0)|+ pGi
∣∣∣∣∫ t
t0
ε(t) dt
∣∣∣∣+ SIi ∣∣∣∣∫ t
t0
ε(t)Q¯(t) dt
∣∣∣∣
≤ δ + pGi
∫ t
t0
|ε(t)| dt+ SIi
∫ t
t0
|ε(t)| Q¯(t) dt
≤ δ + pGiδ(t− t0) + SIiδ
∫ t
t0
Q¯(t) dt
= O(δ) (3.11)
Note that even if the time period, [t, t0], and the integral,
∫ t
t0
Q¯(t) dt, are both
large, the piecewise patient specific parameter terms, pGiδ(t − t0) and
SIiδ
∫ t
t0
Q¯(t) dt, are small compared to the integral patient specific terms,
pGi
∫ t
t0
GT−real(t) dt and SIi
∫ t
t0
GT−real(t)Q¯(t) dt, when it is assumed that the
glucose level is greater than 1 mmol/L, GT−real(t) > 1 mmol/L, which should
always be true for a living patient.
The first two error terms in Equation (3.11) yield
∣∣∣∣∣ pGiδ(t− t0)pGi ∫ tt0 GT−real(t) dt
∣∣∣∣∣ < δ(t− t0)∫ t
t0
1 dt
= δ (3.12)
∣∣∣∣∣ SIiδ
∫ t
t0
Q¯(t) dt
SIi
∫ t
t0
GT−real(t)Q¯(t) dt
∣∣∣∣∣ < δ
∫ t
t0
Q¯(t) dt∫ t
t0
Q¯(t) dt
= δ (3.13)
where GT−real(t) = 1 mmol/L has been used to show the lower limit. More
specifically, δ, as defined in Equation (3.9) measures how well the model captures
the measured data. Thus, the fit is not affected by the linear approximation of
the glucose data when using this integral formulation. Therefore, for a general
time period [t0, t] this approximation of the glucose data can be used to represent
the best fit, GT−real, utilising integral functions, as in Equation (3.5), to identify
the parameters defining the piecewise constant definitions for pG and SI from
Equations (3.6) and (3.7). Importantly, this approximation can be used without
introducing additional error beyond any inherent model error.
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The integrals in Equation (3.5) can be determined for several different time
periods in a given data set to find pG and SI . For example, as shown in Figure
3.1, when the length of the time period is chosen to be 120 min long, [t0, t0+120],
the fractional clearance of glucose, pG, can be defined to take on one value, pG1
and the insulin sensitivity parameter, SI , can be defined to take on two values,
SI1 and SI2 . The end result is three unknowns for this time period, requiring
integrations over three intervals.
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Figure 3.1 Example of functions for pG and SI
To find the patient specific parameter values that give the best fit to the
measured glucose data in this time interval, six equations are proposed with the
generic form:
GT−approx(t0 + 20i)−GT−fit(t0 + 20i) = 0 for i = 1, . . . , 6 (3.14)
To show the equations that result, the first and last of these equations, i = 1 and
i = 6, are given
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GT−approx(t0 + 20)−GT−approx(t0)
− 20pG1GE + pG1
∫ t0+20
t0
GT−approx(t) dt
+ SI1
∫ t0+20
t0
GT−approx(t)Q¯(t) dt
−
∫ t0+20
t0
PV (t) dt
= 0 (3.15)
GT−approx(t0 + 120)−GT−approx(t0)
− 120pG1GE + pG1
∫ t0+120
t0
GT−approx(t) dt
+ SI1
∫ t0+60
t0
GT−approx(t)Q¯(t) dt+ SI2
∫ t0+120
t0+60
GT−approx(t)Q¯(t) dt
−
∫ t0+120
t0
PV (t) dt
= 0 (3.16)
where the integrals in Equations (3.15) and (3.16) can be readily evaluated nu-
merically. The unknowns in these equations are pG1 , and SI1 and SI2 . Therefore,
for i = 1, . . . , 6, Equation (3.14) defines a least squares system of six linear equa-
tions with three unknowns. The convex solution of these parameters consequently
defines the time-varying profile for pG and SI for that time period. Finally, using
integrals, instead of derivative based fitting methods, has the additional advan-
tage of being robust to noise in the measured glucose data, by effectively providing
a low-pass filter in the summations involved in numerically integrating.
3.2 Model Parameter Values and Ranges
There have been numerous studies on a wide variety of metabolic rates, provid-
ing references for glucose-insulin metabolic system parameter values. A compre-
hensive study was performed by Doran [2004], summarising reported parameter
values throughout the literature. A quick summary of reported ranges for the
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parameters used in the model defined in Equations (2.9)–(2.13) is presented in
Table 3.1, with full referencing to the relevant literature within the table.
Table 3.1 Reported range of parameter values
Parameter Reported Range Reference
pG 0.0059 – 0.0466 1/min Avogaro et al. [1989]
Bergman et al. [1981]
Bettini et al. [1995]
Cobelli et al. [1999]
Furler et al. [1985]
McDonald et al. [2000]
Pillonetto et al. [2002]
Vicini et al. [1999]
SI 0.02 – 2.26 ×10−3 L/mU/min Araujo-Vilar et al. [1998]
(majority between [0.02–1.11]×10−3) Avogaro et al. [1989]
Bergman et al. [1981, 1985, 1987]
Cobelli et al. [1999]
DeFronzo et al. [1979]
Duncan et al. [2003]
McDonald et al. [2000]
Natali et al. [2000]
Pillonetto et al. [2002]
Vicini et al. [1999]
Prigeon et al. [1996]
k 0.0053 – 0.0139 1/min Kobayashi et al. [1983]
Nestler et al. [1988]
Natali et al. [2000]
Kraegen and Chisholm [1984]
Turnheim and Waldhausl [1988]
n 0.02 – 0.3 1/min Nestler et al. [1988]
(majority between 0.02–0.16) Turnheim and Waldhausl [1988]
Thorsteinsson [1990]
Bergman et al. [1981]
Kraegen and Chisholm [1984]
Ferrannini and Cobelli [1987a]
αG 0.001 – 0.04 L/mU Natali et al. [2000]
Prigeon et al. [1996]
Nestler et al. [1988]
Transberg et al. [1981]
Turnheim and Waldhausl [1988]
Duckworth and Kitabchi [1981]
αI 0.0005 – 0.0043 L/mU Thorsteinsson [1990]
Prigeon et al. [1996]
Ellemann et al. [1987]
Kuehn and Blundell [1980]
IB 4 – 19 mU/min Ferrannini and Cobelli [1987a]
Ferrannini et al. [2005]
Ellemann et al. [1987]
Van Cauter et al. [1992]
Sherwin et al. [1974]
Bergman et al. [1981]
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3.3 Model Validation
After studying the reported parameter values, the generic values used in the
glucose-insulin model validation are summarised in Table 3.2. These chosen val-
ues are the mean from the reported range, or the most supported literature
values. The distribution volume for this initial model validation is set to 12 L
for both glucose and insulin [Bergman et al., 1981]. The constant C that defines
endogenous insulin suppression under the presence of exogenous insulin is set to
1.0.
Table 3.2 Fitting method verification model parameters
Parameter Value
k 0.0099 [1/min]
n 0.16 [min-1]
αI 0.0017 [L/mU]
αG 0.004 [L/mU]
IB 9.6 [mU/min]
VG = VI = V 12.0 [L]
3.3.1 Model Validation Method and Cohort
The generic model in Equations (2.9)–(2.13) and the integral-based parameter
identification method are used on data from a random selection of 18 patients
from a 201 patient data audit at Christchurch Hospital [Shaw et al., 2004, 2005;
Doran, 2004]. Each patient record had a period greater than 1 day with intervals
between measured data points of 4 hours or less. The data density of 4 hours
was selected to ensure enough measurements to enable a good model evaluation.
The entire length of stay was not always considered, as many patients only had a
shorter period of data that fitted these criteria. This cohort broadly represents the
cross-section of patients seen in the ICU, regarding medical condition, age, sex,
APACHE II scores and mortality, as summarised in Table 3.3. Type 1 and Type
2 diabetes is somewhat over-represented because these patients were often more
frequently measured. Note that body mass index (BMI) is not typically recorded
in most ICUs and was therefore not retrospectively available, limiting patient
specificity in estimating some population parameter values. Ethical consent was
obtained from the Canterbury Ethics Committee for this audit.
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Table 3.3 Retrospective patient cohort background information
Patient Medical APACHE II Age Sex Mortality Diabetes
ID Subgroup Score
R24 Other Medical 25 47 M Y Type 1
R87 Other Medical 26 62 F
R130 Trauma 11 21 M Type 1
R229 Cardiac 15 73 F
R278 Other Medical 20 78 M Type 2
R289 Cardiac 18 70 M
R468 General Surgical 32 76 M
R484 Other Medical 34 30 F
R486 General Surgical 22 76 F Type 2
R519 General Surgical 29 69 M Type 2
R554 Other Medical 26 20 F Type 1
R666 Cardiac 8 44 F Type 2
R847 Other Medical 17 67 F
R1016 General Surgical 20 37 F Type 2
R1025 Pulmonary 36 48 M Type 2
R1090 General Surgical Unknown 37 F
R1099 Pulmonary Unknown 24 M Y
R1125 Other Medical Unknown 72 F Y
For patient specific parameter identification, the endogenous glucose removal,
pG, is held constant over 2-hour periods and the insulin sensitivity, SI , varies every
hour, creating piecewise constant time-varying model parameters. Fitting bounds
on pG are [0.01, 0.02] [1/min], and on SI are [1.0×10−5, 2.5×10−3] [L/mU/min].
Dextrose input is simply modelled as a step-wise function in this initial validation
because it does not vary much through time in this patient data, because it was
not being varied to control glucose. Thus, its value remained largely constant. It
is thus defined:
P (ti ≤ t < ti+1) = P¯i (3.17)
3.3.2 Results
The average patient data interval was 3.0 days, with the longest at 12.3 days.
The absolute average blood glucose fitting error over all patients was 4.57%,
with a range of 0.87–8.83%. These values are close to or within the experimental
glucose measurement error, and match the expectations of other non-linear fitting
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methods [Hovorka and Vicini, 2001]. The summarised results with inter-quartile
range (IQR) are shown in Table 3.4
Table 3.4 Retrospective blood glucose fitting error
Mean Percentage Time Number of
Patient Percentage Error Standard Interval Measurements
Number Error (%) Deviation (%) (days) Total Per Day
R24 4.66 6.84 2.0 32 16.0
R87 2.35 2.69 6.4 48 7.5
R130 7.42 6.17 1.4 31 22.0
R229 5.65 9.72 10.0 78 7.8
R278 8.83 11.17 1.6 13 8.1
R289 6.56 7.68 1.7 13 7.7
R468 5.46 6.10 1.7 17 10.0
R484 2.41 2.04 1.7 18 10.6
R486 6.43 6.89 1.6 16 10.0
R519 3.04 2.55 12.3 82 6.7
R554 5.11 4.58 2.3 40 17.4
R666 3.50 2.38 1.6 15 9.4
R847 4.26 4.36 1.5 12 8.0
R1016 3.87 5.05 1.6 13 8.1
R1025 4.12 4.74 1.7 15 8.8
R1090 0.87 0.80 1.6 10 6.3
R1099 4.47 3.90 1.6 14 8.3
R1125 3.17 2.69 1.7 11 6.5
Average 4.57 5.02 3.0 26.6 10.0
IQR 3.34–5.56 2.69–6.51 1.6–2.2 13.0–31.5 7.7–10.0
Figure 3.2 shows the fitted results for Patient R519. To reduce the impact of
noise and erroneous measurements, the fitted values of pG and SI were replaced
by their smoothed, zero-phase (zero-lag) three-point moving average to produce
the fitted model simulated curve in the figure. Specifically, SI is fitted hourly,
and pG is fitted every two hourly. Therefore, the three-point moving average of
SI at hour n would be the average of fitted SI from hours n−1, n and n+1. The
three-point moving average of two-hourly fitted pG at hour n and n + 1, where
n is an odd number, would be the average of fitted pG of hours n − 2 to n + 3.
The result is a less accurate fit (slightly larger least square error), but a smoother
more physiological time-varying profile for these parameters. Comparisons of
smoothed and raw fitted pG and SI are shown in Figure 3.3.
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Figure 3.2 Patient R519 blood glucose data fit (top), corresponding endogenous glucose
removal pG (middle) and corresponding insulin sensitivity parameter SI (bottom)
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Figure 3.3 Patient R519 fitted pG and SI
52 CHAPTER 3 PARAMETER IDENTIFICATION AND MODEL VALIDATION
Patient R519 had a total length of stay close to 2 weeks and shows the
effectiveness of the model and integral fitting method as the model fitted blood
glucose curve goes through every error bar. The patient specific parameter value
for pG was quasi-constant and SI varied significantly. Both parameters were well
within reported physiological ranges [e.g. Avogaro et al., 1989; Cobelli et al.,
1999; Bergman et al., 1981, 1987; Prigeon et al., 1996; Doran, 2004].
Table 3.5 summarises the pG and SI values found for all the patients. The
standard deviations for pG are all approximately 5–10 times smaller than the
mean value indicating that pG remains relatively constant. This result validates
the use of 2-hour, or longer, and even constant values for pG [Hann et al., 2005].
Similarly, SI is much more variable, indicating the 1-hour, or shorter, window
as appropriate. These results also match clinical expectations and observations
[McDonald et al., 2000; Hovorka et al., 2003; Chase et al., 2005c].
Table 3.5 Retrospective fitted pG and SI
Patient pG [1/min] SI [L/mU/min]
Number Mean std Mean std
R24 0.0101 0.0002 0.00048 0.00016
R87 0.0109 0.0013 0.00076 0.00044
R130 0.0106 0.0010 0.00045 0.00028
R229 0.0111 0.0014 0.00110 0.00060
R278 0.0134 0.0030 0.00130 0.00035
R289 0.0100 0.0010 0.00110 0.00040
R468 0.0108 0.0008 0.00047 0.00024
R484 0.0108 0.0011 0.00049 0.00014
R486 0.0107 0.0010 0.00052 0.00032
R519 0.0114 0.0019 0.00110 0.00060
R554 0.0107 0.0012 0.00084 0.00054
R666 0.0101 0.0002 0.00032 0.00017
R847 0.0114 0.0013 0.00150 0.00060
R1016 0.0112 0.0015 0.00042 0.00019
R1025 0.0109 0.0011 0.00088 0.00045
R1090 0.0114 0.0026 0.00091 0.00017
R1099 0.0123 0.0019 0.00140 0.00040
R1125 0.0101 0.0014 0.00064 0.00037
Average 0.0110 0.0013 0.00082 0.00036
IQR 0.0107–0.0113 0.0010–0.0015 0.00049–0.00110 0.00022–0.00045
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Comparing the computational effort between the integral-based fitting method
to the traditionally preferred NRLS (non-linear least square) method on Patient
R87, the integral fitting method found a global solution within 30 sec, producing
a mean error of 2.35% (std 2.69%). The NRLS method took over 8 hours on the
same computer, with both methods using MATLAB R©, and only found a local
minima, producing a mean error of 4.68% (std 5.52%).
Overall, the integral fitting method is approximately 1,000 times faster, be-
cause it does not require extensive iterations, and guarantees to find the global
solution. This significant computational advantage over the traditionally favored
NRLS method makes the integral-based fitting method a better choice for real-
time clinical control applications where fast identification is required. In addition,
adjustments in other minor parameters can then be quickly tested if necessary in
clinical situations, given the very fast (initial) identification of pG and SI .
3.4 Model Prediction
For control applications, it is essential to know how well the fitted model can
predict glycemic response to an intervention. If the fitted patient specific model
is able to capture the immediate future glycemic changes, it also verifies that the
fitted parameters reflect clinical physiology, and are not merely “molded” to fit
collected data. More specifically, accurate prediction is a significant model and
fitting method validation requirement.
Ten patients were used to test the 1 hour predictive ability of the identified
model. To make a forward prediction from a given point, the model fit from the
data over the previous 8 hours was used. Note that predictions are insensitive
to the length of time fitted prior to prediction, as long as it is greater than 2
hours or 3–4 measurements. The 2 hours or 3–4 measurements criteria are used
because these patient data are generally 2–3 hours apart.
The prediction is made by holding the current identified patient specific pa-
rameters, pG and SI , and the equilibrium glucose level, GE, constant over the
next hour. The resulting model predicted value is compared to the actual data
and the percentage absolute error, ei, calculated. For patients where there was
insufficient consecutive data every hour, the intermediate blood glucose targets
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were obtained via interpolation between data points. This process was repeated
in moving 9-hour blocks, generating 13–76 predictions per patient.
The results in Table 3.6 show that 1-hour predictions have an average absolute
error of 2–11%, which is close to the measurement error with the GlucocardTM
sensor of 7–12% over the glycemic ranges in the data [Arkray, 2001]. Most average
errors are < 6% and well within measurement error. These errors are also within
the clinically acceptable “A” range for glycemic control of approximately ±20%
using the Clarke Error Grid [Clarke, 2005].
Table 3.6 Fitted model prediction errors
Number of Average prediction Standard
Patient predictions error e (%) deviation (%)
R24 22 5.86 4.00
R87 41 4.71 5.21
R130 18 10.12 9.55
R519 76 5.25 5.98
R554 24 10.90 8.89
R666 13 4.66 3.01
R1016 13 7.01 6.27
R1025 14 5.09 4.54
R1090 13 1.86 0.87
R1125 14 6.83 4.78
Average 24.8 6.23 5.31
IQR 13.0–23.0 4.69–6.92 3.51–6.13
3.5 Parameter Sensitivity Study
A sensitivity analysis was done on the population constant parameters k, n,
αI and αG for Patient R87, using variations in individual parameters of −50%,
−10%, +10% and +50% from the assumed values. Table 3.7 shows the resulting
percentage change in the mean and standard deviation of the fitted SI values.
The parameter pG was not included as it was essentially constant and did not
change more than 1%.
Variations of k and αI gave very little change to the identified SI . This
result suggests that k and αI can be fixed at the population values, and that
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Table 3.7 Sensitivity analysis on SI (expressed in % change in SI) for Patient R87
Parameter Percentage change from population value used
-10 +10 -50 +50
Mean std Mean std Mean std Mean std
k 2.6 3.3 0.9 2.0 4.5 3.7 2.5 3.3
n 6.9 2.6 6.0 1.5 32.8 4.9 30.0 8.9
αI 0.2 0.2 3.1 4.7 1.2 1.8 4.1 4.7
αG 6.6 5.1 4.3 2.2 19.3 4.6 17.6 7.2
the resulting errors will have little effect on the identified values of SI or pG.
The standard deviation of SI from changing n is small compared to the mean,
showing that the SI curve is effectively scaled up or down but not changed in
shape. Therefore, n can effectively be fixed at the population value, too. Figure
3.4 demonstrates this scaling effect.
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Figure 3.4 The effect of changing n on Patient R87. The dotted curve of SI corresponds
to n = 0.16 × (1 − 0.5) and the solid curve of SI corresponds to n = 0.16. The blood glucose
curves are essentially overlaid.
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One parameter that does produce a significant change is αG, as shown in
Figure 3.5 and Table 3.7. Note in Figure 3.5 that changes in αG resulted in
several data points being missed in days 4–6, unlike in Figure 3.4, where αG is at
its assumed reported population value for Patient R87. Change in αG also has a
scaling effect on SI , however, as indicated by the poor fit in days 4–6, these SI
values identified are not physiologically accurate. In particular, the SI curve is
reduced as αG is lowered because a lower αG leaves more effective insulin Q¯ for
action. This result suggests a need to further identify αG, but also that it trades
off at higher insulin values with SI [Chase et al., 2004].
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Figure 3.5 The effect of changing αG for Patient R87. The dashed curve of SI corresponds
to αG = 0.04 and the solid curve of SI corresponds to αG = 0.04 × (1 − 0.5). Fitted blood
glucose curve where αG = 0.04 not shown.
All the results in the fitting suggest that pG is essentially constant for each
patient at a patient specific value. In addition, Table 3.5 shows very little vari-
ation in the value of pG over all the patients in the cohort. Thus, the effect of
holding pG = 0.01 [1/min] constant at its approximately average value over the
cohort is examined.
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Fitting error does not significantly differ whether pG is fitted or held at a
constant. The mean fitting error across all 18 patients when pG is fitted is 4.57%,
with a standard deviation of 5.02% in Table 3.4. When pG is held constant at
0.01, the mean fitting error is 4.43%, with a standard deviation of 5.02%. The
nearly identical fitting quality suggests that pG can be held at a population value
(pG = 0.01) similar to k, n and αI .
3.6 Adjustment in Model Parameters
As indicated in the sensitivity studies in Section 3.5, further studies were carried
out on some parameters to “fine tune” the glucose-insulin model presented in
Equations (2.9)–(2.13), as suggested previously in Section 3.1. In addition, many
variables might be more exactly defined with no loss of fitting or prediction error,
all else equal. Finally, such an analysis provides further insights into the modelled
dynamics, critical parameters and parameter sensitivity.
3.6.1 Distribution Volume VG and VI
Initially, one common distribution volume was used for both the glucose and
the insulin compartment, and the value of 12 L was taken as the average value
over all physiological compartments, as reported in Bergman et al. [1981]. The
Minimal Model of insulin kinetics in Bergman et al. [1981] did not deal with
exogenous insulin input or an explicit insulin interstitial distribution space, as
the study was focused on IVGTT (Intravenous Glucose Tolerance Tests). This
difference occurred in part because the IVGTT did not involve exogenous insulin
administration.
In the earlier stage of physiological model development, Doran et al. [2004b]
simplified the Minimal Model into a two-compartment model. The two compart-
ments were glucose and insulin respectively. As Equation (2.10) was introduced
into the physiological model, the interstitial space distribution volume needs to
be reviewed. In particular, many studies on insulin kinetic modelling suggest dif-
ferent volumes for glucose and insulin distribution [Ferrannini and Cobelli, 1987a;
Van Cauter et al., 1992; Sherwin et al., 1974; Insel et al., 1975].
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The insulin distribution volume, which is the plasma volume, is found to be
around 4.5 % body weight, with little variation between individuals [Ferrannini
and Cobelli, 1987a]. However, the estimated total plasma equivalent space for
glucose can vary up to 5-fold depending on modelling methods [Ferrannini and
Cobelli, 1987a], and ranges from 14–27% body weight [e.g. Ferrannini and Cobelli,
1987a; Sherwin et al., 1974; Insel et al., 1975].
Taking VG in Equation (2.9) as 19% of body weight and VI in Equation
(2.11) as 4.5% of body weight for a 70 kg average body weight (as ICU patients’
weights are generally unavailable), the re-fitted SI distribution for the 18-patients
is shown in Figure 3.6. The average fitting error from using VG = 13.3 L and
VI = 3.15 L is 4.31% (std = 5.57%), which is very similar to the results when VG =
VI = 12 L (4.57%, std = 5.02%) in Table 3.4. Comparing the fitted SI , changing
the volumes for VI and VG resulted in a much lower mean SI (3.12 × 10−4 v.s
9.22× 10−4) due to the lower volume and resulting higher insulin concentrations.
However, the relative covariance of hour to hour variations is still similar (0.66
v.s 0.60), indicating the variations from hour to hour are very similar, and that
little change in profile shape has occurred.
In conclusion, changing the volumes did not change the quality of fit. This
result suggests that the fitting method and the parameter SI are very robust to
these volumes although not insensitive. The SI fitted with more physiologically
correct volumes obtained from more in-depth insulin kinetic modelling studies is
now one step closer to indicating the “true” tissue sensitivity to insulin that the
SI parameter represents.
3.6.2 Effective Insulin Half-Life k and Saturation αG
Insulin sensitivity can tradeoff with the parameter for the effective half-life of
insulin (k) and the effective insulin saturation limit (αG) [Chase et al., 2004].
Although frequent re-evaluation of SI can generally produce a good fit to the data,
if its variation is not a realistic reflection of the “true” overall insulin sensitivity,
the use of the model in dynamic patient specific glycemic prediction will be poor.
Therefore, other minor parameters that can tradeoff with SI must be carefully
examined, to minimise unwanted mitigating or compromising effects.
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Figure 3.6 Fitted SI and distribution volumes for 18 retrospective patients
The level of effective insulin saturation, αG, can also have a significant detri-
mental impact on model-based glycemic control. Exacerbating this issue, its
value can vary widely between individuals (0.001–0.04 [L/mU]) [Natali et al.,
2000; Prigeon et al., 1996; Nestler et al., 1988; Transberg et al., 1981; Turnheim
and Waldhausl, 1988; Duckworth and Kitabchi, 1981; Chase et al., 2004]. How-
ever, real-time identification is difficult because its detection is available only
when significant saturation occurs, followed by a large prediction error, and its
ultimate refection in overall poor control [Chase et al., 2004, 2005c].
For patient safety, αG is chosen to be 1/65 L/mU, corresponding to the
highest reported average saturation level [Prigeon et al., 1996]. If the modelled
saturation level is too low, the risk of administering excess insulin increases, due
to seeing the patient as near the saturation limit and requiring insulin for a given
predicted change in blood glucose levels. If a patient does have a low saturation
limit, the patient will then be seen as more insulin resistant, but will not be
at risk of hypoglycemia due to administering excess insulin [Chase et al., 2004,
2005c]. Hence, this selection is primarily made with respect to control safety in
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the absence of any other data. Finally, note that clinical identification of αG in
critical care would require extensive non-therapeutic interventions that are not
ethically possible or likely in regular care and glycemic control.
When k is not approximated correctly, the impact on model dynamics is
transferred into the value of SI . This effect is not observable in the 18-patient
data, because its impact is only seen when data frequency is greater than once
every hour. When data frequency is greater than once every hour, a 1st order
linear SI produces a better fit and can reveal faster dynamics [Chase et al., 2005c].
Under this circumstance, an incorrect k value results in the non-physiological
sawtooth SI profile, as shown in the lower panel of Figure 3.7(a).
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Figure 3.7 SI resembling saw tooth profile
Figure 3.7(a) shows a value of k that is too small, or an effective insulin
half-life that is too long. Therefore, the modelled curve of saturated or effective
interstitial insulin effect, Q¯ in the top panel of Figure 3.7(a) is too “flat”, forcing
the model to require the system to be more insulin sensitive at first, and then
significantly less sensitive later. This effect creates the sawtooth profile in SI
in the lower panel in Figure 3.7(a). Figure 3.7(b) shows the situation when k
is correctly modelled. In this case, SI in the lower panel is relatively constant
because Q¯ in the top panel has the correct shape and decay to match (frequent)
blood glucose data, where the slight sawtooth is likely due to measurement noise.
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If zero order SI is fitted when k is incorrect and the data sampling frequency
is high, the quality of fit can be poor. In the clinical control studies of Chase
et al. [2005c] where data frequency is greater than once every hour, the value of
k is adapted in clinical control trials when sawtooth behaviour in SI is observed.
This approach allowed an adaptation in k that better reflected the true value of
k in those trials. However, such high data density with measurement intervals
less than hourly is not clinically feasible outside a (brief) research study. Thus,
better understanding and a useful population value is still required.
Fitting SI to the 18-patient data with k = 0.0198 (corresponding to t1/2 =
35 min) and αG = 1/65 produced very similar error as when k = 0.0099 (corre-
sponding to t1/2 = 70 min) and αG = 1/25 (4.27, std 5.70% v.s 4.31, std 5.57%).
In both cases, VI = 3.15 L and VG = 13.3 L were used.
Although changing k and αG did not noticeably improve the fitting quality in
the 18-patient cohort, a k corresponding to an effective insulin half-life of 35 min
captures better short term dynamics in 2 of the 3 patients reported in Chase
et al. [2005c], and the 7 patients reported in Wong et al. [2006a], where blood
glucose levels were sampled every 30 min. The median fitting error decreased
from 5.75% to 5.32% when the effective insulin half-life decreased from 70 to
35 min (k = 0.0099→ 0.0198) for all the patients in Wong et al. [2006a]. Finally,
having αG set to a lower saturation level (1/65 as opposed to 1/25 1/min) ensures
better patient safety during a glycemic control trial [Chase et al., 2004, 2005c].
3.6.3 Final Model Parameter Summary
The final decision on parameter values are shown in Table 3.8. Values for kpr and
kpd for the rise and decay of enteral dextrose inputs appearing from the gut and
intestines are set to 0.0347 min−1 and 0.0068 min−1, respectively, corresponding
to half-lives of 20 and 100 min to reflect published results [Kiwanuka et al., 2001;
Ludvik et al., 1997; Radziuk et al., 1978; Nielsen et al., 1998; Basu et al., 2001,
2004; Firth et al., 1985]. The constant C in Equation 2.11 is set to C = 3.15 that
produces good approximation to the 18-patient data.
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Table 3.8 Population and generic model parameters
Parameter Value
k 0.0198 [1/min]
n 0.16 [min-1]
αI 0.0017 [L/mU]
αG 0.0154 [L/mU]
VG 13.3 [L]
VI 3.15 [L]
kpd 0.0069 [1/min]
kpr 0.0347 [1/min]
IB 9.45 [mU/min]
3.7 Summary
The integral-based fitting method presented in this chapter is effective in reducing
a typically non-linear, non-convex optimization problem to a simple convex, linear
system. The integral fitting method is ∼1,000+ times faster than traditional non-
convex NRLS fitting methods for these kinds of non-linear, non-convex dynamic
systems because it does not require extensive iterations, nor multiple starting
points to ensure accurate optimal solutions.
The validation of the integral-based fitting method on retrospective data
from the 18 long term patient cohort produced good quality fits, with errors
within the reported measurement accuracy. All fitted values for pG and SI are
within physiologically valid ranges reported in the literature, while other minor
parameters are fixed at population values. This result verifies the effectiveness of
the fitting method developed, as well as the physiological validity and adequacy
of the glucose-insulin model of Equations (2.9)–(2.11).
Endogenous glucose removal pG remained nearly constant throughout all pa-
tients and tests, suggesting it can be held constant. The insulin sensitivity pa-
rameter SI , showed much greater variation. Some of this variability is due to
the highly variable condition of the critical care patients, which can induce large
variation in the level of counter-regulatory hormones present and hence in insulin
sensitivity [Hann et al., 2005; Chase et al., 2006b]. In addition, drug therapies
such as beta-blockers or vaso-dilators can also have an impact on insulin sensi-
tivity [Chase et al., 2005c; Wong et al., 2006b].
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Sensitivity analysis supports the assumption that pG and SI are the only cru-
cial parameters that drive the dynamics of the glucose-insulin system. Changing
the parameters k, n, and αI from the initially assumed population values did not
significantly affect the fits and the trends of the primary parameters pG and SI .
However, k was later modified based on higher frequency data revealing shorter
term dynamics. The effective insulin saturation parameter αG was also lowered
as a precaution to ensure better patient safety when considering the application
of this physiological model in glycemic control trials.
Forward prediction of glucose values for a period of one hour ahead were
within 2–11% of the measured values, further validating the pG and SI values
obtained. This error is also within the clinically acceptable “A” range for glycemic
control and is also within the 7–12% sensor error.
All of these results demonstrate the potential of this model for clinical control.
More specifically, given the patient specific parameters at any point in time, the
amount of insulin can be directly calculated to regulate a patient’s blood glucose
level to a target level in the next hour. This process could be continued every
hour so that a patient’s glucose level is tightly controlled over their entire stay
at the ICU with minimal variation. Note that holding pG and SI constant dur-
ing the prediction interval only presents the simplified targeted glycemic control
scheme, as it ignores the potentially hidden stochastic behaviours of the param-
eters. Analysis of the stochastic behaviour in these parameters would further
enhance the capability of the physiological model and fitting method as used in
glycemic control to predict the glycemic response to an intervention, as Chapters
5–7 later show.

Chapter 4
Critical Care Glycemic Control
The physiological model developed for critical care glycemic control in Chapter
2 and the integral-based parameter identification method presented in Chapter
3 have been tested in clinical control trials in three stages [Chase et al., 2005b,c;
Wong et al., 2006a,b; Lonergan et al., 2006a]. These trials were carried out in the
Christchurch Hospital Intensive Care Unit, with ethical consent obtained from the
Canterbury Ethics Committee and the South Island Regional Ethics Committee.
The control algorithms implemented are adaptive and predictive. The first
stage of clinical trials used insulin-only control [Chase et al., 2005b,c], and the
second stage added carbohydrate enteral infusion control [Wong et al., 2006a,b].
These first and second stages employed computerised control algorithms, where
a computational unit is used on site. The third stage of the clinical trials, having
proved that the algorithm and overall approach is safe and effective in the first
two stages, transformed the insulin and nutrition adaptive, predictive control
algorithm from computerised into tabulated form. This change made large-scale
clinical implementation simple, and readily adaptable to any intensive care unit
[Lonergan et al., 2006a].
This chapter briefly presents the protocols and results for each stage of the
clinical control trials.
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4.1 Insulin Only (Bolus) Control
The first stage of the clinical trials utilised insulin-only control to test the effi-
cacy of the physiological model of Equations (2.9)–(2.11). Three patients were
admitted to this stage of clinical trials.
Protocol
These proof-of-concept clinical trials span five hours, including an insulin
challenge hour, and four hours of tight blood glucose control. At the end of each
hour during the controlled phase, the blood glucose target to be achieved in the
next hour is set according to both the current blood glucose level and level of
insulin resistance. Generally a 10–20% hourly reduction is chosen. The minimum
target level is 4.5 mmol/L.
All patients were undergoing a constant, unit standard enteral nasal-gastric
feed of approximately 1000 calories of glucose per day, which was the current
standard for the Christchurch Hospital ICU. Selected patients had to be stable,
hyperglycemic and representative of typical ICU conditions. Specific inclusion
criteria include: the presence of constant naso-gastric feed; random blood glucose
concentration being greater than 8 mmol/L; the patient being over 16 years old;
and the presence of an in situ arterial cannula. Exclusion criteria include: the
absence of a naso-gastric tube or arterial catheter; the patient being moribund
or not expected to survive more than 72 hours; patients receiving neuromuscular
blockade; and patients having body mass index above 35 kg/m2.
Trials begin at 0700 hours, at which time any insulin infusion is held constant
with constant naso-gastric feed maintained. Christchurch Hospital ICU patients
are given IsosourceTM enteral feed at a known constant rate (typically 70 ml/hr)
throughout the trial via the naso-gastric tube, which is standard procedure at
this ICU. Blood glucose readings are taken hourly to determine the patients’
equilibrium blood glucose level, GE, at 1000 hours. At 1000 hours, patients are
injected with a fixed 1500 mU bolus of ActrapidTM insulin via an intravenous
cannula using a Graseby 3500 syringe pump. Plasma glucose is measured at 15
min intervals until 1100 hour. Paired blood samples are taken and analysed using
a bedside GlucocardTM Test Strip II glucose testing kit, with 7% absolute error
in readings at typically elevated blood glucose levels [Arkray, 2001].
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Patient specific parameters, pG and SI , are fitted as discontinuous first order
functions using the first hour of data. Based on these values, an insulin bolus
size is calculated by the controller to achieve the target blood glucose level set
for the end of the following hour. Blood glucose is monitored every 30 min, and
patient specific parameters are re-evaluated every hour using the data obtained
in the previous hour. Following each re-evaluation, the controller determines the
insulin bolus required to achieve the targeted blood glucose reduction.
The overall approach is a bolus driven, patient specific adaptive control
method that uses prior data to regularly update the patient specific parameters.
The overall clinical trial procedure is outlined in Figure 4.1.
0 min - 1. Parameter fitting 
2. Calculate predictive 
control insulin dosage 
3. Implement insulin 
injection 
30 min - measure 
BG 
 
1st Hour Repeat for 2nd – 5th Hour 
0 min - Trial Start 
Inject 1.5 U insulin 
30 min - measure 
BG 
 
15 min - measure 
BG 
45 min - measure 
BG 
Figure 4.1 Insulin bolus glycemic control procedure
A bolus-based approach is seen as being potentially safer than continuous
infusions when used in a semi-automated fashion with medical staff in the loop.
More specifically, if medical staff are detained or busy, a bolus-based approach
does not infuse more insulin at a rate that is potentially too high for that up-
coming hour [Chase et al., 2005b].
For patient safety, a limit of 6 U/hr is placed on the insulin bolus to be
administered. In addition, the controller limits saturated interstitial insulin
Q − Q/(1 + αGQ) ≤ 30 mU/L to avoid excess insulin effect saturation. The
glucose and insulin distribution volumes are assumed to be VG = VI = 12 L for
these trials. Blood glucose fluctuations greater than 10% of the blood glucose
level in a given hour are also undesirable. When a patient is predicted to exhibit
a large fluctuation over the next hour, the controller sets an intermediate target
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to be achieved in 30 min using a smaller bolus to eliminate large fluctuations that
result from large boluses.
Trial Results
Figure 4.2 shows the trial results of Patient C301, demonstrating the progres-
sion of a trial. The controller used k corresponding to an effective insulin half-life
of 70 min, and αG = 1/25 [L/mU ]. Modification of these generic constant pa-
rameter values were considered after this trial to better patient safety (changing
αG to 1/65 L/mU), and minimise sawtooth effect seen in SI in the bottom panel
of Figure 4.2, as explained in Section 3.6.2 of Chapter 3. A detailed review on
parameter modification of Patient C301 can be found in Chase et al. [2005c].
Specific predictive control target acquisition error for Patient C301 is presented
in Table 4.1.
Figure 4.2 Insulin bolus glycemic control trial of Patient C301. The top panel displays the
glycemic progression of the controlled patient. The second panel shows the insulin boluses
given. The third panel shows the interstitial insulin and its saturable action. The forth and
last panels are the fitted patient parameters pG and SI .
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Table 4.1 Effectiveness of predictive insulin bolus control represented in target error for
Patient C301
Time Target glucose Achieved glucose % Error (abs) % Revisited trial
(min) (mmol/L) (mmol/L) predicted error (abs)a
120 7.97 6.35 20 (−1.62) 6 (−0.43)
180 6.31 6.13 3 (−0.18) 2 (−0.11)
240 6.08 6.00 1 (−0.08) 3 ( 0.17)
300 5.89 4.90 17 (−0.99) 8 (−0.40)
a Prediction error from post-trial simulation (k changed from 0.0099 to 0.0198 1/min and
αG = 1/65 L/mU).
As Figure 4.2 shows, even though the originally assumed k and αG did not
provide the best fit, the blood glucose level was reduced systematically in a safe
manner. When the parameter values were modified, the predictive control target
acquisition error reduced significantly, as shown in Table 4.1.
Two other trial results are presented in Table 4.2. Most of the larger pre-
diction errors were a result of insulin utilisation saturation, which the controller
predicted. These patients’ detailed trial review and analysis can be found in
Chase et al. [2005b,c]
Table 4.2 Effectiveness of predictive insulin bolus control represented in target error for
Patient C302–3
Patient Time Target glucose Achieved glucose Error (%) (abs)
(min) (mmol/L) (mmol/L)
C302 120 9.81 9.10 7%
180 8.39 8.75 4%
240 7.61∗ 6.00 21%
270 6.54 6.85 5%
300 6.00∗ 7.20 20%
C303 120 8.58 10.40 21%
180 10.98∗ 8.70 21%
240 7.64 7.35 4%
300 6.92∗ 6.90 0%
∗ Target value was compromised because the desired glucose reduction was restricted
by saturation.
In summary, these three first proof-of-concept predictive target glycemic con-
trol trials in the ICU verified the applicability of the physiological model of
Equations (2.9)–(2.11) and the integral-based parameter identification method
presented in Chapter 3 for critical care glycemic control. The controller reduced
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the three patients’ blood glucose from 6.35→ 4.90, 9.10→ 7.20 and 10.40→ 6.90
mmol/L respectively during the 5 hour trials. The mean predictive target acquisi-
tion accuracy was 6.7%, which is less than the typical 7–12% measurement error
[Arkray, 2001], excluding occasions where insulin effect saturation limited the
achievable glycemic reduction.
4.2 Insulin and Nutrition Control
Seeing the proven short term benefits from the insulin-only predictive target
glycemic control in the first stage of clinical trials, the second stage proposed the
use of an additional dextrose control input as well as longer trials. As the first
stage trials showed, insulin-only control has limited performance in the presence
of significant insulin effect saturation, which occurs due to extreme insulin resis-
tance in some of these patients. More specifically, critically ill patients generally
have heightened secretion of counter-regulatory hormones which stimulates en-
dogenous glucose production and increases effective insulin resistance [Mizock,
2001; McCowen et al., 2001; Chase et al., 2005c; Wong et al., 2006b]. Under this
already severely compromised situation, high glucose nutritional regimes often re-
sult in excess glucose [Patino et al., 1999; Weissman, 1999; Woolfson, 1980; Elia
et al., 2005], exacerbating hyperglycemia. As a result, only limited reductions
might be available with insulin alone, necessitating this second control input. In
addition, several recent studies encouraged review of clinical nutrition regimes
because many current practices have hidden adverse effects [Iyer, 2002; Krishnan
et al., 2003; Dickerson et al., 2002; Dickerson, 2005].
Simulated control results using insulin only and insulin plus nutrition control
in Figure 4.3 shows that insulin-nutrition control can better combat insulin re-
sistance. These trials were simulated using the retrospective patient cohort used
for validating the integral-based parameter identification method. The hospital
control data were real clinical data collected for these patients during their stay in
the ICU. Insulin only control only approaches similar control performance when
insulin sensitivity is high. At very low insulin sensitivity, insulin only control ap-
peared even less effective than hospital control data. This result occurs because
the clinicians usually would resort to reducing dextrose feed to severely hyper-
glycemic patients if they did not respond to large doses of insulin. This action
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Figure 4.3 Simulated insulin-only and insulin-nutrition control performances v.s hospital
control data
essentially incorporates some basic nutrition control in the clinical sliding scale
protocol used when insulin sensitivity is low.
Protocol
The trial procedure follows the same outline as the insulin-only trials, with
the addition of controlling dextrose. Patient selection, inclusion and exclusion
criteria are also the same as for the insulin-only control trials, and specific details
can be found in Wong et al. [2006b]. The outline for the insulin-nutrition control
control procedure is shown in Figure 4.4.
Insulin is still administered in boluses for safety from infusions being left on,
and dextrose is given at a constant feeding rate until the controller advises adjust-
ment. Equations (2.12)–(2.13) define the dynamics resulting from the dextrose
interventions. Minimum dextrose is set at 280 kcal/day of glucose or approxi-
mately 30% of goal feed. The goal feed rate is an ideal feed rate determined by
the clinician on admission to the insulin-nutrition glycemic control protocol. This
72 CHAPTER 4 CRITICAL CARE GLYCEMIC CONTROL
0 min - 1. SI fitting 
2. Calculate predictive 
control intervention 
(insulin+nutrition) 
3. Implement 
intervention 
30 min - measure 
BG 
 
1st Hour Repeat from 2nd Hour Onwards 
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BG 
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Figure 4.4 Insulin-nutrition glycemic control procedure
lower limit on feed rate is placed to avoid increased risk of nosocomial infections
[Rubinson et al., 2004]. Wong et al. [2006b] includes a complete description of
the insulin-nutrition glycemic control protocol.
Trial Results
Eight patients participated in the insulin-nutrition glycemic control trials in
the Christchurch Hospital ICU. The background information of these patients are
summarised in Table 4.3. These patients represent a heterogeneous cross-section
in age and sex. The median APACHE II score is 23 with interquartile range
[19, 25], which represents a more critically ill cohort compared with other critical
care hyperglycemia control studies [Van den Berghe et al., 2001; Krinsley, 2003a].
The high proportion of septic patients stems from their severity of condition and,
hence, likelihood of hyperglycemia.
Patients C401–7 had trials spanning 10 hours, and Patient C408 spanned 24
hours. Patient C408 only had data collected hourly from the 2nd hour onwards.
Trials results, expressed in predictive control target acquisition ability, are sum-
marised in Table 4.4. Boxplots for the prediction error for each individual patient
are shown in Figure 4.5.
Overall, 41.9% of targets are achieved within ±5% target acquisition error.
Seven out of n = 86 targets had error > 20%, resulting in 90.7% of all mea-
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Table 4.4 Predictive insulin-nutrition glycemic control trial results
Mean target absolute error
Patient % mmol/L
C401 12.6 0.8
C402 9.9 0.9
C403 7.2 0.3
C404 10.0 0.6
C405 2.4 0.1
C406 7.6 0.4
C407 7.5 0.4
C408 10.5 0.6
average 7.2 0.5
 
1          2          3          4          5          6          7          8 
Patient Number 
Ta
rg
et
 
A
cq
u
is
iti
o
n
 
Er
ro
r 
Figure 4.5 Target acquisition error in insulin-nutrition control trials
surements having a target acquisition error within ±20%. The larger errors are
attributed to significant and rapid changes in patient condition, such as Patient
C402 who suffered from atrial fibrillation [Wong et al., 2006b], which caused the
outlying errors in that case as their condition changed suddenly. Overall, the out-
lying errors in each case are small compared to the measurement error and/or can
be ascribed to clinically verified, acute or sudden changes in patient conditions.
4.3 SPECIALIZED RELATIVE INSULIN AND NUTRITION TABLES (SPRINT) 75
This 8 patient cohort has a significant level of illness as measured by APACHE
II score. With a median APACHE II score of 23 (range [17, 31]), the insulin-
nutrition predictive target glycemic control algorithm showed tight control to less
than 5.5 mmol/L. In comparison, Van den Berghe et al. [2001] achieved similarly
tight control with median APACHE II score of 9 (interquartile range [7, 13], which
represents a much lower level of illness. For a more comparable ICU population,
Krinsley [2003a] showed tight control to a higher 7–7.5 mmol/L target (average
7.3 mmol/L) for a cohort with median APACHE II of 16 (interquartile range
[10, 23]). Both these studies used insulin alone to control glucose levels. Hence,
the added control obtained by modulating nutrition, as well as insulin, to control
glycemic levels is seen in the ability to achieve tight control to a level similar to
that of Van den Berghe et al. [2001], but for a more critically ill ICU cohort.
In conclusion, this stage of insulin-nutrition predictive target glycemic control
trials demonstrates the potential for accurate reduction and tight regulation of
glucose levels despite significant inter-patient variability and time-variant phys-
iological condition. The average absolute error was 0.5 mmol/L, which is small
compared with the 4–6 mmol/L desired range. In addition, the outlying target
errors of 15–20% are not considered clinically significant in the glucose ranges
involved in this ICU clinical environment.
Finally, the clinically verified effective glucose-insulin physiological model of
Equations (2.9)–(2.13), the integral-based parameter identification method pre-
sented in Chapter 3, and the insulin-nutrition predictive algorithm presented
here can, in combination, provide safe and effective glycemic control. Extended
to long-term control studies, it has the potential to reduce ICU mortality and
the risk of severe complications with relatively limited clinical effort and labour.
The next step is larger scale trials to validate these effects.
4.3 Specialized Relative Insulin and Nutrition Tables
(SPRINT)
A robust, easy-to-use protocol “SPRINT” (Specialized Relative Insulin Nutrition
Tables) that employs both insulin and feed modulation is developed from the
computerized insulin-nutrition predictive target glycemic control protocol [Wong
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et al., 2005, 2006b] used in the 2nd stage of the clinical trials. Its goal is to
maintain blood glucose levels in the target band of 4.0–6.1 mmol/L, as well as
being easy to use with performance equivalent to the computerized predecessor
protocol. Thus, SPRINT is implemented through 2 look-up tables in a wheel-
based format, making it simple to use, and readily and widely adaptable in ICU.
Overall, it is designed to mimic the computerised protocol, while providing a
simple interface for easy, large-scale clinical implementation.
Protocol
The SPRINT protocol consists of two wheels dedicated to enteral nutrition
optimization and insulin bolus administration, as shown in Figures 4.6 and 4.7.
The SPRINT algorithm requires the current and previous blood glucose measure-
ments, previous hour’s nutrition feed rate, and previous hour’s insulin bolus size
to determine the nutrition and insulin interventions for the coming interval. The
insulin bolus and feed rate for the next hour are then obtained with the wheels
and instructions in Figures 4.6 and 4.7. SPRINT is used hourly with blood glu-
cose samples taken from the arterial cannula for patient comfort. If no arterial
cannula is present, blood is only taken every 2 hours via pin-stick from the toes
or fingers. Specific limitations on dextrose and insulin adminstration are outlined
in Lonergan et al. [2006a] and Shaw et al. [2006].
When a patient is glycemically stable, measurement frequency is changed
from every hour to every 2 hours. Glycemic stability is defined as 3 hours in the
4.0–6.1 mmol/L band with 3 U or less of insulin/hr and 60% or more of the patient
specific goal feed rate. Such a patient is not significantly insulin resistant and is in
the target band, making sudden changes potentially less likely to occur and that
allows less frequent measurement. In the hour between 2-hourly measurements,
the nurse administers an insulin bolus of the same size as the previous hour, and
leaves the feed rate unchanged.
Any patient who has two consecutive blood glucose measurements greater
than 8 mmol/L over a time period of at least 4 hours is eligible to go on the
SPRINT protocol. At entry, a patient specific percentile conversion sticker is cre-
ated and attached to the feed wheel in Figure 4.6. This sticker converts absolute
percentage goal feed (e.g. 30–100%) to an enteral feed pump rate in ml/hr. The
values on the feed conversion sticker are computed based on the patient’s age,
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Figure 4.6 SPRINT feed wheel with dial (a) and with dial removed (b). Blood glucose (BG)
values are in mmol/L. Reproduced with permission from Lonergan et al. [2006b].
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Figure 4.7 SPRINT insulin wheel with dial (a) and with dial removed (b). Blood glucose
(BG) values are in mmol/L. Reproduced with permission from Lonergan et al. [2006b].
4.3 SPECIALIZED RELATIVE INSULIN AND NUTRITION TABLES (SPRINT) 79
body frame size, and gender. The range of goal nutrition rates is 50–100 mL/h
[Shaw et al., 2006]. Details are found in Lonergan et al. [2006a] and Chase et al.
[2006a].
Trial Results
A total number of 165 patients were enrolled in SPRINT during this study.
Over 15,000 measurements were recorded for over 23,000 hours of patient con-
trol. Patients were measured 2-hourly for 64% of their stay indicating significant
periods of stable control. Table 4.5 presents a summary of glycemic control on
the SPRINT protocol for the 165 patients.
Table 4.5 SPRINT trial results (Data are expressed as median [5th–95th percentile range] as
appropriate)
Overall data
Number of patients 165
Hours of control 23,324 hours
Total BG measurements 15,874
BG mean* 5.9 [4.1–8.3] mmol/L
BG standard deviation* 1.3 mmol/L
Percentage between 4–6.1 mmol/L 61%
Percentage between 4–7.0 mmol/L 82%
Percentage between 4–7.75 mmol/L 89%
Percentage < 4 mmol/L 3.3%
Percentage < 2.5 mmol/L 0.1%
Per-patient data
Hours of control 95 [12–447] hours
Number of measurements 68 [10–271]
BG mean* 5.9 [5.0–7.4] mmol/L
BG standard deviation* 1.1 [0.7–2.3] mmol/L
Median hourly insulin 2.5 [1.3–4.1] U
Median nutrition rate (RESOURCE R© Diabetic) 37.5 [0–80.3] ml/hr
(assuming 1.06 cal/mL [Novartis, 2005]) 954 [0–2043] kCal/day
Median percentage of goal feed 52.7%
[29.7–70.3%]
*Lognormal distribution
Overall, 61% of all measurements were in the 4.0–6.1 mmol/L desirable
glycemic band. Average glycemia was 5.1 ± 1.7 mmol/L. Only 3.3% of all mea-
surements were below 4 mmol/L with 6 hypoglycemic events below 2.2 mmol/L.
Figure 4.8 shows the SPRINT controlled blood glucose measurement distribution
in all trials.
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Figure 4.8 SPRINT trials blood glucose distribution
In conclusion, SPRINT provided successful glycemic management in a highly
dynamic environment. This protocol is implemented by the nursing staff without
the need for physician intervention or interpretation. Because it was developed
using the models and methods for computerised control, SPRINT effectively fur-
thers and mass validates the physiological model of Equations (2.9)–(2.13), the
parameter identification method presented in Chapter 3, and the previously com-
puterised predictive target glycemic control protocol. It did so by converting these
methods to a simpler discretised protocol with minimal labour and hardware re-
quirements to enable this large-scale clinical study.
4.4 Protocol Comparison
The final protocol at the third stage of protocol development, SPRINT, provided
enough data to be compared with the published ICU protocols listed in Table 4.6
[Lonergan et al., 2006b]. These protocols all have a target average glucose level
less than 7.8 mmol/L. SPRINT and the computerised insulin-nutrition control
modulate both feed and insulin, while the remaining protocols utilize insulin only.
The Mayo protocol was designed to maintain blood glucose below 7.8 mmol/L
[Krinsley, 2004]. The Leuven protocol is from the landmark study by Van den
Berghe et al. [2003] with a 6.1 mmol/L target average. The Bath and Yale pro-
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tocols are from other recent ICU glycemic control studies [Laver et al., 2004;
Goldberg et al., 2004b]. The “Canterbury District Health Board (CDHB) Stan-
dard Insulin Sliding Scale” is a standard insulin sliding scale previously used in
the Christchurch ICU, and the “Aggressive Insulin Sliding Scale” protocol is a
more aggressive form [Lonergan et al., 2006b]. Detailed methods for compari-
son using simulation on the same long-term patient cohort used for parameter
identification validation presented in Section 3.3 are presented in Lonergan et al.
[2006b].
Table 4.6 Protocols compared in virtual patient simulations
SPRINT Protocol
Insulin-Nutrition Control Protocol [Wong et al., 2006b]
Mayo Clinic Protocol [Krinsley, 2004]
Leuven Protocol [Van den Berghe et al., 2001]
Bath University Protocol [Laver et al., 2004]
Yale University Protocol [Goldberg et al., 2004b]
CDHB Standard Insulin Sliding Scale Protocol
Aggressive Insulin Sliding Scale Protocol
Figure 4.9 shows the simulated controlled blood glucose distribution from
all protocols. SPRINT provided performance comparable with the computerized
insulin-nutrition control protocol. SPRINT and the insulin-nutrition control pro-
tocol both display much tighter control within the target bands and less incidence
of hypoglycemia. The goal of these two protocols is to maximize time within a
band, not just a limit or average at the edge of the band. Both protocols avoid
insulin saturation, deal with measurement error, and account for inter-patient
variability.
The noticeable outlying protocol was from the Mayo Clinic [Krinsley, 2003a].
However, it was designed to be less intensive with a target average of 7.8 mmol/L,
which it essentially meets. The results in Figure 4.9 are summarized in Table 4.7
using log-normal distributions as the best fit to the resulting data (p<0.005).
A two-sample Kolmogorov-Smirnov Test was carried out on all permutations of
simulation data sets. The results of these non-parametric tests indicate that none
of the data sets can be drawn from the same distribution (p<0.005).
The log median blood glucose values for SPRINT and the insulin-nutrition
control protocol are comparable with the Leuven protocol [Van den Berghe et al.,
2001, 2003]. However, the 2 std range of 3.5–9.6 mmol/L for SPRINT compared
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Figure 4.9 Glycemic control protocol comparison. Target bands by Van den Berghe et al.
[2003] and [Krinsley, 2003b] are indicated.
with that of 2.1–15.2 mmol/L for the Leuven protocol shows much tighter control,
with similar results for the ±1 standard deviation range. The other insulin-only
protocols gave similar larger spreads with higher average levels compared with
SPRINT and the insulin-nutrition control protocol, as seen in Table 4.7. This re-
sult shows that SPRINT and the computerised insulin-nutrition control protocol
can tightly regulate blood glucose without significant risk of hypoglycemia, with
0.50% and 0.057% of patient time, respectively, spent at a blood glucose level less
than 3.3 mmol/L, shown in Table 4.7. The study by Van den Berghe et al. [2001]
details the clinical significance of maintaining normoglycemia, and indicates that
averages outside the target range are associated with poorer outcomes [Van den
Berghe et al., 2003]. This is significant as many of the protocols in Table 4.7 had
simulated averages above the 6.1 mmol/L target limit.
All protocol simulations assumed the same ideal, or goal, feed. SPRINT
had the lowest feed at 61.9% of goal feed. However, there was no evidence to
suggest that feeding patients at this level is associated with adverse outcomes.
In particular, Krishnan et al. [2003] showed that feeding at a level of 33–66%
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of the American College of Chest Physicians (ACCP) goal feed (approximately
9–18 kcal/kg/day) was associated with improved mortality and outcomes com-
pared with the 67–100% rate. Note that the ACCP goal feed rate guidelines are
effectively identical to these used in SPRINT [Shaw et al., 2006].
Finally, Lonergan et al. [2006b] showed that the simulated results compare
well with reported average values, suggesting that the computer simulation method
produced realistic results compared to clinical data. This belief is validated in
comparing simulated and clinical SPRINT data in Figure 4.10. Overall, SPRINT
is seen to be a safe and effective glycemic control protocol through large scale
clinical trials and simulated protocol comparisons. In addition, modulating both
insulin and nutrition is seen to deliver more effective and tighter control. In
addition, the protocol can adapt to both intra- and inter-patient variability.
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Figure 4.10 SPRINT clinical v.s simulated results
4.5 Summary
Through the three stages of protocol development using the glucose-insulin model
of Equations (2.9)–(2.13) and the parameter identification method presented in
Chapter 3, it is clear that an adaptive algorithm that uses both insulin and
nutrition as control means delivers safer and more effective glycemic control.
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The final protocol, SPRINT, is presented in two wheel-based look-up tables,
further enhancing the adaptive insulin-nutrition control algorithm’s adaptability
in critical care environments.
Effectively, the computerised insulin-nutrition control algorithm is mass val-
idated via SPRINT for its minimal labor and hardware requirements. In simu-
lations, the computerised protocol still shows superior glycemic control perfor-
mances compared to existing protocols. Thus, the computerised predictive target
glycemic control algorithm will be the benchmark and the platform for further
enhancements.
The previously developed computerised algorithms presented in this chapter,
use frequent parameter fitting to closely track patient dynamic and parameter
variation. Therefore, the algorithms are adaptive to different patients as well as
evolving patient conditions. The frequent parameter fitting thus enables accurate
predictive control.
Further study into the stochastic behaviour of parameter variations, espe-
cially insulin sensitivity, would add insight into control algorithm development
and possibly enable the controller to be “one step ahead” of the observable pa-
tient dynamics. In addition, a “clinical event predictor” capable of foretelling at
least some clinically significant events or their likelihood, such as atrial fibrillation
which occurred in two computerised insulin-nutrition control trials [Wong et al.,
2006b], can take protocol development to a higher level. It is for capturing this
variability that this thesis develops a stochastic model in the following chapters
to augment and optimise these methods and control approaches to provide better
glycemic control and patient care.

Chapter 5
Stochastic Modelling and Initial Insulin
Sensitivity Model
The control algorithms presented in Chapter 4 all determine interventions by
assuming that the identified pG and SI values are constant between the control
intervention and the one-hour time interval to a pre-selected target. However,
identified profiles of pG and SI have shown that both variables can evolve signif-
icantly through time based on patient condition [Hann et al., 2005; Chase et al.,
2005b,c; Wong et al., 2006b]. In particular, sudden variations may also occur due
to the acute onset of conditions such as atrial fibrillation [Wong et al., 2006b]. A
verified model of the variability of pG and SI overtime would thus significantly
assist clinical control intervention decision making.
Intensive care units are highly dynamic in terms of volatility of patient condi-
tions and rigorous drug therapies. While diurnal variation in glucose tolerance is
evident in healthy and diabetic individuals [Lee et al., 1992; Verrillo et al., 1989;
Radziuk and Pye, 2006; Carroll and Nestel, 1973; Arasaradnam et al., 2002],
there is currently no evidence of this phenomenon in critically ill patients. Being
unconsciously sedated most of the time in an ICU, it is debatable if critically
ill patients experience day and night. Constant enteral or IV nutrition support
further removes any sense of time, or metabolic variation associated with it. In
addition, onset of many acute medical events such as atrial fibrillation do not
have clear known causes. Therefore, deterministic means of predicting a change
in a critically ill patient’s metabolic status is ill suited.
In contrast, a stochastic model that lumps all randomness together, can de-
liver a holistic picture of the metabolic dynamics under critical illness. While it is
often tempting from a medical research point of view to understand and model all
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possible drug therapies and hormones interactions and effects, it is unrealistic for
such model to be used for control applications. A stochastic model that captures
critical illness dynamics as a whole, while being “fuzzy”, can provide the most
realistic view by probability.
Therefore, the proposed stochastic model will reflect, as well as provide in-
sight into, the clinically observed dynamic behaviour of pG and SI , and thus aid
control protocol design. The stochastic knowledge can further act as a patient
simulator. Finally, it can be used to provide probabilistic predictions in clinical
intervention outcome. In particular, for control uses, a probability density dis-
tribution in blood glucose levels can be produced for each clinical intervention,
allowing different intervention possibilities to be explored. The most desirable,
probabilistically favorable blood glucose outcome can then be chosen. In sum-
mary, the stochastic model will enhance clinical glycemic control in the following
major aspects:
1. Provide probabilistic predictions and blood glucose probability intervals for
the outcome of clinical interventions.
2. Minimise the risk of unexpected glycemic excursion, particularly hypo-
glycemia.
The overall outcome will be added safety and better knowledge to glycemic control
protocol design and decision making.
5.1 Model Cohort
An initial proof-of-concept stochastic model was developed from the set of long
term retrospective clinical data from 18 critical care patients in the Department of
Intensive Care Medicine, Christchurch Hospital. These 18 patients are a selection
from a 201-patient data audit at the Christchurch Hospital [Shaw et al., 2005,
2004; Hann et al., 2005; Doran, 2004], and have been presented in Section 3.3.
These patients have a minimum stay in ICU of 1.4 days, with intervals between
measured data points of four hours or less. A summary of this cohort’s back-
ground information is presented in Table 3.3 in Section 3.3. This cohort broadly
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represents a typical cross section of ICU patients, regarding medical condition,
age, sex, APACHE II scores and mortality. The average APACHE II score for
this cohort is 22.6, with a range of 8–36. Diagnosed Type 1 and Type 2 diabetes
are slightly over-represented because they often received greater monitoring.
5.2 Initial Insulin Sensitivity Stochastic Model
Glucose-insulin model (Equations (2.9)–(2.13)) fitted patient values for pG and
SI were used to develop the initial stochastic model. Zero-order piecewise linear
functions are used to define the modelled pG and SI , with a discontinuity every
two hours for pG and every hour for SI using the integral-based parameter identi-
fication method presented in Section 3.3. Constant generic parameter values are
summarised in Table 3.8. This choice of intervals provides 1,278 fitted hourly SI
values and 635 fitted 2-hourly pG values.
The fitted pG and SI profiles from these 18 long term critical care patients
revealed non-uniform variation patterns with respect to the parameter values
themselves. The variation distribution of fitted SI from the 18 patients, plotted
as SIn+1 against SIn, is shown by the dots in Figure 5.1. A similar plot for
2-hourly pG variation is shown in Figure 5.2.
It is clear in both Figures 5.1 and 5.2 that the variability of both parameters
over any given fitting time frame is dependent on its present value, and that the
stochastic behaviour or distribution of these variations also depends on their cur-
rent state. Thus, a 2-dimensional kernel density estimation method was chosen
for constructing the stochastic model that describes the transition of parameter
values from one fitting time frame to the next, with respect to the parameter val-
ues. The method has the advantage of producing a smooth, continuous function
across the parameter range [Simonoff, 1996; Scott, 1992]. The overall result is a
bivariate probability function for the potential parameter values.
Essentially, kernel density estimation methods enable data extrapolation to
the entire population given this type of sample from the population. The 2-
dimensional kernel estimation method provides an approximation to the param-
eter variation behaviour according to how the existing or current data behaves.
Where there is higher density of data, more certainty can be drawn on the “true”
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Figure 5.1 Retrospectively fitted hourly SI variation on 18 ICU patients
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Figure 5.2 Retrospectively fitted hourly pG variation on 18 ICU patients
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behavioural pattern of the variant.
An example of a visually and conceptually simpler one-dimensional kernel
density estimation method is shown in Figure 5.3. The kernel density estimate
ρ(x) is the solid line and the kernel functions that add up to ρ(x) are dashed. Six
sample points were considered in this illustrative example. Note that where the
points are denser, the density estimate has higher values. Hence, these approx-
imations are more certain and thus more accurate in the presence of significant
data points. In contrast, a lack of data cannot be remedied by this approximation,
as might be expected.
Figure 5.3 One-dimensional kernel density estimation (The kernel density estimate ρ(x) is
the solid line; the kernel functions which add up to ρ(x) are dashed.)
On the same principle, the 2-dimensional kernel density estimation process
can be thought of as a sand building exercise for visualisation. If a pile of sand is
dropped onto every data point dot in Figure 5.1, then the resulting sand sculpture
is the simple representation of the kernel density estimate across the SIn−SIn+1
plane, much like the solid line in Figure 5.3. However, in this case, the sand
sculpture is physically constrained to the positive first quadrant. Thus, the prob-
ability of non-positive, physiologically invalid SI values is eliminated with this
added boundary on the density estimate.
Since the probability distribution of a possible future SIn+1 value depends on
SIn, time-varying SI profiles or trajectories can be treated as a Markov chain.
A Markov chain constitutes a sequence of random variables, X0, X1, X2, X3, . . . ,
with the value Xn being the state of the process at time n. The Markov property
states that the conditional probability density functions of future states of the
process, given the present state, depends only upon the current state. Therefore,
the conditional probability density function ofXn+1 given past states is a function
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of Xn alone:
p(Xn+1|X0, X1, X2, . . . , Xn) = p(Xn+1|Xn) (5.1)
Additionally, the conditional probability has the statistical property:
p(A|B) = p(A,B)
p(B)
(5.2)
Therefore, given the Markovian stochastic behaviour of SI , the conditional prob-
ability of SIn+1 taking on a value y can be calculated by knowing or having
identified SIn=x:
p(SIn+1 = y|SIn = x) = p(SIn = x, SIn+1 = y)
p(SIn = x)
(5.3)
Equation (5.3) is the conditional probability function that will provide the
stochastic information needed on potential SI variation. The numerator on the
right hand side, which is the 2-dimensional kernel density estimated joint prob-
ability density p(x, y), is constructed based upon or using the available clinical
data.
p(x, y) =
1
n
n∑
i=1
φ(x;xi, σ
2
xi
)
pxi
φ(y; yi, σ
2
yi
)
pyi
(5.4)
where
pxi =
∫ ∞
0
φ(x;xi, σ
2
xi
) (5.5)
pyi =
∫ ∞
0
φ(y; yi, σ
2
yi
) (5.6)
and xi and yi are the coordinates of each dot in Figure 5.1. Equation (5.4)
is the 2-dimensional kernel density estimator function. Each φ(x;xi, σ
2
xi
) and
φ(y; yi, σ
2
yi
) is a normal probability distribution function centred at corresponding
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xi and yi. To force non-negativity in x and y, Equations (5.5) and (5.6) provide
normalisation in the positive domain, where each pxi and pyi represents the area
under each φ(x;xi, σ
2
xi
) and φ(y; yi, σ
2
yi
) between zero and infinity.
Since p(B) is defined:
p(B) =
∫
p(A,B)dA (5.7)
The denominator on the right hand side of Equation (5.3) can be calculated by
integrating Equation (5.4):
p(x) =
∫
p(x, y)dy
=
1
n
n∑
i=1
φ(x;xi, σ
2
xi
)
pxi
φ(y; yi, σ
2
yi
)
pyi
dy
=
1
n
n∑
i=1
φ(x;xi, σ
2
xi
)
pxi
· 1 (5.8)
Therefore, Equation (5.3) can be calculated from Equations (5.4) and (5.8):
p(SIn+1 = y|SIn = x) =
∑n
i=1
φ(x;xi,σ
2
xi
)
pxi
φ(y;yi,σ
2
yi
)
pyi∑n
i=1
φ(x;xi,σ2xi )
pxi
=
n∑
i=1
ωi(x)
φ(y; yi, σ
2
yi
)
pyi
(5.9)
where
ωi(x) =
φ(x;xi, σ
2
xi
)/pxi∑n
j=1 φ(x;xj, σ
2
xj
)/pxj
(5.10)
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In conclusion, Equations (5.9) and (5.10) define the 2-dimensional kernel
density estimation in conditional SI variability. Note that SIn+1 variability is
“conditional” because it depends on the prior state SIn. More specifically, know-
ing SI at any hour n, SIn = x, the probability of SI at hour n + 1, SIn+1 = y,
can be calculated from Equation (5.9).
The step-by-step description for how p(SIn+1 = y|SIn = x) in Equation (5.9)
is computed is given as follows:
1. For every fitted SI data point, as shown by the dots in Figure 5.1 and iden-
tified as (xi, yi) where i = 1, 2, . . . , n, calculate pxi and pyi using Equations
(5.5) and (5.6). The variance σxi and σyi at each (xi, yi) depends on the
local data density and is calculated directly. Details of the derivation of σ
are shown in Appendix A.
2. Knowing or identifying the value SIn = x, calculate ωi(x) for i = 1, 2, . . . , n
using Equation (5.10).
3. Calculate the probability that SIn+1 = y given SIn = x, p(SIn+1 = y|SIn =
x), by substituting ωi(x) for i = 1, 2, . . . , n into Equation (5.9).
Step 1 only needs to be carried out once, because it depends solely on the existing
data set used to construct the stochastic model. The calculated pxi and pyi can
then be stored for use in steps 2 and 3.
A better illustration of the construction of the (conditional) stochastic model
can be shown by the following example using a data set of only 8 samples for
simplicity, as shown in Figure 5.4. Panel A shows the 8 data points and the con-
tours of the individual kernels for them. Each kernel is a 2-dimensional Gaussian
skewed by a weighting function ωi(x) as defined in Equation (5.10). The weight-
ing function skews the Gaussian kernels in the x direction with respect to the
x axis data density at each data point, as shown in panel B. The overall kernel
density estimation function is then the sum of the individual kernels as defined
in Equation (5.9), shown in panel C.
In summary, the 2-dimensional kernel density estimation method creates a
smooth, continuous model surface that reflects the sample data pattern. Note
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that the example shown is the “conditional” 2-dimensional kernel density estimate
function as defined in Equation (5.9). Every slice of the surface in panel C along
the y axis is the probability distribution in y (SIn+1) given x (SIn), and therefore
its area under the curve along the y axis sums to 1.0. In comparison, the kernel
density estimation joint probability function defined in Equation (5.4) has the
volume under the 3-D surface equal to 1.0. The final 3-D SI stochastic model is
thus developed and shown in Figure 5.5 for the data set used for this study.
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Figure 5.5 Initial 3-dimensional stochastic model of SI variability. Each slice of the surface
along the SIn+1 axis has its area under the curve summing to 1.
Having constructed the SI stochastic model, a grid of data that describes the
surface shown in Figure 5.5 can be stored and used as a look-up table. Having
an identified hourly SI value in clinical situations [Chase et al., 2005b,c; Wong
et al., 2006a,b], the probability distribution, and hence the probability intervals,
can be gathered, as shown in Figure 5.6. The solid line is the kernel density
estimate surface sliced along SIn = 0.6×10−3. This line represents the probability
distribution for potential SIn+1, one hour after having identified the current hour
SIn = 0.6× 10−3. From this distribution, probability intervals are also obtained,
giving the most likely SI value in an hour at 0.58 × 10−3, inter-quartile range
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[0.51×10−3, 0.65×10−3], and the 0.90 probability interval [0.39×10−3, 0.75×10−3].
This probabilistic information can then be used to assist in the assessment of
patient condition and clinical decision making regarding the optimal glycemic
control intervention over the next hour.
inter-quartile probability interval 
0.90 probability interval 
 
0.95 probability interval 
 
raw fitted SI
 
most probable SI forecast 
SI st hour n+1 (SI n+1) [L/mU/min] [L/mU/min] 
p 
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Figure 5.6 SI probability density function from the initial stochastic model
The same kernel density estimation operations described were also applied to
the endogenous glucose removal parameter pG. However, the probability density
across the x−y plane is highly concentrated along the line y = x, and particularly
at the point [0.01, 0.01]. This behaviour is evident in the scatter plot in Figure
5.2. This result reinforces that endogenous clearance, as modelled by pG, generally
stays constant at a patient specific value [Hann et al., 2005]. From Hann et al.
[2005], the variation of PG, when it occurs, is over days rather than hours, and thus
is not as amenable to this approach or as necessary in 1–4 hourly interventions.
Hence, the variability of pG is neglected from here on with regard to stochastic
parameter models and behaviours. In addition, calculating the joint probability
distribution between pG and SI requires significantly more computational effort
and time than considering SI alone for potentially little gain in this instance.
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Finally, as this research is focused on clinical glycemic control, computational
simplicity is essential in permitting fast real-time clinical control interventions.
5.3 Initial Stochastic Model Validation
The stochastic parameter model can be integrated into the glucose-insulin system
model of Equations (2.9)–(2.13). This step allows the blood glucose level prob-
ability distribution one hour following a known insulin [Chase et al., 2005b,c]
and/or nutrition [Wong et al., 2006a,b] intervention to be defined based on the
stochastic model defined distribution of SIn+1.
5.3.1 Initial Validation
Method
The stochastic model developed from the 18-patient cohort was evaluated on
8 previous clinical control trials in the ICU [Wong et al., 2006b]. These 8 patients
have the same median APACHE II score and a narrower range compared to the
18-patient cohort (median [range]: 22 [17–31] v.s 22 [8–36]). The background
information on these 8 patients is presented in Table 4.3. Importantly, these trial
data are independent from the 18-patient cohort used to develop the stochastic
model. The trials were performed according to the protocol presented in Section
4.2.
To assess the stochastic model developed on its clinical control validity, these
8 trials are numerically performed using the following modified cycle of steps:
1. Fit pG and SI to an hourly cycle of blood glucose data using integral-based
parameter identification. (Control inputs are as given in the clinical trial.)
2. Generate probability intervals of potential SI from the time-average iden-
tified SI of the evaluated cycle using the stochastic model developed for
SI .
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3. Calculate blood glucose probability intervals for a given intervention based
on the SI probability intervals. This task is performed using the numerical
model of Equations (2.9)–(2.13), and the SI probability interval values.
4. Compare blood glucose probability intervals to real blood glucose trial mea-
surements.
Results
Blood glucose probability intervals produced at each control intervention are
compared against the measured values one hour later. These results are sum-
marised in Table 5.1. The SI stochastic model can account for 84% of measure-
ments over time with a 0.90 probability, and 45% with a 0.50 probability, over
the 8 clinical control trials used for analysis in the retrospective study.
The simulated result for Patient C402 is shown in Figure 5.7. The top panel
displays blood glucose, where the crosses are the actual clinical measurements
with 7% measurement error, the solid line is the fitted blood glucose profile, and
the circles are the most likely probabilistic blood glucose predictions following
control interventions. The 0.90 and inter-quartile probability intervals are also
shown with each most probable blood glucose forecast. The bottom panel shows
the fitted 1st order linear SI , its constant average hourly value for comparison
to the SIn+1 bounds, and the probabilistic bounds on SIn+1 produced from the
stochastic model.
Patient C402 represents a typical insulin resistant critical care patient, whose
fitted SI value tends to be in the lower physiological population range. The
fitted SI between 120 and 180 minutes departed significantly from the predicted
SI , reflecting a sudden hyperadrenergic event that extensively altered the patient
condition. In this specific case, this event occurred as part of an episode of
atrial fibrillation that was clinically observed and recorded around 150 minutes.
Consequently, the probabilistic prediction made for 180 minutes fails to agree
with the actual measurement.
The results from this patient demonstrated the sufficiency of the stochas-
tic model. Most blood glucose levels were within the 0.90 probability intervals.
The outlying events at 120 and 180 minutes were due to more extreme varia-
tions, which are not uncommon in the critically ill. However, to capture these
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Figure 5.7 Simulated clinical control trial on Patient C402
Table 5.1 Retrospective probabilistic assessment on clinical control trials
Controlled Number Measurement error Measurement error
patient of within inter-quartile within 0.90
ID interventions probability interval probability interval
C401 9 2 (22%) 7 (78%)
C402 9 5 (56%) 7 (78%)
C403 9 1 (11%) 7 (78%)
C404 9 1 (11%) 6 (67%)
C405 9 7 (78%) 9 (100%)
C406 9 8 (89%) 8 (89%)
C407 9 5 (56%) 9 (100%)
C408 23 10 (43%) 19 (83%)
total 86 39 (45%) 72 (84%)
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events, the probability intervals would become meaninglessly wide. Hence, the
0.90 probability level was employed for practicality and usefulness in decision
support.
Figure 5.8 shows the same form of results for Patient C402. This patient
began the blood glucose regulation trial at a normoglycemic level. The blood
glucose briefly dropped below 4 mmol/L during the clinical trial, which was not
initially accounted for with the probabilistic forecast. All other results matched
(qualitative) expectations.
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Figure 5.8 Simulated clinical control trial on Patient C404
Different control interventions to manage the low (∼3.2 mmol/L) glucose
value were then explored in Figure 5.9. More specifically, the low glucose occurs
due to variability. Therefore, the SI stochastic model was used to assist decision
making in re-simulating the trial. A comparison between the clinical trial (panels
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A and C) and the new control interventions determined using the probability
intervals (panels B and D) is shown in Figure 5.9. These panels indicate that
using the distribution of SI enables more effective decision making and control
that can better account for, and more aggressively remedy, the sudden change.
0 100 200 300 400 500 6003
4
5
6
7
8
9
10
B
lo
od
 G
lu
co
se
 (m
mo
l/L
)
Clinical Trial
0 200 400 6003
4
5
6
7
8
9
10
B
lo
od
 G
lu
co
se
 (m
mo
l/L
)
Simulated New Control
0 200 400 6000
1
2
3
4
5
6
Time (min)
Co
nt
ro
l I
np
ut
s
0 200 400 6000
1
2
3
4
5
6
Time (min)
Co
nt
ro
l I
np
ut
s
 
 
Insulin Input (U)
Dextrose Intake (mmol)
A B
C D
Figure 5.9 Clinical trial vs. simulated new control results on Patient C404
The simulated new control protocol aimed to maintain the 0.90 probability
intervals above 4 mmol/L. More aggressive control interventions were thus taken
in the first half of the trial, resulting in the blood glucose levels more tightly
maintained at a lower level up to 300 minutes. The brief blood glucose excursion
below 4 mmol/L was still unavoidable because the change in the patient’s SI
exceeded the 0.90 probability interval limit of the created SI stochastic model.
However, a more vigorous remedy action was taken at 360 minutes in using the
stochastic model probability intervals to result in the blood glucose levels having
a 0.90 probability of being above 4 mmol/L in one hour. Overall, the application
of the SI stochastic model in control protocols, as in this case, delivers tighter,
safer and more responsive glycemic management.
Figure 5.10 shows the simulated results for Patient C408. This patient was
the first 24-hour clinical control trial performed, with a measurement interval of
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one hour [Wong et al., 2006b]. Out of 23 predictions, 7 were outside of the inter-
quartile range, but within the 0.90 probability interval. The fitted SI profile
shows the evolution of the patient condition through a day. The Markovian
SI stochastic model successfully predicts the SI variation trend, shown by the
shifting of the SI probability intervals closely following the identified SI .
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Figure 5.10 Simulated clinical control trial on Patient C408
In this patient, note that when SI increases, the probability interval for the
resulting blood glucose levels also tightens. This tightening is due to the model
of Figure 5.5 having narrower distribution of SIn+1 at (relatively) higher SIn.
Hence, tighter SIn+1 profiles generally result in tighter glucose bounds.
In contrast, the wide range of uncertainties in blood glucose levels associated
with very low SI values reflects a common problem in critical care, where highly
insulin resistant patients with high insulin inputs, as often seen in intensive insulin
therapy, can experience a sudden plunge in blood glucose levels and become
104 CHAPTER 5 INITIAL STOCHASTIC INSULIN SENSITIVITY MODEL
hypoglycemic [Amiel et al., 1987; Bolli et al., 1984; Raskin, 1984]. This type of
situation was also encountered by Patient C404 in Figures 5.8 and 5.9, whose SI
profile also was in the lower physiological range [Hann et al., 2005; Doran, 2004].
Similarly, sudden large drop in SI over 1 hour, as at 120 min in Patient C402 of
Figure 5.7, can result in equally large sudden rises. In summary, the wider SIn+1
distribution of lower SIn thus reflects the clinically observed greater variability
of the more critically ill [Chase et al., 2006b, 2007].
Overall, the stochastic model is well reflected in the 8 patients. However,
these 8 patients’ data are very limited, spanning only 104 hours in total. Further
larger-cohort studies or analyses could further verify the generality of the model
and the method of creating the stochastic model.
5.3.2 Further Validation
Method
Further validation was carried out against the larger data set from the SPRINT
trials presented in Section 4.3. The percentage of model fitted SI for these 165
patients within the initial stochastic model probability intervals was assessed.
These patients also have a similar median APACHE II score to the 18-patient
cohort and the 8-patients tested in the initial validation (median [range]: 19 [1–
43] v.s 22 [8–36] and 22 [17–31]). The range of APACHE II score is significantly
greater, as would be expected for this much larger cohort. The main difference to
note about these patients is that their data were collected while they are on long
term intensive glycemic control. These patients have mostly one-hourly data,
and may thus potentially reflect dynamics that would otherwise not appear in
less frequently measured 3–4+ hourly data.
Results
The fitted SI for these 165 patients are within the 0.90 probability interval
87.26% of the time, and inter-quartile interval 53.70% of the time. These percent-
ages are comparable to the previous analysis on the 8 insulin-nutrition control
patients in Table 5.1. A further study of these 165 patients’ metabolic dynamics
under intensive glycemic control may reveal other, currently hidden dynamics.
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5.4 Summary
The initial SI stochastic model has been verified with 2 other different, inde-
pendent cohorts. Stochastic modelling of SI using the 2-dimensional kernel den-
sity method presented has great potential in delivering probability prediction as-
sisted glycemic control when incorporated into the glucose-insulin system model
of Equations (2.9)–(2.13) utilising the integral-based parameter identification.
This “package” can effectively capture the highly dynamic metabolic dynamics
of the critical care patients. The stochastic model also further enhances the abil-
ity to predict, as well as imitate, typical critical care patient dynamics. Sudden
metabolic changes can be better accounted for, and more aggressively remedied.
Finally, tighter, safer and more responsive glycemic management is delivered.

Chapter 6
Higher Dynamic Stochastic Model and Model
Comparison
The availability of data from 165 patients on the SPRINT protocol presented
in Section 4.3 provides the basis for a more comprehensive and detailed study of
hyperglycemic patient dynamics. These patients were all under intensive glycemic
control, and had data collected primarily 1-hourly. Their data may reveal deeper,
more subtle dynamic behaviour that may otherwise not be observable for data
collected at a lesser frequency. A stochastic model created from this cohort will
thus add dynamics that may be hidden in the initial stochastic model built on a
smaller cohort with lower data density. In addition, these patients represent the
target patient group to which the final stochastic model-based glycemic control
protocol will be applied.
6.1 Higher Dynamic Model Cohort
The 165 SPRINT controlled patients have controlled glycemic data totalling
23,324 hours (over 27,500 hours of total length of patient stay in the ICU). By
comparison, the initial model was only built on close to 1,300 hours of data over
18 patients, none of whom were on intensive glycemic control. Another major
difference between these two sets of data was that the SPRINT blood glucose
data were primarily collected hourly, whereas the blood glucose data for the ini-
tial model of Chapter 5 was generally collected every 3 to 4 hours. Therefore,
SPRINT data provides a potentially better and more complete understanding of
the highly dynamic critically ill metabolism that is more suitable for intensive
glycemic control. Moreover, the SPRINT patients are the exact target group for
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such a stochastic model to be used with glycemic control in the ICU.
A background comparison between these 165 SPRINT controlled patients
is made with 485 hyperglycemic patients from the Christchurch Hospital ICU
between September 2004 and August 2005. The goal is to ensure that the cohort
used to create the model is representative of the cohort to which the model may
be applied in a clinical setting. Thus it is an evaluation of the generality or
representativeness of the cohort, and thus, of the stochastic model that would
result.
As shown in Tables 6.1 and 6.2, the SPRINT cohort is a broad representation
of typical hyperglycemic ICU patients. There is no significant difference between
cohorts for age, sex and APACHE II scores for those patients that had an ICU stay
greater than 3 days (p>= 0.15). There is a difference (p<0.01) between cohorts by
APACHE III diagnosis code, as the retrospective cohort has a larger proportion
of operative cardiac patients with short ICU stay. There is less difference between
the cohorts (p=0.12) for those patients that stay in ICU for at least 3 days, which
is the main target group for long term glycemic control, and consists of 73% of
the 165 patients and 96% of the control hours. Note that the SPRINT patients
who stayed in the ICU for less than 3 days were still also included to broaden the
generalisability of the group. Overall, there is no significant statistical difference
in composition between the SPRINT cohort and the long-staying (>= 3 days)
general ICU cohort in Christchurch.
6.2 Higher Dynamic Model
The same parameter fitting method introduced in Chapter 3 was used to fit
hourly constant SI profiles in the glucose-insulin model defined by Equations
(2.9)–(2.13), using the clinically recorded patient data. The endogenous glucose
removal parameter, pG, was kept at a constant level of 0.01 [1/min], which is
the average of the fitted pG levels for the 18-patient cohort used to create the
initial stochastic model. As explained in Section 5.2, the computational benefits
of leaving pG as a constant largely outweigh the otherwise very little clinically
observable data fitting improvement that might be obtained. Therefore, this
stochastic model, like the initial model, only focuses on SI .
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Where there are no blood glucose measurement entries for more than 5 con-
secutive hours, SI is not fitted. With SPRINT, this gap only occurred due to
removal of the patient from the ICU for surgery or other clinical procedures.
Fitted SI is constrained between physiological limits of 1 × 10−5 and 1 × 10−3
[L/mU/min] [e.g. Doran, 2004; Chase et al., 2004; Natali et al., 2000; Prigeon
et al., 1996]. The 2-dimensional kernel density estimation method presented in
Section 5.2 is then used to construct the stochastic SI model that describes the
transition of parameter values from one hour to the next.
Figure 6.1 shows the distribution of the fitted hour to hour SI and the 2-
dimensional kernel joint probability density. The new 3-dimensional SI stochastic
model is shown in Figure 6.2. This model has a more dynamic structure, where
there are many local peaks and troughs, especially in the higher SIn – lower SIn+1
quadrant (lower right corner in Figure 6.2), compared to the initial stochastic
model of Figure 5.5.
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Figure 6.1 Fitted hourly SI variation and joint kernel probability density for SPRINT pa-
tients
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Figure 6.2 Higher dynamic stochastic model of SI variability
Across the fitted range of SI , the conditional probability density function
is largely uni-modal and symmetric. However, as shown in the cascade plot of
conditional SIn+1 probability density functions across the SIn model range in
Figure 6.3, there are some numerical artefacts near the boundaries of the fitted
range. Probability density functions for SIn peak at boundary values because of
the fitting constraints. For SIn = [1× 10−5, 1× 10−4] and [0.75× 10−3, 1× 10−3]
at the edges of Figure 6.3, the percentile values away from the median do not
consistently or monotonically decrease in probability. These ranges span 34% of
the fitting range [1 × 10−5, 1 × 10−3], in which 20% of the SPRINT data falls
(18% between SIn = [1× 10−5, 1× 10−4] and 2% between [0.75× 10−3, 1× 10−3]
in Figure 6.1).
Note that Figures 6.2 and 6.3 show the conditional probability density func-
tions which are scaled to have the area under each function summing to 1. Thus,
the asymmetry becomes very pronounced in Figures 6.2 and 6.3. The probability
of SI taking on these asymmetric conditional probability density functions is in
fact very low in the overall joint probability density function shown in Figure 6.1,
where the probability density sums to 1 over the entire fitting surface.
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Figure 6.3 Cascade plot of SI probability density functions over fitted SI range. The area
under each curve sums to 1.0
The asymmetric SI probability density functions could perhaps be due to
other not explicitly modelled physiology, such as variations in endogenous glucose
production. More specifically, “bumpy” areas of SI probability density function
in Figure 6.3 may be a sign of SI absorbing physiology that is unmodelled or
undermodelled in Equations (2.9)–(2.13). However, this unmodelled physiology
represents uncommon sudden, or extreme, dynamics, evident by the low overall
joint probability density in these areas in Figure 6.1. Practically, to include
all such variations in the glucose-insulin model would make it overly complicated
and it would thus lose clinical feasibility. Such additions would also require added
assumptions for endogenous insulin or glucose production that are not clinically
measured in real-time.
Assumptions for these responses could also compromise control accuracy, as
both endogenous insulin and glucose productions are known to vary significantly
between patients [Sherwin et al., 1974; Ellemann et al., 1987; Van Cauter et al.,
1992; Ferrannini and Cobelli, 1987b; Ferrannini et al., 2005] and over time. In
addition, endogenous glucose production is suppressed with significant insulin
administration in both normal and stressed states [Thorell et al., 2004], which
is the case for critically ill patients under insulin therapy for glycemic manage-
ment. Similarly, the endogenous insulin production is effectively removed or
significantly reduced in the presence of significant exogenous insulin [Insel et al.,
1975; DeFronzo et al., 1979; Transberg et al., 1981; Ellemann et al., 1987], not
to mention its inhibition in stress hyperglycemia [e.g. McCowen et al., 2001]. It
is therefore in the interest of this model-based clinical control applications, to
have these effects mitigated into SI . The result is a much more clinically feasible
control model, where SI accounts for critically ill population’s overall sensitivity
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to insulin and/or its utilisation.
In Figure 6.1, the lower bound for SI has greater influence on the overall
stochastic model than the upper bound. However, no patients have fitted SI
staying at the lower bound for a prolonged period, again suggesting that these
occasions are more sudden, short term conditions, such as suppressed insulin
sensitivity or utilisation due to drug therapies, rather than long term, or gradual
changes, such as increased glucose production. During numerical fitting, if the
fitted SI stays at the lower bound for a prolonged period of 5 hours, the fitting
method recognises a gradual evolution, and adjusts GE to address factors such
as endogenous glucose production. During the total of 23,324 control hours, only
39 such occurrences were observed, which equals to 0.17% of the time.
The short term changes due to significant drug effects or acute medical con-
ditions such as atrial fibrillation [Wong et al., 2006b] can often cause the fitted SI
to hit the lower bound. However, if unconstrained, these situations often result
in negative, unphysiological SI . In addition, increased endogenous production
with inhibited glucose production can result in an effectively zero or negative
modelled SI . These cases are too wide ranged to be accounted for in the physio-
logical model. Note that an evolving GE that is too high leads to a reduction in
modelled endogenous glucose production, and a higher SI may also result in the
model due to a lower −pGG term. Mitigating the impact of these events into the
fitted SI simplifies the model to be clinically control feasible.
In addition, incorrect modelling of these conditions, which are difficult to
account for, can severely compromise patient safety. More specifically, underes-
timating SI can lead to excess insulin being given. With the aim of applying the
physiological and stochastic models in clinical control, the lower bound of SI thus
plays an important role. Finally, the fitted SI , with higher data concentration
around the lower bound, realistically reflects the highly variable dynamics in the
critical care environment, where drug therapies and acute medical conditions that
result in highly resistant patients are common.
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6.3 Clinical Use of Stochastic Model Probability
Intervals
Having constructed this denser and more dynamic SI stochastic model, a grid
of data that describes the surface shown in Figure 6.2 can be stored and used
as a look-up table, as introduced for the initial stochastic model in Section 5.2.
Given an identified hourly SI value in clinical situations [Chase et al., 2005b,c;
Wong et al., 2006a,b], the probability density, and hence the probability intervals,
can be obtained, as demonstrated in Figure 6.4. The solid line is the kernel
density estimate surface sliced along SIn = 0.6 × 10−3. This line represents
the probability density for potential SIn+1, one hour after having identified the
current hour SIn = 0.6× 10−3. From this density function, probability intervals
are also obtained, giving the median of probable SI values in an hour at a very
similar 0.58 × 10−3, inter-quartile range [0.49 × 10−3, 0.66 × 10−3], and the 0.90
probability interval [0.33× 10−3, 0.79× 10−3].
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This more dynamic model does not have as smooth a probability density
function p[SIn+1|SIn = 0.6× 10−3] as the initial model. This difference is a result
of the denser and greater amount of data used to create the model, and is evident
in Figure 6.5. However, the resulting probability intervals are not very different.
The initial model gives the median as 0.58×10−3 with inter-quartile range [0.51×
10−3, 0.65× 10−3], and the 0.90 probability interval [0.39× 10−3, 0.75× 10−3]. In
comparison, the model presented in this chapter yields a median of 0.58×10−3, an
inter-quartile range of [0.49×10−3, 0.66×10−3], and the 0.90 probability interval
of [0.33× 10−3, 0.79× 10−3].
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Figure 6.5 Comparison of stochastic model probability density functions p[SIn+1|SIn = 0.6×
10−3]
The probability intervals used here for clinical decision making, as shown
in Figure 6.4, are equal-tailed. “Equal-tailed” means that the 0.90 probability
interval is between the 5th percentile and the 95th percentile in the probability
density function. Equal-tailed probability intervals are based on the assumption
and observation that the probability density function is (largely) uni-modal and
symmetric. Thus, the values outside the interval are assumed to have a lower
probability of occurring than the values within the interval, and represent “tails”
of that distribution. Note that this assumption is only valid if the distribution,
as in Figure 6.5, is monotonically or consistently decreasing moving away from
its median.
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6.3.1 Probability Interval Calculation
Using the interval boundary values for SI in Equations (2.9)–(2.13), the corre-
sponding probability intervals in blood glucose levels for a given intervention and
current state can be calculated. This statistical approach holds for any strictly
monotone physiological systems [Casella and Berger, 2002]. More specifically, in
this case, a higher SI value always produces lower blood glucose than a lower SI
value for a given input and state over the time SI is defined.
In the cascade plot of the conditional SIn+1 probability density functions
across the SIn range in Figure 6.3, it is evident that the assumption that the
conditional probability density function is largely uni-modal and symmetric is
true for the bulk of the fitted SI range, but does not hold near the boundaries.
Therefore, in these regions, equal-tailed probability intervals may not give an
accurate representation of the highest probability ranges. More simply, the 5th
and the 95th percentile in the resulting blood glucose level probability distribution
may not contain the 90% most probable blood glucose levels. In particular, due
to the asymmetric boundary density functions in SI , blood glucose levels outside
this range may have a higher probability density than parts within the 0.90
probability interval.
To accurately obtain the probability density function in blood glucose re-
sulting from a known probability density function in SI , Monte Carlo simulation
is the only method. In particular, while the percentile values in SI correspond
to percentile values in blood glucose levels, the “rank” of probability does not
[Casella and Berger, 2002].
This situation is illustrated in Figure 6.6, where the left hand side and right
hand side demonstrate the difference between the 0.90 equal-tailed blood glucose
probability intervals and the probability intervals generated from Monte Carlo
simulations. Panels A and B display the same probability density function (pdf)
(right axis) and the cumulative distribution functions (cdf) (left axis) in SIn+1,
when SIn = 8 × 10−4 is known. Panels C and D show the resulting pdf (right
axis) and cdf (left axis) in blood glucose levels at hour n+ 1 (BGn+1 [mmol/L])
through Monte Carlo Simulation of the model in Equations (2.9)–(2.13). The
pdf and cdf shown in panels C and D are identical and are the solution for the
BGn+1 probability density function given SIn = 8× 10−4. Note that in panels A
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and B, the x-axes are decreasing from left to right, producing a similar shaped
probability density function in blood glucose levels in panels C and D with blood
glucose levels increasing as SIn+1 decreases.
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Figure 6.6 Probability density transition from SI to blood glucose levels. Panels A and B
show the pdf (right axis) and the cdf (left axis) in SIn+1, when SIn = 8 × 10−4 is known.
Panels C and D show the resulting pdf (right axis) and cdf (left axis) in blood glucose levels at
hour n + 1 (BGn+1 [mmol/L]) through Monte Carlo simulation. The transformation through
Equations (2.9)–(2.13) from upper panels to lower panels is denoted by f . The shaded areas
in panel B and D have the highest 90% probability. The 90% most probable SIn+1 intervals in
panel B are between cdf = [a×10−2, b×10−2] and [c×10−2, 1.0]. Note that higher SI values in
the left hand side of the reversed x-axis in panels A and B results in higher BG values on the
right hand side in panels C and D.
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The left hand side of Figure 6.6, panels A and C illustrate how equal-tailed
probability intervals in SIn+1 are translated into the equal-tailed probability in-
tervals in BGn+1. Let f be the transformation function between SIn+1 to BGn+1,
which is the physiological model shown in Equations (2.9)–(2.13), then
BG[100−percentile] = f(SI[percentile]) (6.1)
Thus, the percentile values of SIn+1 in panel A corresponds to the reversed
(100−percentile) values in BGn+1 in panel C. Or more simply, solving Equations
(2.9)–(2.13) using the 5th percentile value in SIn produces the 95
th percentile
blood glucose levels, BG95 = f(SI[5]) given that f is strictly monotone [Casella
and Berger, 2002]. Therefore, the SIn+1 probability interval between the 5
th and
the 95th percentile (SIn+1 = [0.33 × 10−3, 0.98 × 10−3] between . and / in panel
A) consequently gives the BGn+1 probability interval between the 5
th and the
95th percentile (BGn+1 = [1.9, 5.4] between . and / in panel C). More simply, as
shown in the left hand side of Figure 6.6:
• Equal-tailed 0.90 probability interval in SIn+1 = [SI[5], SI[95]]
• Equal-tailed 0.90 probability interval in BGn+1 = [f(SI[95]), f(SI[5])]
However, as illustrated in panel C, theBGn+1 probability interval between the
5th and the 95th percentile (. and /) includes values that have lower probability
density than some BGn+1 values outside this interval. More specifically, . has
a lower probability density than the region to its left. This higher probability
density region outside the 5–95% range is very narrow and at the very extreme
end, however, it shows the discontinuity from a simple equal-tailed assumption.
On the right hand side of Figure 6.6, the 90% most probable SIn+1 values
are identified by the shaded areas in panel B. These values are discontinuous,
and have higher probability of occurring than values outside the shaded areas.
However, taking the boundary values for the 90% most probable SIn+1 values,
and then putting them into Equations (2.9)–(2.13), does not provide the 90%
most probable BGn+1 intervals. More simply, as shown in the right hand side of
Figure 6.6:
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• The 0.90 probability interval of highest probability density in SIn+1 =
shaded intervals in panel B = [SI[a], SI[b]] and [SI[c], SI[100]], where a, b and
c are percentile values of SI[a], SI[b] and SI[c], and
pdf(SI[a]) = pdf(SI[b]) = pdf(SI[c]) (6.2)
cdf(SI[k]) = k for k = a, b, c (6.3)
(100− c) + (b− a) = 90 (6.4)
• The 0.90 probability interval of the most likely BGn+1 = shaded intervals
in panel D 6= [f(SI[100]), f(SI[c])] and [f(SI[b], f(SI[a])], or
pdf(f(SI[a])) 6= pdf(f(SI[b])) 6= pdf(f(SI[c])) (6.5)
Consequently, to obtain the probability intervals according to likelihoods in
BGn+1, Monte Carlo simulations need to be done. In this case, to achieve an
accuracy of 1%, a minimum of 10,000 randomly selected SIn+1 values must be
utilised. While such a Monte Carlo simulation can provide the appropriate prob-
ability density in BGn+1, it is too computationally expensive to generate useful
and effective probability intervals quickly enough for clinical decision support.
6.3.2 Clinical Feasibility of Probability Intervals
An estimated computational comparison between calculating the equal-tailed and
the probability intervals according to likelihoods is summarised in Table 6.3.
The computational time frame for calculating the probability intervals according
to likelihoods is clearly not currently feasible for this type of real-time clinical
control. In conclusion, assuming equal-tailed probability intervals provides fast,
clinically viable and slightly conservative estimates for the most likely ranges of
BGn+1. Therefore, it should not compromise patient safety when used to assist
clinical decision making. As the example in Figure 6.6 shows, the 0.90 equal-
tailed probability interval in BGn+1 ([1.9, 5.4]) covers most of the 0.90 most
probable range ([1.8, 4.5] and [4.7, 4.9]), providing an effective and clinically
useful estimate with far less effort.
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Table 6.3 Comparison between probability interval computational cost for equal-tailed and
Monte Carlo methods
0.90
probability
interval Comp. Comp.
computation Equal-tailed Time Monte Carlo Time
Steps 1. Calculate the 5th ∼0 sec 1. Generate 10,000 2 sec
and 95th percentiles SIn+1 using
in SIn+1, SIn+1[5] the derived pdf
and SIn+1[95] from the stochastic
model
2. Equal-tailed 0.90 1 sec 2. Calculate BGn+1 5,000 sec
probability interval for each of the = 83 min
in BGn+1 = 10,000 SIn+1
[f(SIn+1[95]), values
f(SIn+1[5])]
3. Sort the 10,000 1 sec
BGn+1 values
and find the 5th
and 95th percentiles
Total Time ∼1 sec ∼83 min
6.4 Higher Dynamic Model Validation
Method
Again, the stochastic SI model can be integrated into the glucose-insulin sys-
tem model of Equations (2.9)–(2.13) for use in control. This step allows the blood
glucose level probability intervals one hour following a known insulin and/or nu-
trition intervention to be found directly based on the defined probability density
function of SIn+1. Cross validation was performed to test the generality of the
SPRINT cohort and the method of creating the stochastic model. In addition,
cross validation will ensure that the higher dynamic shown in the stochastic model
is not only from a few outlying patients, but is a genuine behaviour of generic SI
variation in critical care.
For cross validation, the 165 SPRINT patients are divided into 5 random
groups. Each group has comparable medical conditions, sex, age, and APACHE
scores. Five stochastic SI models are then built, each one using fitted SI data
from 4 out of 5 groups, leaving one group out each time. Each stochastic model
is then evaluated against the group that is not used for creating the model.
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Table 6.4 shows the general information on the 5 patient groups used in cross
validation. An example of how a stochastic model created from Groups 1, 2, 3
and 4 is evaluated against a patient in Group 5 is shown in the following steps:
1. At hour 0, the patient’s identified SI is SI0. The stochastic model then
produces the 5th, 25th, 75th and 95th percentiles for probable SI at hour 1,
denoted SI1[5], SI1[25], SI1[75] and SI1[95].
2. Examine if the identified SI1 is within the inter-quartile probability interval
between SI1[25] and SI1[75], and the equal-tailed 0.90 probability interval
between SI1[5] and SI1[95].
3. Do the same procedure for hour 1, and repeat the process until the end of
the patient trial data.
All possible combinations of 4 out of 5 groups are tested.
Results
The percentage of fitted SI within the equal-tailed 0.90 and inter-quartile
probability intervals for the group not used in creating the cross validation model
is summarised in Table 6.5. Each group produced similar results, which were also
comparable to the overall result. Thus, there is no significant difference between
the 5 stochastic models created and the SPRINT cohort can be considered a
generic representation of this ICU population.
More specifically, the mean of per patient average of identified SI values
within the equal-tailed probability intervals is 86.6%, and 54.0% for the inter-
quartile probability intervals. The use of equal tailed 0.90 probability intervals
slightly underestimates the identified SI range, because when SIn is close to its
fitting constraints, the SIn+1 probability density function tends to peak near the
boundary value. This behaviour causes some regions outside of the equal-tailed
0.90 probability intervals to have higher probability density than some regions
within the interval, as shown in Figures 6.3 and 6.6. Thus, the compromise of
using equal-tailed probability intervals has negligible impact compared to the
computational gain over calculating the blood glucose ranges of the highest 0.90
probability density.
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Table 6.5 Stochastic insulin sensitivity model cross validation results
Groups used in Average percentage of Average percentage of fitted
creating fitted SI within equal-tailed SI within inter-quartile
Group stochastic model 0.90 probability interval probability interval
1 [-,2,3,4,5] 85.7% 54.2%
2 [1,-,3,4,5] 83.2% 52.3%
3 [1,2,-,4,5] 87.4% 54.7%
4 [1,2,3,-,5] 88.7% 54.1%
5 [1,2,3,4,-] 87.9% 54.8%
overall [1,2,3,4,5] 86.6% 54.0%
The inter-quartile probability intervals include slightly over 50% of fitted SI ,
suggesting that most of the time the higher probability density is concentrated
about the median of the probability density functions, as also seen in Figures 6.3
and 6.6. Similarly, the 0.90 probability interval has slightly less than 90% of all
measurements, suggesting that there are slightly more outliers than represented in
the model. Both results suggest that the assumptions used are slightly inaccurate,
but within typical variations in fitted SI that might be seen as a result of the
7–12% measurement error [Arkray, 2001; Lotz et al., 2006a].
The higher dynamic stochastic model is also verified against clinical data,
reflecting observed clinical variations. The more dynamic behaviour seen in this
second stochastic model exists across the entire cohort, and cannot be simply
eliminated by data smoothing. The higher dynamic is thus genuine and generic.
Intelligent and careful use of this higher dynamic model will therefore lead to a
more accurate probability prediction assisted glycemic control.
6.5 Comparison to the Initial Model
The stochastic models presented in Chapters 5 and 6 capture the SI variation
dynamics in the critically ill on two levels. The initial model captures fundamental
dynamics, while the higher dynamic model in this chapter uses greater data and
data density to capture additional subtle and higher order dynamics as well. Both
models would be implemented the same way in a clinical setting, despite the more
rigorous effort in the validation of the higher dynamic model. A comparison of the
two models is presented in Table 6.6. The raw data plots are shown in Figure 6.7.
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A pictorial comparison of the 3-dimensional kernel probability density function
is presented in Figure 6.8.
Table 6.6 Stochastic model comparison
Patient cohort used to create model
cohort hours of data
no. of APACHE II fitted frequency
patients med. [range] data (hr)
Initial
Model 18 22 [8–36] 1,278 3–4
Higher
Dynamic 165 19 [1–43] 23,324 mostly 1,
Model occasionally 2
Prediction performance on SPRINT data
%SI within %SI within
0.90 probability inter-quartile
interval interval
Initial
Model 87.3 53.7
Higher
Dynamic 86.6 54.0
Model*
*result from cross validation
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Figure 6.7 Fitted SI comparison
A tighter fitting constraint was placed on fitting SI for the 165 patients, when
creating the second model, as is evident in the shaded areas in Figure 6.8(f). The
same constraint value that was used in the initial model was also used in a first
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Figure 6.8 Stochastic model comparison
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attempt. However, data outside of this region is very sparse in the SPRINT
cohort, and the conditional probability density function in this region became
extremely skewed from normalising to very low joint probability density. The
effect of normalisation across the entire SI range can be seen going from Figure
6.8(a) to 6.8(c) and from Figure 6.8(b) to 6.8(d).
Therefore, a slightly tighter constraint was used, and the resulting quality
of the fit was near identical. In fact, the median probability curve in Figure
6.8(f) is near linear for SIn ≤ 0.001, and flattens out afterwards. Therefore, any
fitted SI ≥ 0.001 may be caused by abnormal, acute or sudden medical events,
for example atrial fibrillation [Wong et al., 2006b]. These events are obviously
reflected in the modelled SI , but do not represent insulin sensitivity variation
literally in this model context. This tighter constraint is further supported by
the very similar probability interval prediction performance on SPRINT between
the initial model and the higher dynamic model in this chapter. Finally, it is
evident from the similarities, that a slightly smaller modelling region does not
exclude clinically observable insulin sensitivity variations, including acute cases.
However, the fact that a higher dynamic model does not noticeably improve
prediction performance was not originally expected. The reason for this dis-
crepancy may be that the higher dynamic model uses equal-tailed probability
intervals that also include regions of outlying lower probability, as explained in
Section 6.2. Note that the percentage values listed in Table 6.6 for the higher
dynamic model are from cross validation testing. A model built using the entire
cohort would increase these percentage values slightly.
For prediction assisted glycemic control application, the wider probability
interval in the higher dynamic model can provide a more conservative, there-
fore safer, prediction based intervention advice than the initial model. In the
end, the higher dynamic model was created using a larger, more representative
glycemic controlled ICU cohort, with 3–4 times higher data density. The validity
of the model was also able to be more optimally tested using cross validation, as
well as against the previous stochastic model. Both comparisons showed good,
predictable and fully generalisable performance. Finally, in practice, both are
represented as similar sized look-up tables. Therefore, the higher dynamic model
represents a better choice going forward.
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6.6 Stochastic Models Summary
The SI stochastic model can define the probability density functions of blood
glucose levels one hour following a known glycemic control intervention, and thus
enable more knowledgeable and accurate prediction for glycemic control. The
2-dimensional kernel density estimation method employed allows the Markovian
SI stochastic model capture the essence of clinically observed variation. The
stochastic model acts as a tool to assist clinical intervention decisions, maximise
the probability of achieving desired glycemic regulation, while maintaining pa-
tient safety. The impact of control inputs on probabilistic blood glucose results
can be assessed, giving confidence in the effectiveness of the control protocol
against evolving patient dynamics, particularly with respect to avoiding hypo-
glycemia.
The initial model created from 18 retrospective study patients was evaluated
on 8 insulin-nutrition control trials and 165 SPRINT trials. Both results agreed
with the model probability intervals. The second finer stochastic model was
created using clinical data from 165 SPRINT trials, resulting in a model with
more complex dynamics. The more dynamic model used data that are 3–4 times
denser than that used for the initial model, and the total duration of data was
also 18 times greater. Both models gave similar probability interval prediction
when tested on data from 165 SPRINT trials. The probability interval prediction
from both models are slightly conservative, but accurately capture the cohort.
For prediction assisted glycemic control, the wider probability interval in the
higher dynamic model provides a more conservative, therefore safer, prediction
based intervention advice than the initial model.
The quality of blood glucose control is closely linked with patient condition,
in particular with respect to insulin sensitivity [Chase et al., 2006b]. Higher iden-
tified SI levels give tighter blood glucose probability intervals, making tighter and
safer control possible with subtle control efforts. Blood glucose probability inter-
vals widen at lower SI levels, limiting the accuracy of tight glycemic regulations.
Caution against sudden reductions in glycemic levels is needed at typically low
levels of SI , where significant doses of insulin are typically administered [Wong
et al., 2006b; Chase et al., 2005c, 2006b], while the range of possible change in
blood glucose levels is broad.
6.6 STOCHASTIC MODELS SUMMARY 129
Finally, it should be noted that the methods presented and their clinical
use can be readily generalised to similar cohorts, such as hyperglycemic patients
in other hospital wards needing glycemic control. Models could also be built,
given enough data, for different patient types/diagnoses and/or APACHE scores
or similar. This approach would provide even greater ability to mimic specific
clinical trials or cohorts in testing or validating models and/or drug delivery
protocols. In addition, the method and approach can be applied to other phar-
macodynamic/drug delivery problems. As many pharmacodynamic systems and
models share great similarity, particularly in turns of drug/stimulus sensitivity,
critical sensitivity parameters can be identified and modelled stochastically to
gain greater knowledge of its metabolic variation and aid the control approach.
An example of this is the agitation-sedation problem [Shaw et al., 2003], which
share very similar pharmacodynamics to the glucose-insulin system. Currently,
there exists no crisp picture of the received effect of stimulus and sedative in
patients. Inter- and intra-patient variability is poorly addressed in this clinical
control problem. A stochastic model of these effects can aid understanding of the
problem and further assist controlling it. Therefore, while the models presented
in Chapters 5 and 6 represent the stochastic modelling applications in critical
care glycemic control, the ability to generalise these modelling methods holds
significant additional promise.

Chapter 7
Virtual Patients and Protocol Simulations
The stochastic model developed has been shown to closely reflect the metabolic
dynamics of hyperglycemic ICU patients. Being able to reflect a typical criti-
cal care patient’s SI variation means that it can also act as a patient simulator
for developing glycemic control protocols. This chapter presents the develop-
ment of “virtual patients” for protocol development and virtual trials, as well
as a computerised glycemic control protocol that utilises the stochastic model’s
probability interval prediction ability. Hence, it independently uses the model
to simulate patients and to assist control by predicting clinical outcomes. As a
further form of validation, both applications are compared to clinical data and
results to clearly identify its clinical potential.
7.1 Creating Virtual Patient Cohort
Incorporating the stochastic model developed into the glucose-insulin system
model presented in Equations (2.9)–(2.13), typical critical care patient dynamics
can be reproduced numerically. The primary requirement is initial conditions in
G, Q and I, along with starting dextrose and insulin inputs. To create a virtual
patient, a starting SI value is also required to initiate the stochastic model.
A cohort of “virtual patients” was generated to be similar to the 165 SPRINT
patients. It can thus serve to test the model’s ability to represent a clinical patient
cohort. Initial conditions to Equations (2.9)–(2.13) are generated to approximate
the statistical distribution of these parameters, as they were recorded from the
SPRINT cohort. Initial SI values are randomly selected from the initial values
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fitted from the SPRINT SI data. Trial lengths were also randomly generated to
create a similar statistical distribution of trial lengths to those in the SPRINT
trial.
Profiles of SI that are representative of ICU patient condition evolution are
then generated according to the stochastic model. Using these profiles with Equa-
tions (2.9)–(2.13), “virtual patients” are created that (statistically) approximate
the SPRINT cohort from which the model was created. This “virtual patient”
cohort then provides a platform for clinical trial simulation and development of
control algorithms, as well as a potential further source of validation in compar-
ison of these protocols’ clinical results to clinical results from SPRINT.
7.2 Probability Interval Assisted Targeted Control
Protocol
For this study, the (virtual) control trial (simulation) protocol consists of hourly
cycles of the following glycemic control steps:
1. Virtual Patient: Generate an hourly SIn+1 value from the stochastic
model defined probability density function of the previous hourly SI value
SIn.
2. Virtual Patient: Generate the end-of-hour virtual blood glucose level
using the generated SIn+1 and the specified control (insulin and nutri-
tion) interventions at hour n + 1 in Equations (2.9)–(2.13). Standard
GlucocardTM blood glucose measurement error [Arkray, 2001] is numer-
ically added to the generated blood glucose level, matching the clinical
conditions in Christchurch Hospital ICU [Wong et al., 2006b].
3. Glycemic Controller: A new SI , denoted SI
′, is fit to the blood glu-
cose levels including random noise that are “measured” during hour n+ 1.
Integral-based parameter identification is used to identify SI
′ [Hann et al.,
2005; Wong et al., 2006b]. Not that SI
′ 6= SI will likely occur due to the
glucose measurement noise added.
4. Glycemic Controller: The median and equal-tailed 0.90 and inter-quartile
probability interval of potential physiological SI are generated from the
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identified SI
′ obtained from step 3, using the identified value of SI ′ in the
stochastic model. This step essentially looks up the probability density
function of p[SIn+1|SIn] at SIn = SI ′ as described in Figure 6.4.
5. Glycemic Controller: Control interventions are determined that position
the median glycemic value and the probability intervals in blood glucose
level one hour later. The actual one hour later position is determined using
criterion defined by the control algorithm.
6. Virtual Patient: Return to step 1 with the stochastic model generated
SIn+1 being the new SIn.
Essentially, a virtual patient’s physiological SI evolution follows the joint
probability density contour in Figure 6.1, making its way to the highest proba-
bility density regions. Each SIn+1 is dependent on the previous state, SIn, where
the probability density function of of SIn+1 is defined in Equations (5.9)–(5.10).
Hence, in step 1 above, SI takes a walk to a point, say y, along the probability
density function curve p(SIn+1 = y|SIn = x) as shown in Figure 6.4. Step 6
then “walk” the SI across (along SIn+1 axis) to where SIn = y, and the process
repeats.
As a result, a physiological stochastic SI profile that is representative of
observed clinical dynamics is generated to define the virtual patient dynamics.
These profiles result in similarly dynamic glycemic profiles. The controller, in
these virtual trials, uses glucose measurements with added noise to identify and
estimate the stochastic model generated SI to determine the control input.
7.2.1 Virtual Trial Control Algorithm
The specific control algorithm designed here is a target-shooting algorithm that
minimises the risk of hypoglycemia in a probabilistic sense. Control interventions
include insulin bolus injections, insulin infusions, and dextrose infusions. The
algorithm obeys the following rules, or criterion, in a prioritised order. Thus,
satisfying each rule does not violate the preceding rules.
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Control and Safety:
1. The lower bound of the equal-tailed 0.90 probability intervals in blood glu-
cose levels resulted from control interventions must never be lower than
4 mmol/L.
2. The controller specified dextrose feeding rate must be greater than or equal
to a clinical specified patient specific minimum [Krishnan et al., 2003; Ru-
binson et al., 2004; Wong et al., 2006b; Lonergan et al., 2006b].
3. The total hourly insulin input must not exceed 6 U [Chase et al., 2004,
2005c].
4. The model-based controller estimated saturation in Q in Equation (2.9)
must not exceed 300 mU/L at any time [Chase et al., 2005c]:
Q− Q
1− αGQ ≤ 300 mU/L (7.1)
Intervention Priority:
5. The target blood glucose level (median of the predicted, one hour later
blood glucose probability density function) is 85% or more of the blood
glucose level at the time of intervention, to a minimum of 4.5 mmol/L.
6. To lower blood glucose levels, the control algorithm seeks to lower the dex-
trose feeding rate before adding insulin in bolus (injection) form. Dextrose
feeding rates are not lowered below the clinically specified minimum (Rule
2). Insulin infusions may be used to lower blood glucose levels without
resulting in excess interstitial insulin saturation (Rule 4) or oversize hourly
doses (Rule 3).
7. To increase low blood glucose levels, the control algorithm reduces insulin
inputs first, and then increases dextrose rates.
The first 4 rules are designed for patient safety. If the target blood glucose
level cannot be achieved without violating any of these first 4 rules, the target
blood glucose level is “bounded” so it can be achieved within these limitations.
The final 3 rules define how the algorithm prioritises achieving the target blood
glucose level using the available control interventions. Rule 5 can fit in either
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category, as setting a maximum rate of fall of 15% per hour is both a safety and
control priority.
Note that the insulin saturation limit in Q in Rule 4 is significantly higher
than the 30 mU/L limit set for the controller in the insulin only glycemic control
protocol presented in Section 4.1. This is because the insulin only protocol used
a model insulin distribution space of VI = 12 L, and a glucose distribution space
of VG = 12 L. The revised insulin and glucose distribution volumes used here
are 3.15 and 13.3 L. Therefore, the saturation limit is raised accordingly. Insulin
injections producing modelled saturation of Q−Q¯ ∼= 300 mU/L when VI = 3.15 L
and VG = 13.3 L roughly produces modelled saturation of Q − Q¯ ∼= 30 mU/L
when VI = VG = 12 L.
7.3 Results and Discussion
A virtual cohort of 200 patients was created to match the SPRINT clinical cohort
and tested in simulated trials. Blood glucose probability intervals were produced
for each control intervention using the stochastic model and identified hourly SI
values (SI
′). Hourly blood glucose measurements, including normally distributed
random measurement noise, were analysed against the probability intervals to
test the predictive ability of the model.
An example of a virtual trial is shown in Figure 7.1. The top panel shows
the blood glucose excursion through time. The bold crosses are the virtually
generated blood glucose levels at one hour intervals, with thick bars indicating the
standard 7% GlucocardTM measurement error [Arkray, 2001]. Hourly constant
insulin sensitivity parameter values, SI
′, are fitted every hour and shown in the
bottom panel. Across 200 virtual trials, the controller fitted hourly SI
′ profiles
closely follow the stochastic model generated virtual SI profiles. The average
percentage difference between the fitted SI
′ and the virtual SI is +4%. The
5th–95th percentile range for the ratio between SI
′ and SI is [0.83, 1.18]. The
difference between SI
′ and SI is a result of the measurement noise added to the
virtually generated blood glucose data, which ranges 7–12%.
The stochastic model is used to derive the median, equal-tailed 0.90 and
inter-quartile probability intervals in SI every hour using the value fitted for the
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Figure 7.1 Example of a virtual trial. The top panel displays the blood glucose evolution,
where bold crosses are virtually generated blood glucose levels at one hour intervals, with thick
bars indicating measurement error. The controller predicted blood glucose levels are shown in
circles, with thin bars indicating their probability intervals. The middle panel shows the control
intervention during the trial. The bottom panel is the controller fitted insulin sensitivity, SI ′,
which closely follows the virtual SI profile (not shown) generated from the stochastic model.
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prior hour. Control interventions are determined hourly and shown in the middle
panel, producing probability median values and intervals in blood glucose levels
shown as circles with bars in the top panel. In this virtual trial example, the
probabilistic predictions accurately capture the evolution of blood glucose levels,
as shown by the measurements falling well within the probability intervals in
almost all cases.
The average fractions of virtual trial blood glucose levels within the equal-
tailed 0.90 and inter-quartile probability intervals for each patient are shown in
Figure 7.2 and approximately follow the logistic distribution. The logistic mean
of percentage blood glucose levels within the equal-tailed 0.90 and inter-quartile
probability interval are 87.0% and 45.7% respectively. These results are in good
general agreement with the stochastic model cross validation results in Table 6.5
in Section 6.4. These per patient results also show the overall validity in total,
as well as over all virtual patients, with very few outlying virtual patients.
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Figure 7.2 Virtual trial probability interval analysis per patient (N=200) for the IQR and
0.90 intervals. The ideal theoretical result is having one spike at 0.5 on the top panel and one
spike at 0.9 on the bottom panel.
A few trials in Figure 7.2 have comparatively lower percentage of blood glu-
cose levels within the corresponding probability intervals. These trials are all
significantly shorter in length. Consequently, a small number of blood glucose
levels outside of the probability intervals are reported as higher percentages of
the total for that trial, leading to the outliers seen in Figure 7.2.
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Figure 7.3 illustrates how shorter trials can produce outliers, where most
variability has disappeared after 50–75 hours. This behaviour might indicate an
increasing stabilised patient condition, or at least glycemia, under long term, tight
glycemic control with little variability in glycemic level. It also shows how, as the
length of the trial increases, the 0.90 and inter-quartile probability intervals are
both slightly conservative estimates by 2–4%. This latter result is also evident in
the median values of Figure 7.2, as well as the cross validation results in Section
6.4.
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Figure 7.3 Virtual trial length versus probability interval accuracy (N=200). Each data
point represents the average fraction of blood glucose levels within either the IQR or the 0.90
interval for a virtual trial.
The control algorithm used to run these virtual trials targets the blood glu-
cose probability density medians at the desired controlled levels. The controller
specified interventions should therefore theoretically result in the probabilistic
median blood glucose level being at the chosen level one hour after implemen-
tation. The distribution of virtual trial blood glucose measurement deviations
(percentage value) from the probability density medians is shown in Figure 7.4.
The mean per patient average deviation is 8.84%, which compares well to the
normally distributed random measurement error of 7–12% [Arkray, 2001]. The
outliers in Figure 7.4 are again associated with shorter trial length.
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Figure 7.4 Percentage deviation of virtual trial blood glucose levels from probabilistic medi-
ans
Examining the signed blood glucose deviations from probabilistic medians,
58% are negative. This result suggests that a slightly higher density may be con-
centrated at higher SI in the probability density functions. For future work, this
blood glucose deviation can perhaps be “corrected” for in the control algorithm
by targeting a percentile higher than the 50th, for example the 58th percentile,
until the deviation is minimised. Such an approach might further improve the
targeting accuracy of this controller. Similar manipulation might also be carried
out to “correct” or optimise the accuracy of the probability intervals.
7.4 Validation of Virtual Trial Results Against Clinical
SPRINT Results
The virtual trials presented used the stochastic model to aid glycemic control.
This stochastic model-based glycemic controller is compared to the actual clinical
SPRINT trial results [Chase et al., 2006a; Lonergan et al., 2006a] to assess the
stochastic model-based controller performance. Simulated SPRINT trials were
also performed on the same virtual cohort as a validation of the model’s ability to
create a virtual trial. The results are summarised in Table 7.1. A similar compar-
ison of blood glucose measurements can be seen in the cumulative distributions
in Figure 7.5.
The simulated SPRINT results compares well with the clinical results. This
result is expected as the stochastic model used to generate the virtual cohort was
created using clinical SPRINT data. Under the stochastic model-based glycemic
controller, the virtual patients’ blood glucose levels are shown to be more tightly
controlled, with a lower mean controlled blood glucose level (5.5 v.s 5.9 and
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Figure 7.5 All blood glucose measurement distribution comparison between virtual trials
under the stochastic model assisted controller presented and the clinical and simulated SPRINT
results
5.7 mmol/L). More precisely, the percentage of blood glucose levels within the
4–6 mmol/L range increases from 61% for the clinical SPRINT result, or 57% for
the simulated SPRINT result, to 72% in Table 7.1. This result shows that the
stochastic targeting controller can more specifically maintain the glycemic levels.
This is a very significant difference as tighter control has been shown to imply a
better mortality outcome [Chase et al., 2007].
Again, the control quality in terms of controlled mean blood glucose levels
and variance for each patient is associated with trial length. Shorter trial length
tends to give a sparser distribution of controlled blood glucose levels and thus
greater variance. This result was also seen clinically in SPRINT where the cohort
with length of stay <3 days had greater glycemic variability.
In Figure 7.5 and Table 7.1, the percentage of blood glucose levels below
4 mmol/L is slightly increased from 3.3% or 3.1% to 4.5%. However, the per-
centage below 2.5 mmol/L decreased to effectively zero from 0.1% or 0.2%. The
percentage of blood glucose values lower than 4 mmol/L that still exists can easily
be reduced in the controller by setting a higher limit on the percentile in Rule 1 of
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the control protocol, and/or by increasing the minimum target from 4.5 mmol/L
to 4.8–5.0 mmol/L (Rule 5).
7.5 Summary
“Virtual patients” created from the stochastic model reflect clinical observed ICU
patient dynamics, and present a platform to experiment different clinical control
protocols with a probabilistic knowledge based on clinically observed evolving
dynamics. Simulated control inputs can be evaluated on realistic virtual patient
dynamics driven by the SI profiles.
The virtual trials performed in this chapter show that a computerised stochas-
tically targeted control can outperform a simplified version of the same basic in-
sulin and nutrition control protocol, demonstrating further benefits of stochastic
modelling and/or computer control in general. Future control protocol devel-
opment enabled with virtual patient simulations has great potential in bringing
better glycemic control with minimal labour input in critical care settings. In
addition, applying the developed stochastic modelling to other patient groups
can eventually extend glycemic control benefits outside ICU, down the control
environment pyramid of 1.2 in Chapter 1.
Chapter 8
Conclusions
The work in this thesis presents a complete system for stochastic, model-based
tight glycemic management in the critical care environment. The system includes
four important components:
1. A valid control-applicable physiological system model
2. A novel, low-computation integral-based convex parameter identification
method
3. A stochastic model of insulin sensitivity variation in the critically ill to aid
prediction and control
4. An insulin and nutrition based glycemic control protocol utilising all 3 ele-
ments above to optimise glycemic control
This work is initiated to reduce the risk and harm of hyperglycemia, and to
reduce the health care burden of hyperglycemia management in intensive care
units. The prevalence of hyperglycemia in critical care has a significant impact
on patient mortality and outcome, as well as health care cost and clinical effort.
Recent studies have shown that a 17–45% reduction in mortality can be gained
if tight glucose regulation is achieved to average levels from 6.1–7.75 mmol/L
[Van den Berghe et al., 2001, 2003; Krinsley, 2003b, 2004]. Significantly reduc-
tions in other negative clinical outcomes can also be reaped. However, it often
comes at a cost of significant clinical effort for an often mixed return. The sec-
ondary goal of this research was to enable reliable and consistent tight control
with minimum clinical effort and (probabilistically) guaranteed results. Finally,
144 CHAPTER 8 CONCLUSIONS
with the growing concern of the global diabetes epidemic, effective glycemic man-
agement solutions may eventually be extended to the wider diabetic population.
Traditional ad-hoc protocols often result in vicious cycles of hyper- and/or
hypoglycemia. The highly dynamic characteristics of critically ill patients present
a particularly difficult challenge. Given the range of sensor technology available,
model-based predictive glycemic control has gotten more attention in recent years.
Model-based glycemic control offers significant advantages over traditional ad-hoc
protocols, which includes:
• It is accurate and adaptable to different patients
• It is adaptable to evolving critical illness
• It provides systematic glycemic reduction or regulation
• It will perform to specifically designed performance criteria
• It can deliver predictions of intervention outcomes
• It ensures better patient safety, particularly against hypoglycemia
These advantages, particularly the last two, promise more intelligent and reliable
glycemic control solutions over other methods.
The physiological model presented in this thesis is robust, adaptable to pa-
tient specific condition, and most importantly, clinically validated and applicable.
The model features an interstitial compartment for insulin storage to account
for the delay between insulin secretion, or infusion, and utilization. Saturation
dynamics reflect plasma insulin pooling and saturable interstitial insulin effect,
addressing several shortcomings seen in the Minimal Model for clinical control
applications.
This model was verified using critical care patient data, is robust to different
clinical interventions, and accurately captures clinical observations. Overall, it
represents a balanced tradeoff of complexity and non-linearity versus simplicity
with respect to other models, which span a range of these tradeoffs.
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The integral-based parameter identification method presented in this thesis
enables fast and accurate identification of patient parameters. The integral fitting
method is ∼1,000+ times faster than traditional non-linear and non-convex fit-
ting methods. This difference in convexity and computational effort is important
given the typically non-linear, non-convex dynamic systems of glucose-insulin reg-
ulatory system models. In particular, it does not require extensive iterations, nor
multiple starting points to ensure accurate, optimal solutions. The most critical
patient specific parameter for glycemic control was identified as the insulin sensi-
tivity parameter, SI , with the endogenous glucose removal parameter, pG, being
the second most critical patient specific parameter but also effectively constant.
Sensitivity studies on other parameters indicate the adequacy of adapting generic
population values.
Insulin sensitivity is seen to exhibit significant variation over time, reflecting
the highly dynamic critical care patients. Some of this variability is due to the
highly variable condition of critical care patients, characterised by large variations
in the level of counter-regulatory hormones present and hence in effective insulin
sensitivity. In addition, drug therapies such as beta-blockers or vaso-active drugs
can also have a significant impact on effective insulin sensitivity. Overall, insulin
sensitivity is shown to be a highly variable parameter in this population that
drives the glycemia of the critically ill patient.
The physiological model and the integral-based parameter identification
method were validated clinically in glycemic control trials in the ICU [Chase
et al., 2005b,c; Wong et al., 2006a,b]. These trials followed model predictive
control protocols, where the controller determined insulin and/or nutrition inter-
ventions based on prediction into the future glycemia. The model and the fitting
method were verified to be clinically effective and accurate for glycemic control
applications. It was also concluded that utilising both insulin and nutrition de-
livers the best glycemic management. Nutritional adjustment provides a means
to regulate glycemic levels even in the presence of insulin resistant and/or insulin
effect saturation.
While these methods achieved good clinical predictive accuracy, there were
also occasions where significant changes in insulin sensitivity were encountered.
Therefore, further understanding of the stochastic behaviour of patient specific
parameters, particularly SI , was investigated to further aid controller predictive
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performance. A stochastic model of SI behavior for ICU was thus developed as
the major focus and contribution of this thesis.
The SI stochastic model can define the probability density functions of blood
glucose levels one hour following a known glycemic control intervention. It thus
enables likelihood-based clinical intervention decision support. Clinicians can
have more confidence in implementing interventions, and avoid hypoglycemia in
particular. In addition, the stochastic model ascribes the difference between the
targeted blood glucose level and the actual resulting patient blood glucose level
in terms of the expected and the wider ranges of patient variation. Thus, this
approach effectively differentiates the hour to hour changes in patient condition
from model or measurement errors. Essentially, the stochastic model can better
delineate model error and patient variability in assessing control efficacy.
The stochastic model was created with a 2-dimensional kernel density estima-
tion method. This method allows the Markovian SI stochastic model capturing
the essence of clinically observed variation. Therefore, this model developed using
ICU data specifically reflects critically ill patients’ insulin sensitivity dynamics.
Two stochastic insulin sensitivity models were created using two different
critically ill cohorts. The initial model was created from 18 retrospective study
patients, whose data was collected 3–4 hourly, totalling 1,277 hours of data. The
second model was created using 165 SPRINT trial patients, whose data was col-
lected primarily hourly, and occasionally 2 hourly, totalling 23,324 control hours.
The second model has more complex dynamics, possibly because of the much
denser data available in its creation. However, both models gave largely simi-
lar and similarly accurate probability interval prediction when tested on clinical
SPRINT trial data. The probability interval prediction from both models are
slightly conservative, but accurately capture the cohort. For assisting model-
based predictive glycemic control, the wider probability interval in the higher
dynamic model provides a more conservative, therefore safer, prediction based
intervention advice than the initial model.
It is also shown that “Virtual patients” created using the stochastic model
can reflect clinically observed ICU patient dynamics. They thus create a platform
to experiment with different clinical control protocols using a probabilistic knowl-
edge based on clinically observed evolving dynamics. Simulated control inputs
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can then be evaluated on realistic, validated virtual patient dynamics driven by
the SI profiles.
The virtual trial results reported in Chapter 7 show that a computerised
stochastically targeted control can outperform a simplified version of the same
basic insulin and nutrition control protocol. This result further demonstrates the
benefits of stochastic modelling to aid control decision making, as well as com-
puter control of hyperglycemia in general. Future control protocol development
enabled with virtual patient simulations has great potential in bringing better
glycemic control with minimal labour input in critical care settings. In addition,
applying the developed stochastic modelling to other patient groups can eventu-
ally extend glycemic control benefits outside the ICU, extending these solutions
to wider populations suffering from diabetes.
In summary, the glycemic control system presented in this thesis has a strong
focus on clinical control feasibility and patient safety. The system has been tested
through 4 stages of clinical trials in the ICU. The stochastic insulin sensitivity
variation model has yet to be implemented in clinical trials. However, it has been
validated against a wealth of clinical data to ensure its ability to capture patient
variation. This stochastic model can thus help deliver more intelligible glycemic
control, and promise better patient safety. The overall work presents a novel,
knowledgeable contribution to solving the critical care glycemic control problem.
Furthermore, its methods and approach may be readily generalised.

Chapter 9
Future Avenues
The work in this thesis presents a glycemic control system for critical care envi-
ronments. The system is effective and novel, with a pronounced focus on clinical
control feasibility and patient safety. This work thus addresses the main require-
ments for glycemic control in the ICU. However, it is also readily generalised in
method, mathematics and approach to wider situations and similar problems, It
thus opens many doors to other areas of applications that may have significant
potential.
9.1 Further Glycemic Control Protocol Experimentation
using Virtual Patients
Chapter 7 demonstrates the power of virtual patients in permitting fast and safe
development of control protocols for glycemic control and broader drug delivery
problems. Virtual patients can create realistic virtual cohorts that are statistically
indifferent to real clinical cohorts. The control algorithm presented in Chapter 7
is only an example of one possible algorithm. Many other control algorithms are
yet to be tested and compared for this glycemic control problem.
Currently, it is difficult to assess the performance between protocols from
different research studies. First of all, the patient cohort is variable. Second,
different groups measure controller performance with different metrics. With
“virtual patients”, this difficulty in objectively assessing protocol performance
can be resolved. With decades of research in the broader glycemic control field,
comparisons and experiments can be performed amongst the vast range of con-
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trol theories. For example, the long studied proportional-derivative (PD) and
proportional-integral-derivative (PID) controllers [e.g. Chee et al., 2003b; Steil
et al., 2004] can be experimented with different gains, and objectively compared
without the variability in small clinical studies over different cohorts. The options
are almost literally endless.
As a further example, the SPRINT study results show that a very simplified,
easy to use look-up table protocol can deliver very similar performance to the
computerised predecessor it mimics. Therefore, it is not impossible to further
fine tune the protocol to have it achieving closer performance to the computerised
version by using virtual patients. Overall, the concept of developing a desired
protocol and then systematically reducing it to a simpler form followed by further
fine tuning, can be done with ease at each step using virtual patients.
In summary, protocol experimentations on virtual patients can lead to im-
provements in the likelihood of a particular trial producing positive results. In
addition, this benefit can also be generalised to other hospitals or areas of medical
treatment.
9.2 Investigation of Stochastic Behaviours in Different
Critical Care Patient Groups
The stochastic models presented in this thesis are created using general ICU
patient data. This data may be readily broken down into different patient groups
by factors such as age, gender, APACHE II score, septic or non-septic diagnosis,
trauma or non-trauma. Given enough patients to define each group well, this
breakdown will perhaps isolate some particular characteristics of a specific patient
group in the resulting stochastic model. Otherwise, it can help by confirming that
insulin sensitivity variation, as modelled, is generic across critically ill patients.
If this study results in different stochastic models for different patient cohorts,
it can further help developing different protocols for different patient groups.
Glycemic management could then become even more patient specific. The overall
result would be more certainty and better tailored control.
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9.3 Computerised Protocol and Graphical User Interface
The clinical results from SPRINT show that the ease of use of the SPRINT look-
up wheels significantly contribute to its large-scale adoption by clinical staff and
effective implementation. The nursing staff at the Christchurch Hospital ICU
favour SPRINT over other protocols for its ready adaptability to the ICU envi-
ronment. However, deviations from protocols can not be accounted for. Thus,
any deviation presents an interruption to SPRINT. These deviations include clin-
ician prescribed change in infusion, surgeries, medical examinations, all of which
are common practice in the ICU.
As computer power advances, hospitals are growingly adopting computerised
systems at various levels in their practice. These computerised systems can syn-
chronise and manage patient data, as well as being increasingly used for various
clinical decision support systems. One major advantage of such a computerised
system is that it can be patient specific and account for different aspects concern-
ing their treatment. Specifically speaking of the glycemic management problem,
deviations from any designed protocol can be managed. Thus, the consequent
recovery to the designed protocol and control goals can be faster utilising the
computational power.
Therefore, a computerised protocol, implemented through an easily used
graphical user interface, could be designed to fit into the busy ICU environment.
The graphical user interface should definitely satisfy the following requirements
to ensure ready adoption and uptake:
• Clear in its purpose — blood glucose control
• Clearly display the current patient blood glucose level
• Accept deviations from the protocol at any time
• Advise on data collection times and requirements
• Advise on control interventions and estimated trajectories
• Provide for audit of glycemic control and compliance
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The design process of the graphical user interface layout should also include
consultation to promote clarity and user-friendliness without hindering efficacy.
9.4 Optimising Glucose Sensor Usage and Frequency
The work presented in this thesis used pin-stick bedside test kits to measure
blood glucose levels. These test kits are currently the standard sensors in most,
if not all, ICUs, as well as for most ambulatory diabetic individuals. They offer
rapid results and comparatively well accepted accuracy. However, measuring with
these sensors requires pricking extremities, or the presence of an arterial canula
for drawing blood. Thus, the feasible measuring frequency is not higher than
once every 1–2 hours, as any higher frequency starts to interfere with ICU labour
requirements.
The insulin sensitivity stochastic models reveal that the majority of the SI
variation tends to be mild, and can be accounted for with great certainty (the
lower left corners of Figures 5.5 and 6.2. Therefore, the allowable or optimal
measuring intervals can be explored using virtual patient simulation. SPRINT
has already applied the concept that stable patients require less monitoring of
their blood glucose levels. Further simulation studies can lead to more knowl-
edgable determination of measuring frequency and control quality, including the
potential for customised and variable sampling based on the evolution of patient
condition.
Finally, emerging continuous glucose sensors have long been the hoped-for
ideal for control applications. However, these sensors do not provide satisfac-
tory accuracy to be directly applied into control systems. Thus, advanced signal
processing is certainly an area worthy of research, to better utilise the current
technology until better accuracy can be delivered by these sensors. The stochas-
tic model developed here can be integrated with these studies to optimise the
integration of sensor and control protocol with no loss of control performance.
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9.5 Clinical Trials and Data Audit
All simulation work eventually should lead to clinical testing to realistically jus-
tify the performance of the developed protocol. Clinical testing will also help
strengthen the protocols. It is this systematic and calculated trial and errors
process that will eventually perfect any such control solution.
The first set of clinical testing should be the implementation of the stochastic
models developed in this thesis. This will help verifying the control applicability
of the yet to be fully clinically validated work in this thesis. From the results,
any shortcoming can be identified and improved as required.
9.6 Extension to Other Glycemic Control Problems
The work in this thesis presents initial successful glycemic management in the
ICUs. Sharing similar glucose-insulin dynamics with the ICU glycemic control
problem, the work presented here can act as a starting point for other environ-
ments with glycemic control problems.
Critical care units present a highly controlled environment where the con-
trol system’s inputs and outputs are more easily accounted for. Extending the
glycemic control system from this research to other glycemic control problems
will require re-evaluation of the physiological model used in this thesis. Variables
that account for uncertainties outside ICUs will need to be added. Some patient
dynamics such as endogenous insulin and/or glucose production will also need to
be reassessed.
To start, hospital wards, such as cardiac ICUs and neonatal ICUs that share
similarities to the general ICU, can probably more readily adapt the control
system developed in this thesis. Eventually, the research in this thesis can work
its way down the control environment pyramid of Figure 1.2 in Chapter 1 to
ambulatory diabetic individuals.
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9.7 Extension to Other Pharmacokinetic Drug Delivery
Problems
Many human pharmacodynamic systems share similar characteristics with the
glucose-insulin regulatory system. Therefore, it is possible that the same control
system development presented in this thesis can apply to other pharmacodynamic
control problems. In particular, the application of stochastic models can help
gaining insights into critical system parameters. This will lead to an overall
better understanding and appreciation to the problem presented. Whether the
probability interval assisted decision support concept will be applicable or not,
the stochastic model will provide better knowledge into the pharmacodynamic
system’s behaviour. At least, the stochastic model will act as a patient simulator,
enabling faster and safer protocol developments.
Appendix A
Local SI Data Variance
In the 2-dimensional kernel estimation method used for building the glucose-
insulin model (Equations (2.9)–(2.13)) parameter stochastic models, the form of
the kernel chosen is the Gaussian kernel, ρ, as defined in Equation (5.4). The
variance of the kernel depends on the local data density such that the shape of the
kernel is optimised to produce smooth approximation of the true data behaviour.
To define the local data density, standard orthonormalisation is performed. Let
x = SIn and y = SIn+1, n = 1, 2, . . . , k, totalling a data set of k samples. Both x
and y are column vectors. The orthonormalisation steps are as follows.
1. Solve for the covariance of [x, y].
C = cov ([x, y]) (A.1)
where
C(1, 1) =
k∑
i
(xi − x¯)2
k
(A.2)
C(2, 2) =
k∑
i
(yi − y¯)2
k
(A.3)
C(1, 2) = C(2, 1) =
k∑
i
(xi − x¯)(yi − y¯)
k
(A.4)
2. Perform a Cholesky factorisation on C.
C = RRT (A.5)
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3. Calculate the transformation matrix A.
A = (RT )
−1
(A.6)
4. Centre the samples and perform a space transformation with A.
xˆ = x− x¯ (A.7)
yˆ = y − y¯ (A.8)
[x˜ y˜] = A · [xˆ yˆ] (A.9)
The 18-patient cohort data samples before and after orthonormalisation are
shown in Figure A.1.
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Figure A.1 18-patient cohort data sample space orthonormalisation. Panel A is the original
space and panel B is the orthonormalised space.
5. Define the spread of the samples in the transformed space by calculating
the maximum distance between the furthest sample and the origin. (Also
see Figure A.1, panel B).
Ra = max
(√
x˜2 + y˜2
)
(A.10)
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6. Calculate the variance σx and σy.
Sx = min
(
std(x),
IQR(x)
1.348
)
(A.11)
Sy = min
(
std(y),
IQR(y)
1.348
)
(A.12)
σx = Sx
(
mR2ak
1/3
)−1/6
(A.13)
σy = Sy
(
mR2ak
1/3
)−1/6
(A.14)
wherem = the number of samples within a radius of k−1/6 from correspond-
ing entries of [x˜, y˜].
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